Development of a Stem Cell-Based Tissue Engineered Vascular Graft by Soletti, Lorenzo
 DEVELOPMENT OF A STEM CELL-BASED TISSUE ENGINEERED VASCULAR 
GRAFT 
 
 
 
 
 
 
 
 
by 
Lorenzo Soletti 
Master of Science, Politecnico di Milano, 2002 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
The Swanson School of Engineering in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
 
 
2008 
UNIVERSITY OF PITTSBURGH 
SWANSON SCHOOL OF ENGINEERING 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Lorenzo Soletti 
 
 
 
It was defended on 
September 8th, 2008 
and approved by 
Dr. William R. Wagner, Professor, Surgery and Bioengineering 
Dr. Johnny Huard, Professor, Orthopaedic Surgery, Molecular Genetics, Biochemistry, 
Bioengineering, and Pathology 
Dr. Bradley Keller, Professor, Pediatrics, School of Medicine 
 Dissertation Director: Dr. David A. Vorp, Associate Professor, Surgery and Bioengineering  
 
 ii 
Copyright © by Lorenzo Soletti 
2008 
 iii 
DEVELOPMENT OF A STEM CELL-BASED TISSUE ENGINEERED VASCULAR 
GRAFT 
Lorenzo Soletti, Ph.D. 
University of Pittsburgh, 2008
 
Limited autologous vascular graft availability and poor patency rates of synthetic grafts for 
small-diameter revascularization (e.g., coronary artery bypass, peripheral bypass, arteriovenous 
graft for hemodyalisis access, etc.) remain a concern in the surgical community.  A tissue 
engineering vascular graft (TEVG), including suitable cell source, scaffold, seeding, and culture 
methods can potentially solve these limitations.  Muscle-derived stem cells (MDSCs) are 
multipotent cells, with long-term proliferation and self-renewal capabilities, which represent a 
valid candidate for vascular tissue engineering applications due to their plasticity/heterogeneity.  
The poly(ester urethane) urea (PEUU) is also an attractive potential candidate for use as a TEVG 
due to its elasticity and tunable mechanical and degradation properties.  We hypothesized that a 
novel scaffold optimally seeded with stem cells, acutely cultured and stimulated in vitro, and 
ultimately implanted in vivo will remodel into a functional vascular tissue.   
To test this hypothesis, we developed an innovative, multidisciplinary framework to 
fabricate and culture a TEVG in a timeframe compatible with clinical practice.  In this approach, 
MDSCs were incorporated into a newly-designed and characterized PEUU-based scaffold via a 
novel seeding device, which was tested quantitatively for cell seeding uniformity and viability.  
The seeded TEVGs were acutely cultured in dynamic conditions and assessed for cell phenotype, 
proliferation, and spreading.  The conduits were then implanted systemically in a small and a 
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large animal model and assessed, at different time points, for patency rate, remodeling, and 
cellular engraftment and phenotype.  
The seeding technology demonstrated a rapid, efficient, reproducible, and quantitatively 
uniform seeding without affecting cell viability.  The PEUU scaffold that was developed is 
suitable for arterial applications, exhibiting appropriate strength, compliance, and suture 
retention properties.  The dynamic culture resulted in cell proliferation and spreading within the 
3D scaffold environment.  Rat preclinical studies suggested a role of the seeded MDSCs in the 
maintenance of patency and in the remodeling of the TEVG toward a native-like structure.  Pig 
studies were inconclusive due to a poor pre-implantation cell density.    
Future work should address this and other issues encountered during the large animal 
study, and should test longer time points in both models.  Finally, this approach might benefit 
from a more readily available cell source such as the bone marrow. 
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1.0  INTRODUCTION 
Cardiovascular disease is the leading cause of mortality in the United States [1] and in Europe 
[2].  Coronary artery disease, in particular, accounts for approximately 50% of the total mortality 
[1, 2].  Other conditions such as peripheral artery disease and end stage renal disease are 
associated with overwhelming mortality, morbidity, and costs [3, 4].  These three pathologies 
have in common the therapeutic need for surgical revascularization or vascular access which is 
usually accomplished via vascular bypass utilizing autologous portions of the vasculature 
(Figure 1.1).  Synthetic biodurable grafts have been successfully used to bypass large caliber 
high-flow blood vessels, but have invariably failed when used to reconstruct small-caliber 
arteries [5].  The lack of a suitable vascular graft material coupled with the tremendous need for 
a viable vascular substitute has stimulated many attempts to make small-diameter (ID < 5 mm) 
tissue engineered vascular grafts (TEVGs).  This can be accomplished by incorporating cells or 
other biological components (e.g., growth factors, cytokines, etc.) in a variety of bioerodable 
tubular scaffolds or by just providing acellular, temporary conduits to allow natural vascular 
remodeling events to take place [6].  Although some of the previous approaches have shown 
promising results, most of them have exhibited mechanical, functional, or practical inadequacies 
hampering their clinical translation.  
This introductory chapter reviews the clinical significance of the need for alternative 
vascular substitutes, important structural and functional features of native arteries, and a 
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comprehensive literature review describing previous attempts in the development of TEVGs.  In 
this way, the reader will be provided with a better understanding of the problem and the solutions 
proposed in this work. 
 
 
 
 
Figure 1.1  Clinical need for TEVGs.  The figure shows the most common uses of small-diameter vascular grafts in 
the clinic.  Left:  During coronary artery bypass procedures small autologous vessels (usually saphenous vein and 
the ITA) are used to bypass stenoses or obstructions in different locations of the coronary tree.  The bypass grafts are 
anastomosed proximally to the ascending aorta, and distally, downstream of the coronary obstructions.  When using 
the ITA (gold standard for single bypass), a redirection of the artery is performed with a single distal anastomosis 
downstream of the coronary obstruction.  Center:  During lower limbs revascularization procedures, long segments 
of veins (usually saphenous vein), are used to bypass segments of obstructed arteries in the leg.  Two end-to-side 
anastomoses are performed.  Right:  Patients with end-stage kidney failure require repeated access to high-flow 
vascular conduits for hemodialysis.  In many cases a vascular graft is implanted to create an arteriovenous 
connection allowing arterial flow withdraw in a subcutaneous (venous) location. 
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1.1 CLINICAL SIGNIFICANCE 
In the United States approximately 600,000 surgical procedures are performed yearly to bypass 
coronary or peripheral arteries (Figure 1.1) [1, 3] affected by common pathologies such as 
atherosclerosis or deteriorated by diabetes complications.  In particular, coronary artery bypass 
represents the most common operation and relies mostly on the use of patient’s saphenous veins 
or distal redirection of the internal thoracic artery (ITA).  Over 30% of the patients bypassed 
with venous portions fail to reach a 10-12 year period free of re-operations or percutaneous 
transluminal angioplasty [7].  Further, the use of more effective arterial segments such as ITA, 
radial artery, or gastroepiploic artery is limited by their size, availability, and/or co-morbidities 
related to the loss of functional arterial segments.  Synthetic grafts such as expanded 
polytetrafluoroethylene (ePTFE AKA Goretex®) and polyethylene terephthalate (PET AKA 
Dacron®) have invariantly failed in these small caliber applications due to thrombosis, intimal 
hyperplasia, or calcification [8].   
The prevalence of patients receiving hemodialysis is approximately 340,000 in the U.S. 
[4].  Hemodialysis requires consistent and repeated access to the systemic circulation and 
adequate blood flow rate to enable a dialysis membrane to achieve complete blood detoxification 
in a reasonable amount of time.  The most effective dialysis access configuration is currently the 
one represented by the native radial artery to cephalic vein fistula (Figure 1.1).  However, 77% 
of the patients in the U.S. rely on access constituted either by a synthetic PTFE graft [9] or 
chronic catheters [10].  All of these currently-used vascular access solutions are prone to 
stenosis, chronic inflammation, and infections [5, 11].  Therefore, development of a successful 
TEVG  could have significant clinical implications.   
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Another critical area of possible application for TEVGs is the one related to traumatic 
injuries from accidents or from the battlefield, including those deriving from severe lacerations, 
blunt trauma, explosion, or gunshots.  These injuries often involve damage or loss of consistent 
portions of tissues including major arteries or veins, and necessitating conduit replacement [12, 
13].  Larger blood vessels may be replaced or bypassed with synthetic vascular grafts to 
reestablish blood supply in a reconstructed tissue portion.  However, these synthetic options are, 
again, not suitable for small diameter blood vessels, including those of the extremities (e.g., tibial 
artery, radial artery, etc.).  The graft of choice is often the saphenous vein for lower limb injuries 
[14].  
The cost of cardiovascular diseases and stroke is estimated to be $403.1 billion per year 
in the U.S., according to the American Heart Association and the National Heart, Lung, and 
Blood Institute (NHLBI) [1].  Therefore, a large margin exists for the development of new 
technologies aimed to reduce costs while improving outcomes.  The development of a rapidly 
available TEVG, able to mechanically and functionally mimic the native vasculature and to self-
repair in the case of damage would alleviate the overwhelming need of healthy artery substitutes 
associated with cardiovascular disease, hemodialysis treatment, or traumatic vascular injuries.  
1.2 ARTERIAL ANATOMY AND PHYSIOLOGY 
Arteries are biological conduits carrying the blood from the heart to the tissues via a hierarchical 
branching system spanning in size from the large arteries (internal diameter (ID) ~ 2-3 cm) to the 
capillaries (ID ~ 8-10 μm) and in function from elastic arteries to mass exchange vessels [15].  
The arterial wall is a complex biological structure made of three different concentric layers 
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namely, the tunica intima, media, and adventitia (Figure 1.2).  Each layer has its own specific 
features, but also its own peculiar mechanical, structural, and functional role.  Usually, 
depending on the caliber of the artery and its location in the arterial branching system, structural 
and functional differences exist among homologous layers.  In general, the tunica intima consists 
of the endothelium, a single epithelial layer of interconnected (with gap junctions) endothelial 
cells (ECs) firmly adhered onto a thin collagenous (type IV) layer called basal lamina.  The 
endothelium is responsible for a variety of vascular functions including hemostasis, regulation of 
vasoactivity, angiogenesis, secretion of cytokines, and selective control of mass transport across 
the arterial wall [16]. 
The tunica media is a thick, multilaminar layer including smooth muscle cells (SMCs) 
oriented circumferentially to the blood vessel centerline and several concentric fenestrated elastic 
laminas providing mechanical energy storage and allowing for transmural mass transport.  SMCs 
are embedded in an extracellular matrix (ECM) made of collagen (mostly, type III), 
proteoglycans, glycosamino-glycans (GAGs), and elastin.  The medial layer provides mechanical 
support to the artery to withstand the wall stresses deriving from arterial pressure, but also to 
properly reflect via elastic recoil the pressure waveforms generated by the heart contractions 
[17].  The tunica media is innervated and vascularized by vasa-vasorum, and is responsible for 
the vasoactivity (vasoconstriction and vasodilation) of the arterial wall. 
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 Figure 1.2  Anatomy of a pig carotid artery visualized via Movat’s Pentachrome stain.  The three different layers of 
a native artery are indicated.  Innermost, the tunica intima is in contact with the blood and consists of endothelial 
cells tightly attached to each other and to an underlying collagenous basal lamina (or basement membrane).  In an 
intermediate position, the tunica media provides most of the structural support for the artery and consists of smooth 
muscle cells embedded in a matrix made of concentric laminas of collagen and elastin.  Outermost, the tunica 
adventitia provides external structural support and attachment to surrounding tissues and is made of collagen and 
fibroblasts. 
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SMCs are compacted and interconnected (e.g., via gap junctions) in smooth muscle fibers 
wrapping around the artery, and have the necessary protein machinery to generate fiber 
contractions.  Coordinated contractions or relaxations of smooth muscle fibers cause variations 
in caliber of the artery as a response to biochemical stimuli [15].   
Finally, the tunica adventitia is a vascularized fibrous layer wrapping the other two layers 
of the artery, providing mechanical support and anchorage to perivascular and surrounding 
tissues or organs.  Fibroblasts, pericytes, microvascular endothelial cells, and mast cells are the 
main cellular components of the adventitial layer [16].  These cell types are mainly responsible 
for the synthesis of ECM and for the vascular response to injury.      
Arteries have the important function of storing mechanical energy during pulse wave 
propagation (systole) and returning it during diastole in the form of elastic recoil.  This property 
is known as the Winkessel effect and allows for the maintenance of blood flow through 
downstream arteries also during diastole.  The mechanical properties of an artery, in particular 
the compliance – defined as intraluminal variation in volume due to variations in pressure 
(dV/dP) – influence the propagation of the mechanical pulse wave.  Therefore, the mechanical 
properties of the arterial wall influence the hemodynamics within it.  In some pathological 
vascular conditions causing changes in mechanical properties, the resulting variations in 
hemodynamics have been associated with endothelial dysfunctions leading the increased risk of 
atherosclerosis [18].   Sudden local variations in compliance, for example, due to the coupling of 
the arterial wall with a highly stiffer vascular graft, have been related to intimal hyperplasia [19, 
20].  This phenomenon is commonly called “compliance mismatch”.  
Another critical function of the arterial tree is the regulation of the blood pressure through 
vasoactivity.  The mechanisms of blood pressure regulation are multiple and their explanation is 
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beyond the scope of the current dissertation.  However, one of those mechanisms involves the 
response of the arterial tissue to biochemical stimuli inducing contractions or relaxation of the 
smooth muscle fibers as previously described.  Changes in arterial caliber result in variations in 
vascular resistance causing pressure and flow modulations [17]. 
1.3 TEVG APPROACHES 
Although the term “Tissue Engineering” was first proposed by Y.C. Fung, a pioneer in the fields 
of biomechanics and bioengineering in 1985 [21], and its concepts were formally elaborated in 
the late 1980s by Joseph Vacanti and Robert Langer [22], it was Eugene Bell that in the late 
1970’s first explored the possibility of culturing cells within biological matrices for the purpose 
of tissue regeneration [23].  A definition for tissue engineering provided by Robert Nerem in the 
early 1990s was: “(tissue engineering is) the use of living cells, together with extracellular 
components, either natural or synthetic, in the development of implantable parts or devices for 
the restoration or replacement of function” [24].  The extracellular component (or scaffold) 
provides a temporary architecture on which seeded cells can organize and develop into the 
desired tissue prior to implantation with concurrent ECM deposition.  During the formation, 
deposition, and organization of the newly generated ECM, the scaffold is degraded and hopefully 
metabolized, eventually leaving behind a functional tissue.  Ideally, the scaffold should not 
persist once the cells have produced their own matrix [25].  The classic paradigm of tissue 
engineering is based on five different steps.  The first consist of harvesting and isolating cells 
either from an autologous, allogeneic, or xenogeneic source.  The second is the culturing and 
expansion of cells to the desired cell number.  In the third step the cells obtained are seeded into 
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or onto a scaffold.  The resulting construct is subsequently cultivated and stimulated in vitro 
during the fourth step.  The final step is the implantation (Figure 1.3).  
There is a difference that must be underlined between tissue engineering approaches that 
entail a cellular component and those that rely on guided tissue regeneration in vivo without 
previous cell seeding.  These approaches use acellular matrices that are repopulated by the host 
organism after implantation. 
 
 
 
 
Figure 1.3  Tissue engineering paradigm.  The pictorial represents the classic tissue engineering pipeline in which 
the cells are initially harvested and isolated from the patient (1), cultured and expanded in vitro (2), and then seeded 
into or onto temporary matrices or scaffolds (3).  The seeded scaffolds are cultured into bioreactors for a variable 
amount of time (4), and then are finally implanted into the patient to restore and replace functional or structural 
tissues. 
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Over the last three decades, several approaches have been attempted to incorporate 
“biological” components and functionality into tubular conduits to overcome the limitations of 
the existing biodurable, small-diameter vascular grafts.  Early attempts toward this end were 
pioneered by Zilla et al. and consisted of luminal surface seeding of ECs onto existing synthetic 
graft materials such as Goretex® or Dacron®, or surface modifications to promote EC adhesion in 
vivo [26].  The rationale behind this approach was to reduce graft thrombogenicity and to extend 
graft patency by means of an internal lining of ECs.  These approaches lead to several clinical 
trials; however, several drawbacks limited their success.  In particular, the lack of the graft 
mechanical compliance due to the intrinsic stiffness of the materials, the absence of a capillary 
support system of the formed neointimal tissue, and the loss of cellular contents over time [27].  
In general, the absence of biodegradation of synthetic materials might hinder the normal tissue 
remodeling response, thus becoming a physical barrier to long-term outcomes and a source of 
infection and calcification [28].   
The first approach to develop a fully biological vascular conduit made of cells and ECM 
was described by Weinberg et al. who reported a tissue-like tube consisting of three layers 
composed, respectively, of allogeneic ECs, smooth muscle cells (SMCs), and fibroblasts [29].  
However, in order to withstand physiologic arterial pressures, these constructs required 
additional support sleeves made of Dacron®, thus jeopardizing the benefits derived from the 
completely biological nature of the constructs.  L’Heureux et al. described a novel technique 
using sheets made of cells embedded into their own ECM coaxially wrapped around a mandrel 
[30, 31].  This technique allowed for the creation of an allogeneic collagen-based construct with 
suitable mechanical properties.  More recently, this group has been pursuing the same approach 
using skin fibrosblasts [32].  However, this approach might be limited in its clinical and 
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commercial feasibility due to the extensive culture periods necessary to fabricate the TEVGs (6-
9 months).  Campbell et al. proposed the use of in vivo natural remodeling processes to generate 
cellularized matrix tubes around a tube implanted in the peritoneal or pleural cavities [33].  The 
tubes were mechanically sound but were composed essentially of myofibroblasts, limiting the 
functional properties of the constructs and requiring a dedicated surgical procedure for the 
harvesting of the TEVGs.  Nerem et al. extensively investigated the effect of mechanical 
stimulations applied to vascular cells in vitro [34], and postulated the critical role of 
biomechanics in vascular TE [35].  Niklason et al. pioneered the integration of cells into porous, 
synthetic tubular scaffolds and the effect of several biochemical factors in the in vitro culture of 
TEVGs [36, 37].  Shin’oka et al. proposed the use of a porous biodegradable scaffold seeded in 
the surgical setup with autologous bone marrow-derived cells and implanted with no 
intermediate tissue culture [38, 39]. 
1.4 SCAFFOLDS FOR TEVGS 
One of the heaviest areas of investigation in vascular tissue engineering is the development of an 
optimal tubular scaffold to foster cell adhesion, integration, remodeling, and functionality, as 
well as to provide the necessary mechanical integrity over an extended period of time to 
withstand physiologic pressures and flows [40].  The scaffold should also possess mechanical 
properties similar to native vasculature.  High material stiffness, for example, has been 
implicated in failure due to “compliance mismatch”.  This condition can further lead to 
myointimal hyperplasia and consequent graft failure.  Moreover, the scaffold should not possess 
significant plastic behavior when exposed to physiological ranges of stress and strain since this 
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can lead to aneurysm formation.  The fundamental difference between a traditional vascular graft 
and a TEVG based on scaffolds is the biodegradation of the scaffold material of construction.  
TEVGs thus depend on the capacity of donor- and host-derived cells to secrete and remodel 
ECM into a native-like structure in tandem with scaffold resorption.  
The materials used as scaffolds for vascular tissue engineering applications have varied, 
ranging from biodegradable synthetic polymers to natural biopolymers or decellularized native 
tissue.  Additionally, surface modification of these materials is an expanding research field 
aimed at modulating cell-material interaction acting upon the surface chemistry.  Each of these 
approaches has its pros and cons and the tissue engineering community has not found a 
consensus in defining the most promising approach to pursue.  Summarized below are some 
examples of previously investigated classes of scaffolds or surface modifications.  
1.4.1 Biodegradable synthetic materials 
Synthetic materials have the advantage of being highly tunable and reproducible in their 
mechanical and structural properties as well as in their degradation kinetics.  The synthesis of the 
polymer and the processing and manufacturing into scaffolds are, in fact, completely performed 
under controllable conditions.  Changing the molecular weight or the concentration of the 
polymer or altering its backbone with other chemistries affects the physical and mechanical 
properties of the scaffold.  Generally, higher molecular weights or concentration results in an 
increase in stiffness and strength and in a subsequent reduction of the degradation rate [41].  
Also a physical blend of the material with other polymers, or a chemical modification of the 
polymer backbone with other monomer species can affect the mechanical properties and 
degradation behavior.  The resulting blend or copolymer will have some properties of the newly 
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introduced species depending on the mixture ratio used [42].  The processing of the polymer is 
another variable influencing the properties of the scaffold.  In particular, the processing 
technique defines the scaffold geometry, and its structural and microstructural features.  
Different processing will result in different textures spanning from a dense to a spongy-like or 
fibrous microstructure.  The microstructure of the scaffold will influence not only the physical, 
mechanical and degradation properties of the scaffold [43] but also its affinity for cell adhesion 
and motility [44].  Porosity and pore connectivity can be obtained and controlled via specific 
processing such as salt leaching, thermally induced phase separation (TIPS), and 
microfabrication technology.  Fibers, meshes, and felts can be generated by other processing 
including 3D fiber deposition, and electrospinning (ES).  
Common synthetic biodegradable biomaterials used for fabricating a TEVG are the 
aliphatic polyesters.  Examples of this class of material are the poly-L-lactic acid (PLLA), 
polyglycolic acid (PGA), polycaprolactone (PCA), and their related copolymers [45, 46].  These 
materials have shown supra-physiologic stiffness levels and lack of biocompatibility of their 
degradation products, thereby limiting their applications in cardiovascular applications [47].  
Their high stiffness has been related to compliance mismatch, while the local acidic environment 
generated by the degradation bioproducts of this class of polymers has been shown to cause an 
adverse inflammatory response [48, 49].   Polyhydroxyalkanoates (PHAs) are bacterial-derived 
biopolyesters produced by fermentation of sugars or lipids.  The material has high elasticity and 
mechanical strength and, depending upon its composition, may be modulated to desired material 
properties, ranging from stiff and strong to flexible and ductile.  A copolymer PHA-PGA 
scaffold has been fabricated to increase the elasticity and prevent the observed aneurysm 
formation in simple PGA tubular grafts [50].   
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Biodegradable polyurethanes represent attractive potential candidates for use in TEVG 
scaffold fabrication due to their elasticity and tunable mechanical and degradation properties.  In 
particular, a class of biodegradable, elastomeric poly(ester urethane)urea (PEUU) polymer has 
been shown to be cytocompatible, yield non-toxic degradation products, and to be processable 
into scaffolds via different techniques [51, 52].  A TIPS process has been used to produce highly 
porous scaffolds [53].  This process has been shown to yield a microstructural milieu capable of 
promoting efficient cell integration, cell attachment, and diffusion of nutrients allowing for 
culture in vitro [54, 55].  ES is a different processing technique, which can yield nanofibrous 
PEUU with similar architectural and mechanical properties to those of native collagenous ECM 
[56, 57].  It was demonstrated that by varying the rotational speed of the target onto which the 
PEUU was deposited, that the degree of structural anisotropy and associated mechanical 
properties could be reproducibly controlled and mathematically modeled [56].  More recently, 
the challenge of evenly distributing cells throughout the thickness of these relatively tight porous 
ES scaffolds has been largely overcome by a novel process in which cells and PEUU are co-
deposited, termed “cellular microintegration” [57, 58].  Collectively, the flexibilities of PEUU 
chemistry and processing techniques provide a plethora of permutations from which to choose 
and combine in designing a new scaffold for vascular tissue engineering applications. 
1.4.2 Natural biopolymers or decellularized native tissue 
Natural polymers provide a better environment for cell growth and have a reduced inflammatory 
response following in vivo degradation.  Within this category, three different approaches can be 
identified: fashioning of materials derived from natural matrix into a tubular construct [59-62], 
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formation of a tubular construct from decellularized ECM materials [63], or use of intact, 
decellularized blood vessels [64].   
Tubular constructs fabricated from molded matrix/cell suspensions undergo cell-mediated 
compaction via cellular attachment to the gel matrix and its cell-mediated contraction resulting in 
water release from the gel within days of gelation.  This phenomenon typically confers improved 
mechanical properties due to increased material density and structural organization, and can 
induce cell alignment in the presence of physical constraints such as a rigid mandrel within the 
tube.  However, biological hydrogel-based matrices are often limited by reduced mechanical 
properties and poor reproducibility [60, 65].  Type I collagen cross-linked with enzymes such as 
transglutaminase [65] or temporarily supported by an internal silicone sleeve [66] have shown 
potential for vascular tissue engineering applications, however, suboptimal mechanical 
properties still remain problematic.  Hybrid constructs obtained with mixtures of collagen and 
fibrin gel or elastin have shown a significant improvement in mechanical properties over 
collagen alone [59, 67].  These approaches are limited by the length of the process—a common 
roadblock to clinical feasibility.  Using a different construction technique, mixtures of collagen 
and elastin have been electrospun on mandrels to obtain tubular three-layered fibrous constructs 
that mimic the natural morphology and structure of arteries and have demonstrated good cell 
integration [68].  Other biological molecules such as GAGs have also been used for TEVGs. In 
particular, scaffolds derived from the esterification of the hyaluronic acid have been used to 
conduct studies in vitro [61] and in vivo [69].  
Another alternative for natural polymers are those derived from decellularized tissue 
ECM such as small intestinal submucosa or urinary bladder matrix [70, 71].  This approach has 
been extensively studied in several tissue engineering applications and the ease of processing and 
 15 
good biocompatibility has led to wide acceptance in the clinical community.  During the process 
of tissue regeneration, the implanted native ECM-derived scaffold is gradually degraded until, 
eventually, only the cells and tissues that have been deposited by the host remain in place of the 
scaffold.  The scaffold consists of a collection of both structural and functional proteins, which 
fundamentally alters the healing response [70].  The ECM serves as an inductive scaffold for 
deposition of organized tissues, rather than simple scar tissue formation, similar to that which 
occurs during fetal development.  The acellular nature of the scaffold removes the antigenic 
stimulus that would otherwise cause an adverse immune response [72].  Although cell loading 
might be an alternative to enhance regeneration for this type of approach, the nonporous nature 
of these scaffolds makes cell incorporation in vitro difficult.  Furthermore, the highly 
thrombogenic nature of collagenous ECM-based constructs might lead to graft failure for small 
diameter vascular constructs [70].  
A third type of approach consists of intact decellularized veins or arteries.  In this 
approach, native vessels are harvested and processed to extract all the cellular components 
usually by means of detergent solutions, and are then subsequently sterilized.  The acellular 
nature of the scaffold partially eliminates the immune response as in the ECM-derived scaffolds, 
but the mechanical and structural integrity of the original vessel is preserved [73, 74].  Although 
different animal species or cadavers can be used as sources to obtain these grafts, the procedure 
is labor intensive, difficult to scale-up, and raises some concerns for the possibility of disease 
transmission.   
Clinically relevant features for the scaffolds described above are ranked and summarized 
in Table 1-1.  
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Table 1-1  Ranking of scaffolds for four key considerations of clinical viability for use in creating a TEVG.  Table 
from [75]. 
 
Mechanical properties Cell seeding Biocompatibility Scale-up
Synthetic polymers Very good Very good Fair Very good
Biological gels Fair Very good Very good  Fair
Decellularized ECM scaffolds Good Poor Very good Very good
Decellularized vessels Very good Poor Very good Fair  
Mechanical properties were ranked based on published work.  Cell seeding was ranked based on off-the shelf 
availability.  Biocompatibility was ranked taking into account cell incorporation and the inflammatory reaction 
triggered after implantation.  Scale-up was based on the feasibility to industrialize the construction process. 
 
 
 
1.4.3 Surface modifications 
The surface of most scaffolds can be engineered to interact with cells at the molecular level.  For 
example, covalent incorporation of cell adhesion-promoting oligopeptides such as RGD, YIGSR, 
or REDV on the surface of polymers can increase the steric availability of these ligands to cell-
membrane integrin receptors [76].  The concentration and distribution of adhesive ligands 
influence the strength of cell attachment, extent of cell spreading, and the speed of cell migration 
[77], and allows for the modulation and control of these parameters.  Cell-specific ligands can be 
used, for example, to foster cell adhesion of targeted cell types in desired locations while 
inhibiting the adhesion of undesirable cell types [78].  
Enhancement of adhesion can also be obtained with deposition of self-assembled films. 
Nanopolyelectrolyte films made of poly(D-lysine) or poly(allylamine hydrochloride) have been 
shown to increase adhesion of ECs in a controllable manner without protein precoating [79].  
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Another desirable feature of such films is their ability to incorporate enzymatic recognition sites 
to give to the scaffold a specific proteolytic sensitivity that can help direct the desired 
remodeling of the scaffold upon in vivo implantation [78].  
Incorporation of growth factors into the scaffold is another strategy to control cell 
attachment and regulate cell proliferation, migration, differentiation, and protein expression.  For 
example, collagen matrices covalently incorporated with heparin and loaded with vascular 
endothelial growth factor (VEGF) have been shown to significantly enhance angiogenesis in the 
collagen matrices, thereby increasing EC proliferation [80].  
More recently, polymeric gene delivery has been considered to induce the expression of 
functional proteins, thereby avoiding the cytotoxicity and immunogenicity issues related to the 
use of viral gene delivery systems [81].  This approach might allow a controlled overexpression 
of anticoagulant and anti-inflammatory proteins such as thrombomodulin and/or inhibitors of 
procoagulant and proinflammatory proteins such as vascular cell adhesion molecule-1 (VCAM-
1) and intracellular adhesion molecule-1 (ICAM-1). 
1.5 CELL SOURCE 
Two different cell sources have been used to produce a cellular TEVG: terminally differentiated 
cells or stem cells.   
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1.5.1 Adult differentiated cells 
The use of terminally differentiated vascular cells permits the fabrication of a TEVG with the 
same cellular constituents of a native artery, which may potentially reproduce functionality.  
However, this approach requires a very large initial number of cells and their retrieval might be 
difficult to accomplish without an invasive procedure for the patient and the harvesting of 
significant amounts of functional, native tissues (for autologous approaches).  Non-autologous 
cells, derived from different donors (including cadavers), would require an undesirable (or even 
unacceptable) immunosuppression therapy or other interventions to prevent rejection.  
Differentiated cells have usually a low proliferative rate and a limited number of divisions 
available due to cell senescence; therefore these cells have restricted possibilities of expansion 
[82].  Although some groups have tried to genetically manipulate the proliferation kinetics of 
differentiated cells by reintroducing the reverse transcriptase telomerase subunit into the adult 
cell genome [83], the genetic intervention remains a major concern for the scientific community 
and, therefore, an obstacle to clinical feasibility. 
Luminal seeding of endothelial cells (ECs) to confer antithrombogenic properties to the 
conduit lumen is also a common approach for biodegradable scaffolds.  Human umbilical vein 
ECs cells have been used in this manner, though bovine and porcine aortic ECs have also been 
used [84, 85].  Smooth muscle cells (SMCs) have been utilized in several approaches to create a 
TEVG, including seeding on synthetic biodegradable scaffolds [46], culture in biological gels 
[60], or as component of cell-based constructs [30, 31].  Dermal fibroblasts have been used to 
construct a ‘‘self-assembled’’ TEVG, using extensive cell culture and relying on accelerated 
ECM production by the cells [32]. 
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1.5.2 Adult stem cells 
Stem cells have a great potential for use in tissue engineering applications and may circumvent 
many of the shortcomings associated with other solutions to cell sourcing.  A first distinction 
should be made between adult stem cells and embryonic stem cells.  Almost all tissues possess 
latent populations of adult stem cells that become active in determined circumstances such as in 
case of injury or remodeling, and are chemo-attracted to determined sites by specifically released 
cytokines [86].  Adult stem cells can be harvested from several autologous tissue sources with 
varying levels of invasiveness including bone marrow, body fat, and striated muscles [87-89] 
without compromising the functionality of the donor tissue.  Adult stem cells usually display a 
rapid, almost endless expansion capability when cultured in expansion media (usually rich in 
fetal serum) and therefore, are ideal candidates for tissue engineering which requires availability 
of large amount of undifferentiated cells in a short amount of time.  
The therapeutic use of bone marrow (BM) (e.g., in bone marrow transplantation) has 
created an extensive background of knowledge on this particular cell source.  BM contains 
different types of progenitor cells at various stages of differentiation.  BM includes 
hematopoietic stem cells (positive for the protein markers CD34, Sca-1, and c-Kit) [90], 
mesenchymal stem cells (CD105+ and CD73+ and negative for CD34) [91], and endothelial 
progenitor cells (EPCs; CD133+, CD34+, and VEGFR-2+) [92].  Hematopoietic stem cells are 
responsible for the generation of all blood cells including erythrocytes, leukocytes and 
thrombocytes.  Mesenchymal stem cells, instead, can differentiate into many different cell types 
including osteocytes, adipocytes, neurocytes, chondrocytes, and myocytes and have high 
proliferative kinetics [93].  Mesenchymal stem cells have also been shown to differentiate to 
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SMCs, making them a valid candidate for vascular applications [94].  EPCs, finally, have been 
shown to differentiate into ECs and produce capillary networks in vitro [95].  
Several TEVG approaches have used BM progenitor cells (BMPCs).  Some of them have 
relied on an in vitro maturation and pre-differentiation of BMPCs into ECs and SMCs [73].  
Other approaches utilized undifferentiated BMPCs relying on their in vivo differentiation and 
remodeling [96].  
Adipose-derived stem cells (ASCs) are another promising candidate for tissue 
engineering since the availability of autologous fat is high and does not require highly invasive 
procedures for harvesting (liposuction) [89].  ASCs have been shown to differentiate into 
multiple cell lines, including bone, fat, smooth muscle, and cartilage [97], as well as endothelial 
cells [98].  
The skeletal muscle is another source of progenitor cells.  Muscle-derived stem cells 
(MDSCs) isolated from the striated muscle exhibit multipotentiality toward vascular lineages 
(SMCs and ECs), self-renewal capabilities, and have a direct role in tissue remodeling and 
regeneration both in vitro and in vivo [99-101]. MDSCs are SCA-1+, CD34+, and they represent 
a promising alternative for vascular tissue engineering applications.  
1.5.3 Embryonic stem cells  
Embryonic stem cells (ESCs) are pluripotent cells capable, with the appropriate environmental 
cues, either generating any cellular lineage or self-renew.  Self-renewal is the capacity of making 
a perfect cellular copy an unlimited number of times.  ESCs are obtained from the inner cell 
mass of the blastocyst (a very early developmental stage of the embryo) causing the loss of the 
fertilized egg.  Therefore, the use of human ESCs has raised a number of ethical dilemmas, 
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thereby limiting their use.  Differentiation of ESCs cells into ECs and SMCs has been achieved 
showing angiogenesis and formation of microvascular structures in vitro [102] and in vivo [103, 
104].  However, beyond the ethical issues, immunogenic and tumorgenic problems continue to 
represent obstacles to clinical applications of ESCs. 
1.6 SEEDING TECHNIQUES 
Cell seeding represents a fundamental step in any tissue engineering application that incorporates 
cells into or onto scaffolds prior to culture or implantation [105].  Desirable features for any 
seeding technique include, minimized cell injury, uniform cell distribution, high seeding 
efficiency, reduced seeding time, high reproducibility, and user independence.  The 
incorporation of cells into tubular scaffolds is generally more challenging than the one into flat 
sheets of scaffolds, and it is desirable in a variety of tissue engineering applications such as those 
for the vascular, cardio-respiratory, urological, neurological, and gastrointestinal systems.  A 
distinction should be made between surface seeding, e.g., lining cells on a luminal surface, and 
bulk seeding, which implies delivery of cells through the thickness of the scaffold.  Most of the 
current seeding techniques have involved the seeding of cells onto surfaces.  Previously 
described seeding techniques take advantage of different, single driving forces such as 
sedimentation [106],  electric/magnetic fields [107, 108], rotation [109], or vacuum/filtration 
[110, 111].  Recently, acoustic waves have been used to increase the depth of cell penetration 
into the scaffold surface as well [112].  The use of a seeding device is often challenging since 
mechanical forces are usually involved in seeding procedures and can be responsible for damage 
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via membrane lysis or triggering of apoptotic pathways [113, 114].  Bulk seeding is a more 
difficult task to accomplish especially in a controllable manner.  
The complex micro-architecture of the scaffolds often hampers the passive incorporation 
of cells within them.  In a three dimensional environment it might be beneficial to provide a 
uniform and controllable distribution of cells to foster homogeneous tissue remodeling and to 
avoid competition for nutrients in areas with a higher density of cells [111].  Surface seeding by 
dripping a cell suspension on the matrix is a very simple, and the most common technique for 
bulk incorporation of cells into scaffolds [115, 116].  However, this technique neither produces a 
high yield of cells included within the scaffold nor affords a “quality control” on the final 
engineered tissue due to the manual nature of the procedure.  Incorporation of cells in matrix 
suspensions such as collagen or fibrin gel or a synthetic hydrogel [60] is an easy and effective 
seeding technique but the applications are limited by the poor mechanical properties of hydrogels 
(recall Section 1.4.2).  Recently a novel technique called “microintegration” based on 
simultaneous electrospinning of polymer and a cell suspension to produce a cellularized 
construct was reported [117]; this technique may affect cell viability due to the strong electrical 
field and to the cytotoxicity related to the polymer solution solvent.  A technique called “cell 
printing” allows for a multilayered deposition of cells and hydrogels in complex 3D shapes via a 
modified ink-jet printing technology [118].  This technique allows for detailed control of scaffold 
and cell deposition but the process is still complex and costly.   
Figure 1.4 summarizes the seeding methods previously described in the literature. 
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 Figure 1.4  Overview of previously reported seeding techniques.  A.  Pipetting cells suspensions on top of flat 
sheets of scaffold materials allows for gravity-mediated cell sedimentation onto the surface.  B.  When a porous 
scaffold is placed in a column between a seeding suspension and an applied vacuum, a transmural flow is generated 
by the pressure gradient resulting in an entrapment of cells in the scaffold matrix.  C.  Immuno-labelling cells with 
electrical of magnetic particles allows for scaffold seeding driven by electric or magnetic fields.  D-E.  Cell 
suspensions cyclically moved on top the scaffold (either via flow generated by a pump of via rotation of the 
scaffold) will induce the progressive recruitment of cells onto its surface.  F.  Acoustic waves oriented toward a cell 
suspension in contact with a porous scaffold improve the penetration of cells into the pores.  G.  Pouring 
cell/hydrogel suspensions into molds will cause the creation of a cellularized scaffold upon gelation.  A similar 
concept is pursued with the “cell sheets” technique in which the cells are initially embedded in their own produced 
ECM in forms of sheets.  The sheets are then used to create different shapes by means of external supports.  H.  The 
concurrent deposition of polymer via electrospinning and cells via electrospraying has been shown to produce 
densely cellularized constructs.  I.  Ink-jet printer modified systems allowed a highly controlled 3D deposition of 
cell/hydrogel suspensions to create scaffolds with a seeded micro-architecture.  
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1.7 IN VITRO STUDIES OF TEVGS 
In vitro approaches requiring mechanical or biochemical conditioning regimens rely on the 
cellular remodeling mechanisms of the engineered tissue to build the ECM structure, increasing 
the mechanical properties of TEVGs, or inducing cell proliferation and/or differentiation before 
implantation.  However, these natural processes are often slow to occur in vitro, requiring culture 
times (weeks to months) that might not be compatible with the clinical translation in which the 
ideal paradigm is to provide “off-the-shelf” or at least readily available products.  Therefore, 
extenuating in vitro culture and maturation times for engineered tissues, while providing very 
valuable insights on controlled tissue formation, might not be ideal for a translational approach. 
1.7.1 Bioreactors 
Most tissue-engineered constructs lack mechanical and functional properties necessary for a 
successful in vivo implantation immediately following seeding.  Therefore, the use of bioreactors 
for in vitro culture and maturation has become a major area of investigation in tissue 
engineering.  The goal of a bioreactor is to create a sterile physiological environment in which 
TEVG constructs can be cultured and exposed to biochemical (e.g., growth factors, cytokines, 
etc.) and biophysical stimuli (e.g., mechanical forces, etc.).  Bioreactors can guide the tissue 
development and growth until complete maturation of the engineered tissue before implantation.  
Several bioreactors for TE have been described in the literature with various levels of complexity 
and performance.  Basic types of bioreactors include spinner flasks [119] and rotational culture 
systems [120].  These devices enhance mass transport of nutrients and gases by adding 
convective components to the mass transport equations [121] (induced by the constant 
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stirring/movement of culture media within the bioreactor), and have the relevant advantage of 
being simple, cost effective, and promptly useful following seeding due to their delicate culture 
conditions.  These bioreactors are not designed to exert mechanical forces on tubular constructs 
or to perfuse them with a continuous flow.  More complicated perfusion bioreactors, instead, can 
subject tubular constructs to steady or time-varying mechanical stresses such as shear stress, 
hydrostatic pressure, and circumferential stress, thus mimicking the cardiovascular environment 
[37, 66, 122].  Both the magnitude and frequency of mechanical stimulation have effects on the 
development of the tissue in vitro [123]. 
1.7.2 Biochemical stimulation 
Mechanical stimulation has been coupled with biochemical factors in order to recreate the 
complex natural milieu encountered during tissue development.  Bioactive chemicals such as 
ascorbic acid, copper sulfate, and amino acids have been shown to enhance matrix deposition 
and cross-linking [37] and ultimately, the strength of the engineered tissue.  Growth factors such 
as basic fibroblastic growth factor (bFGF), platelet-derived growth factor (PDGF), transforming 
growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF) have been utilized 
to stimulate engineered tissues.  Both bFGF and PDGF are mitogens for SMCs and ECs [124, 
125], which allows for faster proliferation of cells into the engineered tissue.  TGF-β is involved 
in mitogenesis and morphogenesis and increases ECM matrix deposition [126]. TGF-β has also 
shown to increase α-SMA expression and matrix production in collagen gels exposed to both 
static and dynamic culture [127, 128].  TGF-β also induces differentiation of BMPCs toward 
SMC lineages [129].  VEGF has mitogenic effects for ECs and progenitor cells [125] and can 
induce EC differentiation in progenitor cells [130].  
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 1.8 IN VIVO STUDIES OF TEVGS 
Several studies have focused on the body’s ability to restore and regenerate functional tissues 
starting with temporary engineered tissues [72, 131, 132].  In these works, the living organism 
has been utilized as a ‘‘bioreactor’’ to complete the formation of the engineered graft via host-
mediated remodeling mechanisms.  The role of the scaffold in this approach is to provide 
temporary structural and mechanical support, and in some cases, to provide biochemical cues to 
direct remodeling [133].  Several approaches have successfully utilized this model for vascular 
applications with different levels of success.   
Acellular biological grafts have been implanted in dogs showing good patency rates, 
absence of infections and intimal hyperplasia.  However, several of these grafts developed 
aneurysms within the first 48 weeks of implantation thus limiting this application in future 
studies [134, 135].  TEVGs were obtained via host-response (encapsulation) to Silastic tubes 
implanted into the peritoneal cavity of rats and rabbits [33].  This approach might be limited by 
the need of an additional surgery to retrieve the TEVG introducing additional morbidity to the 
process.  Cho et al. [73] seeded scaffolds with labeled BMPCs pre-differentiated in vitro into 
SMCs and ECs.  Eight-week follow-up showed increase in patency rate of the seeded grafts 
compared to the unseeded controls.  Moreover, the seeded cells where engrafted into the 
remodeled grafts showing their contribution in the vascular remodeling process.  With a similar 
approach, another group reached a 100-week post-implantation period with positive outcome in a 
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growth model in lambs, thus showing also the ability of the TEVG to growth with the host 
animal [136]. 
The architectural structure of the scaffold, such as pore size, porosity, and 
interconnectivity, has a significant impact on the in vivo mechanisms of remodeling [137].  The 
cellular component incorporated into the scaffolds prior to implantation also plays a critical role 
in the TEVG remodeling and functionality in vivo [138].  Despite years of research, the in vivo 
mechanisms of remodeling remain not completely understood and no clear consensus on the best 
approach to pursue has been achieved yet. 
1.9 CLINICAL TRANSLATION 
To be clinically viable, a TEVG must meet several requirements extending beyond its successful 
preclinical testing.  From a commercial standpoint, a short overall fabrication time for the TEVG 
is a critical prerequisite for its future clinical translation.  A long manufacturing process would 
generate high production and quality control costs consistently affecting the price of the final 
product and its chance to be reimbursed by insurance companies.  The cost of a TEVG will be an 
important indicator of its capacity to penetrate the market, thus becoming available to patients.  
Reproducibility of the TEVG characteristics and functionality is also critical for quality control 
purposes and in order to test and predict clinical outcomes in different patient populations.  
Therefore, research efforts should be focused on a manufacturing process in which most of the 
steps involved in the construction of the TEVG are automatic and user independent.  This is a 
very important consideration especially when dealing with complex bioreactors that require a 
high degree of skill for their use.  From a clinical standpoint, a product’s availability off-the-
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shelf would be the ideal situation mainly because it would be widely accepted by the vascular 
and cardiac surgical community.  Moreover, for the approximate 50% of the patients requiring 
urgent or emergent CABG surgery [139] or for the trauma patients, an off-the-shelf, or more 
feasibly, a short time-frame approach would be the only possible answer.   
Those TEVG approaches using cellular components have intrinsic constraints for their 
complete off-the-shelf availability due to their need for cell isolation and expansion; ideally, they 
should rely on a manufacturing process being completed within the sterile operating room setup 
where the patient’s own cells would be integrated into an off-the-shelf available scaffold before 
the implantation.  This model would require operative infrastructures that are not currently 
implemented in hospitals.  While many within the vascular tissue engineering field believe that 
we are at least a decade away from a complete clinical application of TEVG, some clinical trials 
have already been conducted with promising results.  Shin’oka and coworkers [38, 115] have 
successfully implanted a porous P(CL/LA) scaffold reinforced with an external sleeve of 
nonwoven PGA seeded manually with autologous BMPCs.  The cells were isolated concurrently 
with the procedure to repair single ventricle anomalies using a total cavopulmonary connection.  
They reported eight patients who were asymptomatic and with no need of reoperation at an 
average follow-up of 13 months.  L’Heureux et al. [140] reported six hemodialysis patients with 
failing arteriovenous shunts implanted with autologous TEVGs as arteriovenous graft with a 
follow up of 13 months.  Three of the patients successfully completed the follow-up period with 
no issues, resisting repeated needle punctures.    
These encouraging results provide evidence that although widespread clinical 
applications of vascular tissue engineering may be a long way off, clinical translation of this 
emerging science is clearly feasible. 
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1.10 HYPOTHESIS AND SPECIFIC AIMS 
A critical analysis of the literature with a particular emphasis on the pitfalls that limited the 
positive outcome of previous TEVG approaches led to the formation of the following hypothesis: 
 
Working Hypothesis:  A novel scaffold optimally seeded with stem cells, acutely cultured and 
stimulated in vitro, and ultimately implanted in vivo will remodel into a functional vascular 
tissue.   
 
This hypothesis was addressed in this dissertation by the following specific aims:  
 
Specific Aim 1: Development and optimization a seeding device to rapidly and efficiently 
deliver cells uniformly and reproducibly through porous, tubular scaffolds.  
One of the challenges in the tissue engineering of tubular tissues and organs is 
the efficient seeding of porous scaffolds with the desired cell type and density 
in a short period of time, and without affecting cell viability.  Though different 
seeding techniques have been investigated, a fast, reproducible, and efficient 
bulk seeding method with uniform cellular distribution was yet to be reported.  
The purpose of this aim was to overcome the limitations of the previous 
seeding techniques for porous tubular constructs. 
 
Specific Aim 2: Development of a composite scaffold to mimic the mechanical and structural 
properties of native arteries.  The use for vascular tissue engineering of two 
different types of PEUU scaffolds (TIPS PEUU and ES PEUU) has been 
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previously investigated.  Each of these scaffolds have shown distinct positive 
features such as excellent cell integration upon seeding (TIPS) or excellent 
mechanical properties (ES).  A rationally-guided, hybrid ES-TIPS PEUU 
scaffold was designed and developed to incorporate both these features into the 
same scaffold.  
 
Specific Aim 3: Determination of the ideal acute culture conditions to optimize the construct via 
cellular proliferation, migration, and spreading.  Upon seeding, the TEVGs 
require a transitional quasi-static culture period before any flow or mechanical 
force can be applied.  The purpose of this aim was to investigate the ideal 
culture protocol to consistently achieve a completely populated and 
undifferentiated stem cell-based construct suitable for in vivo implantation.       
 
Specific Aim 4:  Assessment of the remodeling, patency, phenotype, and mechanical properties 
following in vivo remodeling.  Natural mechanisms of vascular healing and 
remodeling are the results of the synergistic action of multiple biochemical 
and biomechanical factors.  We have adopted a “black box” approach to 
evaluate the final result at different time points rather than establishing a 
mechanistic model of remodeling which was beyond the scope of the current 
dissertation. 
 
In this research work, we have explored a multidisciplinary framework incorporating 
adult stem cells, biomaterial technologies, a novel seeding device, and preclinical animal studies 
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to develop and test TEVGs.  The aforementioned framework was rationally designed and 
oriented to meet clinical translation criteria (described in Section 1.9) with respect to the TEVG 
fabrication time frame, reproducibility, and practical feasibility.  The goal of the proposed 
research was to develop a viable and functional TEVG in time periods compatible with the 
clinical practice.  Therefore, the following dissertation can be considered a translational (or 
applied) research project involving a wide variety of research disciplines and subjects.  
Naturally, many points of this work have been carried out deliberately refraining from 
establishing mechanistic bases of functioning.  In many circumstances, only an observational 
(“black-box”) approach has been pursued, thus introducing several limitations to the study.  
The following two chapters (Chapter 2 and 3) will explore the development of several 
versions of a seeding device for porous tubular scaffolds (Specific Aim 1), which can be 
considered the pillar of this research endeavor and the basis for a possible future commercial 
venue for the development of a TEVG.  Chapter 4 will focus on the development of the ES-
TIPS PEUU scaffold (Specific Aim 2) with a particular emphasis to its mechanical 
characterization in comparison with its two single components (TIPS and ES PEUU) and native 
blood vessels.  Chapter 5 will describe the interactions between cells (MDSCs) and PEUU-
based scaffolds within dynamic culture conditions (Specific Aim 3).  The chapter will also cover 
the development and testing of a novel perfusion bioreactor.  Chapter 6 will be dedicated to the 
in vivo preclinical studies (Specific Aim 4) performed in rats (allogeneic approach), while 
Chapter 7 will describe the pilot study perfomed in pigs (autologous approach).  The chapter 
will also mention about the isolation of a heterogeneous population of adult stem cells derived 
from the striated muscle of pigs.  Finally, Chapter 8 will draw conclusions from the results 
obtained in each specific aim, describing the advantages and limitations of each, and propose 
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future directions and improvement of the technologies based on lessons learned from this 
dissertation work.  
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2.0  SPECIFIC AIM 1, PART 1: DEVELOPMENT OF A SEEDING DEVICE FOR 
TUBULAR SCAFFOLDS 
The seeding of porous scaffolds is a fundamental part of our tissue engineering paradigm, and 
should comply with a number of requirements.  For example, tissue engineered scaffolds should 
be uniformly bulk-seeded with cells to promote rapid, homogeneous, full-thickness tissue 
formation.  A homogeneous cell distribution is critical since regions in which cells are not seeded 
will likely have a delay in tissue formation and remodeling.  In addition, if used as a vascular 
graft, the luminal surface of an engineered tubular construct should ideally be lined with a 
confluent endothelial layer to inhibit thrombosis and maintain graft patency.  When cell 
availability is an issue (e.g., when autologous differentiated cells are used), it is necessary to seed 
the scaffold with a high efficiency in order to deliver the highest percentage of the initial cell 
count used.  Finally, to be clinically viable, a tissue engineered construct should be fabricated in 
a minimal amount of time and in a reproducible and user-independent fashion. 
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2.1 INITIAL DESIGN OF A VACUUM SEEDING DEVICE FOR TUBULAR 
SCAFFOLDS  
2.1.1 Design principles 
The initial design of a novel device to incorporate cells into the wall of tubular scaffolds was 
focused on two main design criteria: rapid bulk cellular integration and seeding uniformity.  The 
need for rapid cell penetration into the wall of a porous conduit suggested the need for a 
transmural flow of a cell suspension through the scaffold wall.  In this way, the cells are 
transported into the bulk of the material along with the liquid solution, and the resulting scaffold 
acts as a filter for the seeding suspension (i.e., the scaffold retains cells within its pores via the 
process of cell suspension filtration).  This filtration process makes the seeding outcome 
intrinsically correlated to the physical and structural characteristics of the scaffold (e.g., 
hydrophilicity, permeability, porosity, pore size, etc.).  A seeding process utilizing a filtration 
mechanism inherently requires a permeable scaffold to allow for transluminal flow.  Creation of 
a transmural flow across a permeable media (filter) requires a transmural pressure gradient.  The 
vacuum applied downstream to a filter creates a positive pressure gradient upstream to the 
porous media, thereby inducing a movement of fluid across the filter.  This method is commonly 
used in a variety of laboratory applications such as bottle-top filter devices for the sterilization of 
fluids, or DNA purification columns.  The same concept has been described in literature for 
surface cell seeding of mostly flat scaffolds [141, 142], but also commercially available vascular 
grafts [110].  
Inducing a transmural flow through the wall of a porous tubular scaffold with the 
specification of uniform distribution of the flow rate along the longitudinal and circumferential 
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directions is not a trivial task.  To address these challenging specifications, it was proposed to 
apply the vacuum externally to the tubular scaffold while the liquid cell suspension was fed 
internally via two opposite tees connected to syringes.   
2.1.2 First prototype and bench-top testing 
The first prototype of vacuum seeding device (Figure 2.1) served as a proof of concept, and 
consisted of an airtight chamber modified from a previously developed tissue housing chamber 
for vascular segments and two stainless steel (SS) tees, each connected distally to a 5 mL syringe 
filled with a seeding suspension.  An additional 30 mL syringe filled with saline was connected 
to one tee via a three-way stopcock (along with one of the two seeding syringes) with the 
purpose of flushing the remaining luminal seeding suspension throughout the scaffold wall at the 
end of the seeding process.  The syringes were used as collapsible containers to allow for passive 
withdraw of the fluid contained within upon application of vacuum inside the chamber. 
Several bench-top tests of the first working prototype allowed for a better understanding 
of the seeding mechanisms and to troubleshoot several issues related to the initial design of the 
vacuum seeding device.  The lesson learned from these initial experiments was paramount for 
the development of the first generation of the functional seeding device later described in 
Section 2.2. 
The application of a negative pressure inside the chamber directly from the laboratory 
vacuum line (as shown in Figure 2.1A) induced a passive withdraw of seeding suspension from 
the two seeding syringes and its exudation throughout the scaffold wall, as expected.  The flow 
rate across a porous media is normally described by the Darcy’s law, given here in its extended 
form as: 
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Δ−= 2-1 
 
where A is the exudation area, α is the permeability of the porous media, ΔP is the pressure 
gradient across the porous media, μ is the dynamic viscosity, L is the thickness of the porous 
media, and n is the porosity. 
 
 
 
 
Figure 2.1  First working vacuum seeding device prototype.  A.  The device consists of an airtight chamber directly 
connected to the laboratory vacuum line.  The chamber holds two aligned tees connected to two seeding and one 
flushing syringe.  A lid with an intermediate rubber gasket is secured via thumb screws (not shown) to retain the 
internal pressure.  B.  The tubular scaffold is reversibly secured internally to the chamber to the two opposite tees 
via silk suture ligations allowing for exudation of the seeding suspension throughout its wall.  The chamber acts also 
as a reservoir to recollect the exuded seeding suspension for cell counting purposes to measure seeding efficiency.  
Seeding efficiency is defined as the ratio between the number of cells recollected into the chamber and the number 
of seeded cells.  
 37 
However, the presence of the seeding syringes upstream to the flow path in the first prototype 
did not allow this formula to correctly model the flow rate for a given ΔP.  This effect was due to 
the energetic cost required to overcome the drag force necessary to move the syringe rubber 
piston.  This force has different values depending on the size and type of syringe used.  
Therefore, Equation 2-1 grossly overestimates the flow rate throughout the porous media in 
such a case.  Note that the pressure gradient across the porous wall is equal to the applied 
vacuum inside the chamber (i.e., “downstream pressure” = vacuum level, “upstream pressure” = 
atmospheric pressure).   
Additionally, the absence of a regulator system for the vacuum was causing the seeding 
flow rate to be too high since the chamber was directly connected with the maximum available 
vacuum level (usually ~ -30 inHg (-760 mmHg)) from the laboratory vacuum line.  Therefore, 
the need for an external vacuum regulator system was evident.  For this purpose, a regulator 
circuit was designed and built (see Figure 2.2).  The circuit consists of a multi-turn needle valve 
(Cole-Parmer, Vernon Hills, IL) acting as a flow regulator connected in series to the circuit, a 0.2 
μm ePTFE filter (Acro® 50, Pall Corporation, East Hills, NY) placed in parallel to the circuit, a 
digital vacuum gauge (ACSI, Irvine, CA), a switch represented by a three-way stopcock, and a 
quick-disconnect tube coupling with shut-off valves (McMaster-Carr) to rapidly connect and 
disconnect the circuit to the seeding chamber.  All the components are connected to each other 
and to the laboratory vacuum line via polyvinyl chloride (PVC) tubing.  The vacuum regulator 
circuit takes advantage of flow-dependent, localized pressure losses into the flow regulator valve 
and into the ePTFE filter to reduce the level of available vacuum into the seeding chamber.  The 
reduction of the vacuum level is created by inducing a flow of air moving from the ePTFE filter 
outlet into the vacuum line (dashed arrows in Figure 2.2), leading to a controllable pressure loss.  
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The vacuum level can be adjusted with the flow regulator and observed with the vacuum gauge 
while the downstream switch is in an off position.  Immediately after the switch is turned on, a 
transient flow of air (dotted line in Figure 2.2) is mobilized from the chamber to the vacuum line 
until a steady vacuum level (equilibrating the vacuum level previously selected with the switch 
in its off position) is reached into the chamber.  The recorded vacuum range for the developed 
vacuum regulator circuit was 0 to -16 inHg obtained with either a fully closed or open regulator 
valve.  The flow rate inside the chamber for different levels of vacuum was recorded by 
measuring the time necessary to release 10 mL of water from the two 5 mL syringes with 
increasing levels of vacuum from -1 to -8 inHg (Figure 2.3). 
 
 
 
 
Figure 2.2  Vacuum regulator circuit.  By increasing the level of closure of the needle valve (flow regulator), it is 
possible to increase the localized pressure drop across it (reducing the flow of air) leading to a reduction of available 
vacuum in the chamber.   
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 Figure 2.3  Flow rate generated inside the vacuum seeding device for different levels of vacuum.  The data 
represented was obtained with the same TIPS PEUU scaffolds used in the initial seeding experiments. 
 
 
 
While developing the first prototype, it was also determined that there was need for 
scaffold adaptors for a rapid and effective connection and disconnection of the tubular scaffolds 
to the two tees without the use of a direct suture ligation.  The purpose was also to limit the 
direct handling of the scaffold with surgical instruments after seeding to avoid squeezing of the 
porous matrix and accidental cell loss.  To this end, adaptor tips were designed and built by 
modifying common micropipette tips (Figure 2.4).  The distal end of the conical micropipette tip 
was cut with a razor to enlarge its opening.  Polypropylene tubing (Intramedic) was pressure-fit 
inside the central channel by pulling a guiding silk suture string through it (Figure 2.4B) which 
was previously ligated to the tip of the small tubing.  The scaffold ends were subsequently 
ligated to two custom tips with silk suture strands.  Before applying the sutures, a SS wire was 
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inserted into the channel of the custom-made tips to avoid the collapse of the tubing while 
tightening the knots.  The concept of tee adaptor was applied to a large variety of scaffold sizes 
with several different design modifications covering a wide range of tube IDs (1-25 mm).  An 
example of a custom made adaptor used to seed a large diameter scaffold (see Section 2.2.6.1) is 
shown in Figure A.1. 
 
 
 
 
Figure 2.4  Adaptor tips fabrication for scaffold ID of ~1 mm.  A. The pipette tip was cleaved with a razor.  B.  A 
silk strand was used as a guide to pull and pressure-fit an internal small tubing.  C.  Appearance of the completed 
custom-tip.  D.  The scaffold attached to two tips for a rapid connection/disconnection to the seeding tees.  
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 2.1.3 Seeding testing 
The first seeding experiments (Figure 2.5) were performed using the vacuum regulator circuit 
(Figure 2.2) and custom-made adaptors (Figure 2.4).  The device was sterilized prior to seeding 
by ethylene oxide (EtO) gas diffusion for 16 hours (Andersen Product Inc.).  The scaffolds used 
for the initial testing were porous PEUU obtained via TIPS [53] (Length = 2.5 cm, ID = 3.3 mm, 
thickness = 1 mm; see Chapter 4 for a detailed description of this scaffold).  
Rat bone marrow derived progenitor cells (rBMPCs) were isolated using a previously 
reported technique [143].  Briefly, the bone marrow obtained from the femurs of Sprague-
Dawley rats was mixed in a 1:1 volume with Dulbecco’s modified Eagle’s medium (DMEM) 
(Sigma), supplemented with 10% fetal calf serum (FCS) (Gibco, Invitrogen Corporation) and 1% 
penicillin/streptomyocin (P/S) (Gibco, Invitrogen Corporation), filtered with a 70μm cell strainer 
filter (BD Biosciences) and centrifuged at 1000 rpm for 5 min.  The resulting cell pellet was 
resuspended and the cells were plated in 175 cm2 flasks and cultured for 7 days at 37°C in 5% 
CO2.  After 7 days of culture, non-adherent cells and floating debris were removed, and the 
remaining rBMPCs were then expanded to the required cell number for each seeding experiment.  
Cells were suspended in DMEM supplemented with 10% FCS and 1% P/S.   Initial seeding 
assessment was performed by seeding three tubular scaffolds with 2 million rBMPCs, each 
suspended in 10 mL of culture media.  The vacuum level applied to the chamber was -5 inHg.  
Immediately after seeding, each scaffold was cultured in static conditions for 2 hours, and then 
fixed in 4% paraformaldehyde for 1 hour.   
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 Figure 2.5  Initial seeding experiments performed with the first prototype of vacuum seeding device.  The process 
was performed under a laminar flow hood to avoid contamination (A).  Note the pinkish color of the scaffold (B) 
(cell culture media) following seeding due to the transmural flow of cell suspension. 
 
 
 
After washing in phosphate buffered saline (PBS) and overnight immersion in 30% sucrose 
solution, the specimens were embedded in tissue freezing medium (TBS, Triangle Biomedical 
Sciences, Durham, NC) and sectioned with a cryostat (Cryotome, ThermoShandon, Pittsburgh, 
PA).  The 10-μm sections were stained with the nuclear stain DAPI (bisbenzimide, Sigma) for 
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one minute.  The sections were observed via epifluorescence microscopy using an Eclipse E800 
(Nikon, Melville, NY) with a UV filter.  
Simple qualitative assessment of the seeding results (Figure 2.6) suggested an imbalance 
between the amount of cells seeded in the two hemi-cylinders of the scaffold (top and bottom), 
likely due to a cell sedimentation effect induced by gravity.  Therefore, a basic image-based 
quantification of cell nuclei was performed via ImageJ software (NIH, Bethesda, MD) 
demonstrating that the bottom of the scaffold was receiving 60.8±2.9% of the total cell number 
compared to the 39.2±2.9% (mean ± standard deviation, n = 3) incorporated in the top half. 
Additional important observations were made following the initial seeding experiments.  
First, the two seeding syringes were not synchronous during the seeding.  In particular, one of 
the two syringes started and almost completed its run before the second syringe started its 
release, jeopardizing the symmetry of the outflow from the two tees and theoretically, the 
longitudinal uniformity of cell distribution.  Second, the flow rate of the seeding suspension for a 
determined vacuum level and for a given pair of syringes was not consistent (the average flow 
rate was calculated dividing the total volume of seeding suspension by the time necessary to 
complete the release of seeding bolus from both the syringes).  Both these effects were 
unpredictable, and presumably due to slight differences in the resistance that the rubber tip of 
different syringe pistons were exerting on their relative internal plastic syringe body.   
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 Figure 2.6  Representative section showing nuclear stain following seeding with the first seeding device.  The 
picture was inverted to increase the contrast.  The external and internal scaffold perimeter was highlighted 
artificially in black.  Note a qualitative increase in cell number in the lower portion of the scaffold due to cell 
sedimentation.  The arrow indicates the gravitational axis during seeding. 
 
 
 
A lower resistance of one of the two syringes would explain the earlier cell suspension release 
starting by upon application of vacuum inside the chamber.  Moreover, an average increase in 
resistance in a given pair of syringes used for one seeding would result in a lower average flow 
rate compared to another pair of syringes with less average resistance for a given vacuum level 
inside the chamber, affecting the reproducibility of seeding.  Both of these relevant shortcomings 
were the result of the use of the vacuum as the sole driver for the flow of seeding suspension 
released from syringes.  
It was clear that the first prototype of the seeding device required additional 
modifications to improve the seeding capabilities and the reproducibility of the seeding.  In 
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particular, the issue of cell sedimentation in the lower half of the scaffold (qualitatively shown in 
Figure 2.6) suggested the use of a rotating scaffold around its longitudinal axis while the seeding 
suspension was released throughout its wall.  Moreover, the variability in flow rate from the 
syringes for a given level of vacuum suggested the use of a precision syringe pump to 
reproducibly control the flow rate of the seeding suspension for each seeding process.   
The incorporation of these two additional features driven by rationally- and empirically-
based criteria applied to the design of an initial vacuum seeding device led to the fabrication of 
the first generation of a rotational vacuum seeding device (RVSD) as described in the following 
section. 
2.2 FIRST GENERATION OF RVSD 
The RVSD was designed to take advantage of the synergistic actions of the vacuum applied 
inside the chamber and the flow generated by a syringe pump to induce a transmural flow 
through the porous polymer scaffold wall.  During this phase, the cells infused by the syringe 
become entrapped within the pores of the scaffold while the liquid phase of the cell suspension 
exudes through its wall.  The tubular scaffold simultaneously rotates around its longitudinal axis 
during the seeding in order to increase the uniformity of seeding along its circumferential 
direction. 
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 Figure 2.7  Operating principle of the seeding technique.  A transmural flow is induced by an external vacuum and 
intraluminal infusion of a cell suspension.  The porous nature of the scaffold allows for the liquid phase to exude 
through while the cells become entrapped in the pores.  Rotation is employed to yield a uniform circumferential 
seeding distribution.  Image from [55]. 
 
 
 
2.2.1 Chamber design 
Several incremental steps were performed to complete the transition between the very first 
prototype described previously (Figure 2.1) and the final, functional prototype of first generation 
of RVSD.  Most of these steps consisted in replacements of used materials or components, or in 
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the custom-modifications of determined parts.  Therefore, for brevity, while describing the first 
generation of RVSD, only the final materials and components used will be described here.  
The creation of the first RVSD required the design of several custom-made components.  
The design and drawing of all the parts was made with Solidworks 2005 software (Solidworks 
Corp., Concord, MA).  Drawings are shown in APPENDIX A.   A new airtight chamber 
(internal dimensions: 10x3x5 cm, Figure A.2) was machined with a computer-controlled milling 
machine from a solid block of cast acrylic.  A cast acrylic top lid was created for the chamber 
(thickness = 5 mm, Figure A.3) and secured to its top opening via 8 SS thumb screws 
(McMaster-Carr) and an intermediate rubber gasket laid on top of the chamber aperture to avoid 
pressure loss during seeding.   
A cast acrylic sheet (45x30x1.5 cm) was used as a base for the RVSD.  Feet (5x5x2 cm) 
made of cast acrylic were solvent-welded with methylene chloride (Sigma) to each of the four 
corners of the base (Figure A.4).  Two threaded holes were made in the chamber in order to 
allow for horizontal placement of two identical, coaxial SS tees (OD = 6.35 mm, ID = 2 mm, 
length = 10 cm, Figure A.5) by means of two intermediate sealed joints.  These joints were 
obtained by modifying SS Yor-Lock compression tube fittings (male pipe adapter, McMaster-
Carr) by removing the internal double-sleeve, and machining a bore (Ø = 6.4 mm) throughout 
the main body of the adapter (to remove the default internal step), enabling its use as a sleeve 
bearing for the rotating SS tees.  An airtight seal between the sleeve bearing and the rotating tee 
was obtained by inserting a fluoroelastomer V-ring seal (SKF, Göteborg, Sweden) between the 
body of the tube fitting and its back nut.  PTFE grease (Magnalube-G, Saunders Enterprises, Inc., 
Long Island City, NY) was used to lubricate the custom sealed sleeve bearings and the rotating 
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tees (shafts).  The sealed joints were screwed into the threaded hole made in the chamber and 
allowed for the rotation of the tees across the wall of the acrylic chamber without pressure loss.   
The two tees were coupled inside the chamber by a custom-built SS 316L torque 
transmission device (Figure A.6 and Figure A.7) transferring the rotary movement from an 
externally rotated tee (“Driving Tee”) to the other (“Driven Tee”) (Figure 2.8 and Figure 2.9).  
This component creates a mechanical connection between the two tees by expanding them 
peripherally to its axis leaving a central gap between the two tees (where the scaffold can be 
connected).  The torque transmission was provided to the tees via two opposite SS socket set 
screws for each side.  Another threaded hole was made laterally in the chamber wall to host a 
nylon barbed port to connect the chamber to the laboratory vacuum line via the described 
vacuum regulation system (Figure 2.2).  The goal of the regulator was to maintain a constant and 
controllable negative relative pressure inside the chamber.   
A precision aluminum timing belt pulley (SDP/SI, New Hyde park, NY) was mounted on 
the Driving Tee and driven by a polyurethane/kevlar timing belt (SDP/SI, New Hyde park, NY) 
by an identical pulley mounted on the shaft of a base mount geared AC motor (Rex Engineering, 
Titusville, FL).  The tees were connected distally, outside the chamber, to hydraulic rotating 
joints (Deublin Co., Waukegan, IL) via Kynar® compression tube fitting adapters (McMaster-
Carr).  The rotating joints were mounted with a barbed port and connected via PVC tubing to 
syringes mounted onto a programmable precision syringe pump (Model: PHD 22/2000, Harvard 
Apparatus Inc., Holliston, MA).  Each RVSD inlet port was provided with a disposable shut-off 
valve (Clearlink Luer Activated Valve, Baxter) to prevent loss of fluid from the RVSD when 
syringes were not connected.  The rotating joints allowed for the uninterrupted flow of seeding 
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suspension from a stationary tube to a rotating tee without pressure loss or seeding suspension 
spills.   
The RVSD chamber mounted with all its components was fixed to its base via two 
custom-made Delrin® mounting towers for the rotating joints (Figure A.8), and anchored to the 
RVSD base via thumb screws.  The mounting towers provided a circular socket for the rotating 
joints to be laid on and to be firmly held by a semicircular cap tightened by knurled thumb 
screws (Figure A.9).  Both mounting towers were provided with two 3 cm-long tracks to enable 
their translation on the RVSD base to modify the distance between the two tees when seeding 
different scaffold lengths.  The chamber was aligned to the base via two machined cone-shaped 
Delrin® pins secured onto the base and matching two holes on the bottom of the RVSD chamber.  
Figure 2.8 provides an expanded schematic of the first generation of RVSD, while Figure 2.9 
shows most of the technical features described above.  
  The RVSD was subsequently tested to demonstrate its fluid dynamics performance and 
its cell seeding capabilities.  The following paragraphs will provide a comprehensive description 
of such testing. 
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 Figure 2.8  Schematic of the RVSD.  A cell suspension is infused intra-luminally into both ends of a porous tubular 
scaffold by means of a syringe pump.  Applied vacuum in the chamber fosters the radial exudation of the liquid 
phase of the cell suspension across the thickness of the polymer.  An electrical motor rotates the construct, 
promoting a homogeneous distribution of cells around the circumference.  Image from [55]. 
 
 
 
2.2.2 Fluid dynamic modeling 
2.2.2.1 Methods 
The computational fluid dynamics (CFD) software Fluent (version 6.2, Fluent Inc., Lebanon NH) 
was used to calculate the fluid shear stresses acting on the cells in the lumen of the rotating 
scaffold and to visualize the complex internal fluid dynamics during seeding.   
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 Figure 2.9  RVSD under a laminar flow hood during a seeding process. 
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For this purpose a 4.5x105 wedges volume mesh was created (Gambit 2.2, Fluent Inc., Lebanon, 
NH) with boundary layers on the luminal surface of the area of interest (scaffold lumen).  The 
model consisted of a series of adjacent cylinders modeling the fluid domain of the two tees and 
the lumen of the central scaffold.  The fluid domain of the scaffold lumen was surrounded by an 
external, concentric tube representing the scaffold Figure 2.10.   
 
 
 
 
Figure 2.10  3D Mesh used during the CFD analysis.  A.  Perspective of the whole fluid domain including the two 
tees and the central scaffold.  B.  Close-up of the boundary layer used to model the transition between the lumen of 
the scaffold and its wall.  
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The tubular volume of the scaffold was modeled as a “porous medium” which is an 
implicit function provided by the software.  This function adds a local energetic loss.  
Analytically, this model introduces an additional source of momentum to the Navier-Stokes 
equations, which describe the motion of fluids.  This consists of two terms, a viscous loss and an 
inertial loss, which are completely described as [144]: 
 
2-2 
 
where Si is the additional source of momentum for the i-direction, µ is the dynamic viscosity of 
the fluid, vj is the j component of the fluid velocity, ρ is the desity of the fluid,  and Dij and Cij are 
components of defined matrices representing the 3D components of permeability and inertial 
resistance, respectively.  This term of loss contributes to the resolution of the pressure gradient 
within the cells defined as “porous media” with a linear and second-order proportionality to the 
velocity of the fluid crossing those elements.   In case of homogenous porous media, the matrices 
D and C are diagonal with 1/α and C2, respectively on the diagonals and zero for the other 
elements.  Equation 2-2 becomes: 
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where α is the permeability of the porous media and C2 is a term representing the inertial loss.   
In the case of laminar flow, the pressure loss is typically proportional to the velocity of the fluid 
crossing the porous media, and the constant C2 can be considered negligible.   
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Finally, ignoring the convective acceleration and the diffusive terms due to the low velocities 
involved, the Navier-Stokes equation becomes the Darcy’s law which describe the flow of a fluid 
through a porous media: 
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The software uses this equation for each of the three directions associated to the porous volume. 
Equation 2-4 in a finite form becomes:  
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where i = x,y,z, the terms 1/αij are the elements of the matrix D, μ is the dynamic viscosity, vj are 
the components of the velocity vector, and Δni  are the thicknesses of the “porous” elements in 
the three directions.   
The permeability α of the polymer scaffold was calculated empirically using Darcy’s law 
by measuring the average pressure loss per unit of surface area of the scaffold for a set exudation 
rate of saline (flow rate = 16 mL/min, n = 3).  A simple circuit was created by connecting a 
syringe to the scaffold via tubing and a tee, and clamping the scaffold downstream with a 
surgical clamp.  The set flow rate was produced via a precision syringe pump (Model: PHD 
22/2000, Harvard Apparatus Inc., Holliston, MA), and the resulting pressure was monitored via 
an in-line pressure transducer (model TJE, Honeywell Sensotec, Columbus, OH).  The 
dimensions of the scaffold were measured via a digital caliper (Fisher Scientific) to calculate the 
luminal area of the internal surface (with the assumption of homogeneous exudation flow rate 
within the internal surface of the scaffold).  The dynamic viscosity μ of the cell suspension was 
vp α
μ−=∇
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measured with a capillary viscometer (Cannon-Manning, Cannon Instruments Company, State 
College, PA), and a rheologic curve was generated with a digital cone and plate rheometer (DV-
III, Brookfield Engineering Labs, Middleboro, MA) in order to demonstrate the Newtonian 
properties of the fluid under shear rate ranges obtained with the device.  Both measures were 
performed at 21ºC, consistently with the conditions used during seeding.   
The CFD simulation was performed assuming steady state conditions.  The solver was 
segregated with implicit formulation and SIMPLE pressure-velocity coupling.  A spatially 
uniform velocity (corresponding to a flow rate of 8 mL/min for each tee) was assigned to the two 
tee inlets with 10 diameters of flow extension to allow for complete flow profile development.  
The rotation of the tees and the scaffold around their longitudinal axis was simulated with a 
moving mesh function (rotational speed = 350 rpm).  Convergence of the solution was 
demonstrated with residual values ≤ 10-4, and confirmed with the stability of two surface 
monitors (the average absolute pressure on the outlet surface and the average velocity on the 
interior surface).  The outlet (outer surface of the scaffold) was modeled with a constant negative 
pressure equal to the vacuum pressure inside the chamber (-5 inHg).  The wall shear stress 
(WSS) on the luminal surface of the model was determined during post-processing by the 
software, while the WSS acting on the scaffold pores was estimated analytically.  In brief, the 
conservation of momentum in laminar flow conditions was considered for a rigid, cylindrical 
pore and modified with the Hagen-Poiseuille equation for a determined pressure drop [121].  The 
resulting equation for the WSS is: 
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where Q is the flow rate in the pore, μ the dynamic viscosity, and R the pore radius, which was 
taken as 10 μm (consistent with the smallest pores of the porous polymer).  The flow rate in the 
pore was set by considering the total flow rate entering the scaffold (from both tees) divided by 
the effective open area of the luminal surface of the scaffold (effective open area = porosity x 
internal luminal cylindrical area) multiplied by the average pore area, with the assumption of 
even distribution of the inlet flow rate in the porous luminal surface of the scaffold.   
2.2.2.2 Results 
The permeability of the polymer scaffold used for seeding was found to be 2.6±0.2x10-13 m2, 
while the dynamic viscosity was found to be 1.03 cP.  The cell suspension was found to be 
approximately Newtonian due to its relatively flat rheological curve (Figure 2.11).  
The density of the fluid was proportionally calculated for a 10% serum (1025 kg/m3) 
solution in culture media (1008 kg/m3) and determined to be 1010 kg/m3 (i.e., density of fluid = 
1/10 · density of serum + 9/10 · density of culture media).  
  The wall shear stress distribution on the luminal surface of the CFD model was 
negligible (i.e. < 1 dyne/cm2).  The calculated wall shear stress in the representative smallest 
pore diameter was 5.4 dyne/cm2.  The CFD simulation also described the pathlines of the seeding 
suspension during seeding (Figure 2.12).  The liquid suspension starts to twist inside the tees 
due to the viscous transfer of momentum to the fluid from the rotating walls.  Once entered the 
rotating scaffold lumen the cell suspension starts to expand toward the scaffold wall and to 
gradually exude throughout the entire length of the scaffold.  
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 Figure 2.11  Rheological curve measured for the seeding suspension at 21ºC.  Note the near-Newtonian behavior of 
the fluid. 
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Figure 2.12  Pathlines of the fluid flow into the RVSD obtained via CFD.  The sequence was obtained by releasing 
pathlines from the two surfaces representing the tee inlets within a total timeframe of 1.33 seconds.   
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2.2.3 Bulk seeding performance 
2.2.3.1 Qualitative and quantitative assessment of bulk seeding 
The performance and reproducibility of the RVSD was qualitatively and quantitatively 
investigated.  The scaffolds used for the bulk seeding experiments (porosity 90%, pore size range 
10-200 μm) were prepared via TIPS processing of PEUU as previously described [53] to 2 cm 
length, 4.0 mm ID, and 200-300 μm wall thickness.  Two different cell types were used in this 
evaluation.  Murine muscle-derived stem cells (MDSCs) obtained from the laboratory of Dr. 
Johnny Huard via an established pre-plating technique [99] were cultured and seeded in DMEM 
(Sigma) supplemented with 1% P/S (Gibco, Invitrogen Corporation, Carlsbad, CA), 10% FCS 
(Atlanta Biologicals, Norcross, GA), and 10% horse serum  (HS; Gibco, Invitrogen 
Corporation).  rBMPCs isolated as previously reported [143] were cultured and seeded in 
DMEM (Sigma) supplemented with 10% bovine serum (Gibco, Invitrogen Corporation) and 1% 
P/S (Gibco, Invitrogen Corporation).   
Qualitative evaluation of the seeding was performed by seeding three TIPS tubular 
scaffolds with 10x106 rBMPCs or MDSCs suspended in 10 mL of culture media using a flow 
rate of 6.8 mL/min (the flow rate in the RVSD is referred to each syringe; therefore, the total 
flow rate exuding through the scaffold is 2·Q), a rotation speed of 120 rpm, and an applied 
vacuum of -5 inHg.  These parameters were chosen empirically by a qualitative assessment of 
the seeding suspension exudation patterns during seeding (data not shown).  The total seeded cell 
number was obtained by multiplying the cell density of the seeding suspension by the set seeding 
volume (volume released by the syringe pump in each seeding).   
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Immediately after seeding constructs were removed from the RVSD and left in static 
culture for two hours.  The samples were fixed in 4% paraformaldehyde for 1 hour and 
subsequently washed in PBS.  After embedding a small ring of each construct in tissue freezing 
medium (TBS, Triangle Biomedical Sciences, Durham, NC), the specimens were frozen and 
sectioned (thickness = 10 μm).  Sections were stained for cytoskeleton (F-actin) by 
permeabilizing in Triton-X-100 solution (Fisher Scientific, Fair Lawn, NJ) for 15 minutes, and 
incubating with 1:250 dilution of phalloidin conjugated to Alexa 488 (Molecular Probes, Eugene, 
OR) for an hour in a moist chamber to prevent drying of the samples.  Unbound phalloidin was 
removed by subsequent washes in PBS.  The sections were then counterstained with the nuclear 
stain DAPI (bisbenzimide, Sigma) for one minute and mounted in gelvatol.  The sections were 
observed via epifluorescence microscopy using an Eclipse E800 (Nikon, Melville, NY) with UV 
filter for the DAPI stain and with FITC filter for the phalloidin stain. 
Quantitative evaluation of the seeding was performed by calculating the seeding 
efficiency of seeded scaffolds and also via the two dedicated experiments described below.  The 
seeding efficiency (percent of the total number of cells incorporated into the scaffold) was 
calculated by determining the cell count in the seeding solution after seeding using a 
hemocytometer, and comparing to the cell count prior to seeding. 
The first experiment was designed to assess the cell distribution along the longitudinal 
direction of the scaffold.  For this, 15x106 MDSCs were suspended in 20 mL of culture media (2 
10mL syringes) and infused into TIPS tubular scaffolds (n = 6, flow rate = 8 mL/min, rotation 
speed = 350 rpm, vacuum = -5 inHg).  The increased flow rate (compared to the previous 
qualitative testing) was chosen to guarantee a good longitudinal ejection of seeding suspension, 
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while the increased rotational velocity was similarly chosen to improve the circumferential 
uniformity of seeding. 
After seeding, each construct was kept for two hours in static culture and subsequently 
cut into 9 serial equi-sized rings.  Each ring underwent metabolic-based cell counting (MTT) as 
described below, in order to measure the cell number in each ring and, therefore, in each 
longitudinal location of the seeded constructs.  Those rings from the bulk seeding experiments 
dedicated for viability and cell number analysis were placed in 200 µL of media supplemented 
with 20 µL of MTT solution [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
(Sigma) into a single well of a 96 multiwell plate immediately after culture.  The specimens were 
kept for 4 hours at 37°C.  Samples were then immersed in 200 µL of 0.04 N HCl in 2-propanol 
solution and kept for 24 hours at 4ºC.  The adsorbance was read at 570 nm with a microplate 
reader (model 680, Bio-Rad, Hercules, CA) and normalized to the dry weight of each ring and 
the total cell number in each construct.  The cell number was obtained with a previously derived 
standard curve for the cell type of interest.  Statistical analysis of the data, as described below, 
allowed assessment of the uniformity of the longitudinal distribution of cells in the constructs 
and the reproducibility of the device.  
The second experiment was designed to assess the cell distribution along the 
circumferential direction.  For this, a single TIPS tubular scaffold was seeded using the same 
conditions as the first experiment described above, cultured, and cut using the same cells, 
conditions and parameters as the first experiment.  However, the construct was slit open with a 
single longitudinal cut in order to identify the relative circumferential position among different 
cross-sections.  Nine total serial rings were processed for nuclear staining as previously 
described in this section.  Each stained section was digitally photographed and reconstructed 
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from 16 consecutive fields of view at 200X.  Subsequently, the images were reconstructed and 
used to generate four composite images representing the four circumferential quadrants (0°-89°, 
90°-179°, 180°-269°, 270°-359°), where the 0°-89° quadrant was the first quarter of the 
circumference clockwise from the longitudinal slit that was cut and so on.  Each quadrant of each 
section underwent image-based quantification of the cell number with an intensity threshold 
filter (Scion Image 4.0, Scion Corporation).  The cell number in each quadrant was assessed by 
dividing the total measured area occupied by the nuclei divided by the average area occupied by 
one nucleus.  This was calculated by averaging the area of 30 different nuclei in a field of view. 
2.2.3.2 Statistical analysis   
The Kolmogorov-Smirnov test (Matlab 7.0) was used to check the normality of the data.  
The Kruskal-Wallis test (Matlab 7.0) was used for assessing longitudinal and circumferential 
uniformity and reproducibility.  To assess longitudinal uniformity, comparisons were made of 
the percentage of total cell number among each longitudinal portion of each seeded construct 
(rows analysis).  For the reproducibility assessment, instead, comparisons were made of the 
percentage of total cell number per general location (any of the 9) among the different seeded 
constructs (columns analysis).  Therefore, reproducibility was considered as the capacity of 
consistently incorporating the same fraction of the total cell number, ideally 1/9 of the total 
available (11.11%).   Finally, to assess circumferential uniformity, comparisons were made of 
the number of cells in each circumferential quadrant of each section used.  
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2.2.3.3 Results 
A representative section of a TIPS scaffold bulk seeded with rBMPCs and stained for cell nuclei, 
1 hour after seeding, is shown in comparison with a native rat aorta in Figure 2.13.  Note the 
similarity in cell distribution and density throughout the thickness.  The MDSCs incorporated 
into the scaffolds maintained a spherical shape two hours after seeding (Figure 2.14) 
demonstrating incomplete cell attachment.  The morphology and spreading of the MDSCs as 
shown here was representative of the other two cell types used.   
The cell seeding efficiency was 77.2±12.5 % in the tested constructs.  The viability 2 h 
after seeding was > 95% of the initial effective cell number incorporated into the scaffold. Each 
seeding procedure took approximately 1–2 min. 
The bulk seeding experiments (n = 6) exhibited a high level of longitudinal uniformity 
represented by the comparison of the normalized average cell number percentage for each of the 
9 longitudinal segments (Figure 2.15, p = 0.99).  The seeding was also reproducible as 
represented by the comparison of the average cell number per longitudinal location among 
different constructs (Figure 2.16, p = 0.24).  The seeded scaffolds also exhibited circumferential 
seeding uniformity based on a similarity in cell numbers in the four quadrants of the seeded 
construct (Figure 2.17, p=0.25). 
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 Figure 2.13  Comparison between the nuclei distribution of a rBMPC-seeded tube and a native rat aorta 1 hour after 
seeding.  The arrows indicate the luminal surface of the conduits.  Magnification = 100X.  Image from [55]. 
 
 
Figure 2.14  MDSC morphology 2 hours after seeding.  Note that the cells still maintain a spherical shape.  The 
arrow indicates the luminal surface of the scaffold.  Blue = nuclei, Green = F-actin, Magnification = 200X.  Image  
from [55]. 
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Figure 2.15  Assessment of longitudinal bulk cell seeding uniformity of MDSCs into 2 cm long TIPS PEUU 
scaffolds.  Top.   Representative nuclear staining of the 9 longitudinal positions of the scaffold (qualitative 
assessment).  Bottom.  Longitudinal cell distribution indicated by the percentage of cells present in each of 9 
longitudinal segments of the seeded scaffolds (mean ± standard deviation; n = 6).  The dashed line shows the ideal 
case of perfect distribution correspondent to the 11.11% of the total cell number included in each longitudinal 
location of the scaffold.  Image adapted from [55]. 
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Figure 2.16  Assessment of reproducibility.  Each of the 6 seeded constructs received the same percentage of total 
cells per average longitudinal location (mean ± standard deviation; n = 9).  The dashed line shows the ideal case of 
perfect reproducibility corresponding to 11.11% of the total cell number included in the average longitudinal 
location of the scaffold.  Image adapted from [55]. 
   
 
 
Figure 2.17  Assessment of circumferential cell distribution.  Average percentage of the total cells included in each 
of the four circumferential quadrants of the scaffold.  The dashed line shows the ideal case of perfect circumferential 
distribution corresponding to 25% of the total cell number included in each quadrant.  Image adapted from [55]. 
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2.2.4 Surface seeding performance 
2.2.4.1 Qualitative assessment of surface seeding 
The scaffold utilized for assessing the surface seeding capabilities of the RVSD was fabricated 
by electrospinning PEUU onto a rotating 3.5 mm SS mandrel to a length of 2 cm, and a wall 
thickness of 200 μm  (porosity 90%, pore size ~5 µm) using a previously described method [57].  
Bovine aortic endothelial cells (bAECs) (Cambrex Corporation, East Rutherford, NJ) were 
cultured and seeded in endothelial microvascular growth media (EGM-MV) (Cambrex).   
The luminal surface seeding capability of the device was tested with dedicated 
experiments where in three 2 cm long, electrospun tubular constructs were seeded with either 
rBMPCs, bAECs, or MDSCs.  The small pore size of the electrospun polymer scaffold prevented 
the passage of cells through the conduit wall but not the passage of the liquid phase, thereby 
allowing for luminal surface seeding.  The constructs were seeded with 8x106 cells suspended in 
20 mL of culture media using the same seeding parameters used for the bulk seeding 
experiments.  A ring of each seeded construct was cut 1 hour after seeding, fixed, and stained 
with nuclear stain, while the remainder was kept for 12 hours in static culture conditions to allow 
the cells to spread on the surface.   
 After 12 hours of static culture, the specimens were fixed in 2.5% glutaraldehyde for one 
hour, washed in PBS and re-fixed in 1% osmium tetroxide (OsO4) for another hour.  After 
multiple washes in PBS the specimens were dehydrated with an ethanol gradient (from 30% to 
100%), and subsequently processed with critical point drying (Emscope CPD 750, Emscope 
Lab., Ashford, UK) with 4 cycles of liquid CO2 soaking and venting at 10ºC before reaching the 
critical point for CO2 at 31.1ºC at 1100 psi.  After complete dehydration the specimens were 
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gold/palladium sputter coated (Sputter Coater 108 auto, Cressington Scientific Instruments Inc., 
Cranberry Twp., PA) with a 3 nm thick layer of gold.  The luminal surfaces in different locations 
of the seeded scaffolds were observed with field emission scanning electron microscopy (SEM) 
(JSM-6330F, JEOL ltd. Tokyo, Japan).  The constructs were then fixed and processed for 
fluorescent markers (F-actin, nuclear staining) and qualitatively analyzed.  Different fields of 
view in the SEM and fluorescence microscopy images were analyzed to provide a qualitative 
assessment of seeding uniformity. The scaffolds seeded with MDSCs were also processed for 
confocal microscopy.  Briefly,  samples were rinsed with PBS, fixed with 4% paraformaldehyde, 
permeabilized with 0.1% Triton x-100 and stained with rhodamine phalloidin (Molecular Probes) 
for F-actin and draq-5 (Biostatus Ltd) for nuclei.  Imaging was done on a Leica TCS-SL laser 
scanning confocal microscope (Leica Microsystems Inc., Bannockburn, IL) acquiring a stack of 
images relative to a 30μm depth from the luminal surface of the scaffolds. 
2.2.4.2 Results 
Shortly after seeding (1 hour), the three electrospun PEUU constructs each seeded with a 
different cell type (rBMPCs, bAECs, or MDSCs) showed an accumulation and passive adhesion 
of cells on the luminal surface (Figure 2.18).  Cells were homogeneously distributed in both the 
circumferential and the longitudinal direction of the constructs (qualitatively assessed only).  
After 12 hours of static culture, the luminal surface was completely lined with spread cells that 
formed a continuous layer on the electrospun polymer (Figure 2.19).  The other three cell types 
similarly covered the luminal surface of the electrospun scaffold after 12 hours of static culture 
(Figure 2.20).  Maximum intensity projection (MIP) image generated from the stack of confocal 
images taken from the MDSC-seeded scaffolds confirmed the spreading of cells Figure 2.21. 
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 Figure 2.18  Accumulation of MDSCs on the luminal surface of the electrospun PEUU 1 hour after seeding.  Cell 
nuclei appear black.  The polymer was visualized under UV light and is artificially indicated by the grey region. 
These results are representative, as those for rBMPC, bAEC are similar.  Magnification = 100X.  Image from [55]. 
 
 
Figure 2.19  MDSCs distribution (blue = nuclei, green = F-actin) on the luminal surface of the electrospun PEUU 
scaffold (red) after 12 hours of static culture.  The arrow indicates the luminal surface of the scaffold.  These results 
are representative, as those for rBMPC, bAEC are similar.  Magnification 200X.  Image from [55]. 
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 Figure 2.20  Representative SEM images of luminally surface-seeded electrospun PEUU scaffolds.  Left.   Low 
magnification.   Right.  High magnification.  A-B.  Control, unseeded scaffold.  C-D.  Seeded BMPCs after 12 
hours of static culture.  E-F.  Seeded bAECs after 12 hours of static culture.  G-H.  Seeded MDSCs after 12 hours of 
static culture.  A-F.  from [55]. 
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Figure 2.21  Confocal microscopy of MDSC-surface-seeded ES PEUU scaffolds.  MIP 3D reconstruction on the 
lumen of the scaffold.  Blue  =  nuclei, green  =  F-actin on the luminal surface of the electrospun PEUU scaffold 
after 12 hours of static culture.  Magnification 200X. 
 
 
 
2.2.5 Summary and limitations 
The compact seeding device developed, combining the synergistic action of vacuum, rotation, 
and flow, was able to produce a rapid, efficient, reproducible, and uniform seeding of tubular 
porous constructs without generating injurious mechanical conditions for the cells.  The analysis 
of the shear stresses generated inside the rotating scaffold during seeding performed with 
computational and analytical tools suggested absence of damaging conditions for the cells.  The 
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metabolic-based viability assay performed after seeding (MTT) confirmed the absence of 
deteriorating conditions for the cells during seeding. 
The quantitative analysis of the RVSD performance described in Sections 2.2.2 and 2.2.3 
was carried out using only a few combinations of relevant seeding parameters (i.e., vacuum 
level, rotational speed, and flow rate) based on empirical observations.  The chosen combination 
of parameters delivered more than acceptable results in terms of bulk seeding uniformity, 
reproducibility, and efficiency (see Section 2.2.3); however, an analytical characterization and 
its empirical validation would provide a better understanding of the functioning of the device, 
and it would possibly lead toward performance optimization.  This concept will be expanded in 
Section 2.2.6. 
A theoretical limitation in the design of the first generation of RVSD is the length of the 
construct suitable for quantitatively uniform longitudinal seeding.  This is not only due to the 
size of the seeding chamber, but also to the physical, structural, and geometrical features of the 
scaffold.  In fact, the seeding process is likely affected by the scaffold characteristics.  This can 
be considered another intrinsic limitation of the current design.  The bulk cell seeding assessment 
was performed using only one type of polymer scaffold (TIPS PEUU) with cell types mostly 
relevant for muscular tube applications; therefore, further experiments are required to 
demonstrate the flexibility of RVSD use for different scaffold materials or tissue engineering 
applications.  We will address these concerns and limitations in the following sections.   
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2.2.6 Additional studies toward functional characterization 
An analytical model of the hydrodynamic forces involved in the cell seeding of TIPS PEUU 
porous scaffolds via the RVSD with and without rotation was implemented to better understand 
the mechanisms behind the seeding process.   
2.2.6.1 Analytical model of the hydrodynamic forces involved in the RVSD operation 
The transmural pressure drop, , across the tubular scaffold wall during cell seeding can be 
estimated by assuming the luminal surface, S, of the TIPS PEUU scaffold made of cylindrical 
pores of average diameter, dp, through which Poiseuille flow of culture media occurs, governed 
by [121]:  
wPδ
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where μ is the dynamic viscosity of the seeding suspension, t is the length of the pore (the 
scaffold wall thickness), and qp is the volumetric flow passing through one pore. qp can be 
estimated by dividing the total flow rate Q infused through the scaffold by the total number of 
pores np (assuming homogeneous distribution of flow within the scaffold) as:   
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where ε is the porosity of the scaffold. Substituting qp into Equation 2-7 results in:  
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If we assume a pore diameter of 20 μm (typical smallest pore size of TIPS PEUU scaffolds), 
then, using the same parameters used for the bulk seeding experiments in Section 2.2.3 (i.e., µ 
= 1.03 cP, t = 250 μm, Q = 16 mL/min, ε = 0.95, S = 2.5 cm2) 
Sd
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p
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μδ 232
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20 dyne/cm2 or 0.02 
mmHg.  In a horizontal tubular scaffold, the hydrostatic pressure variation from the top to 
bottom of the scaffold lumen is given by ρ=δ , where ρ is the density of the seeding 
suspension and Di is the internal diameter of the scaffold.  For Di = 4 mm,  400 dyne/cm2 
or 0.3 mmHg.  With a uniform vacuum imposed on the outside of the scaffold, the large 
intraluminal hydrostatic pressure variation relative to this transmural pressure variation will drive 
a radial perfusion of cell suspension through the tubular porous scaffold.  This perfusion varies 
significantly from the top to the bottom of the lumen, leading in turn to non-uniform cell seeding 
around the circumference of the scaffold as previously observed (see Section 
≈δ hP
cP
2.1.3, Figure 2.6).  
This model underscores the need of rotation during seeding. 
There are two possible mechanisms through which rotating the tubular scaffold can 
improve the uniformity of cell seeding as observed.  First, as initially thought, centrifugal forces 
are generated by rotation and produce circumferentially uniform radial media flow.  For this to 
occur, centrifugal forces would need to create a pressure gradient from the center of rotation to 
the scaffold wall which is large enough to overcome the hydrostatic pressure variation from the 
top to bottom of the tubular lumen (i.e., to render hydrostatic pressure variation negligible 
compared to the centrifugal pressure variation).  The pressure variation due to centrifugal 
forces,δ , is approximately given by (APPENDIX B): 
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where ω is the angular velocity.  For our case this results in ≈δ cP
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15 dyne/cm2 or 0.01 mmHg.  
As this is an order-of-magnitude less than the hydrostatic pressure variation, centrifugal forces 
are unlikely to be large enough to produce a circumferentially uniform radial perfusion of the 
scaffold wall and uniform cell seeding.  Scaffold rotation rates would need to be 10-100 times 
faster to create centrifugal forces that could impact cell media perfusion and cell seeding of the 
scaffold.  
The second possible mechanism underlying the effect of rotation on cell seeding is 
simply that the rotation brings all circumferential sectors of the scaffold wall to the bottom 
position, where gravitationally drive cell media perfusion is predominately occurring.  For this 
mechanism to be effective, the rotation period should be small compared to the time for 
gravitationally-driven flow to occur from the top to the bottom of the tubular conduit.  An order-
of magnitude estimate of the top-to-bottom velocity of gravitational flow is V , L 
being the length of the scaffold, and for the time from top to bottom is .  Using these 
estimates, we the required frequency of rotation would be: 
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For the parameters used in Section 2.2.3  0.8 s-1 or 50 rpm.  The performed bulk-seeding 
study which demonstrated circumferential cell uniformity (Figure 2.17) was performed at an 
even higher rotation speed (350 rpm). 
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If centrifugal forces are not playing a direct role in cell seeding within rotating tubular 
scaffolds (as hypothesized), and if the role of rotation is merely to compensate for the hydrostatic 
variation in luminal pressure and the resulting imbalance in top-to-bottom flow of media, then 
the possibility exists for an alternative approach to bulk cell seeding that could also produce 
circumferentially uniform cell distributions within a tubular porous scaffold.  For example, one 
alternative approach would be if the vacuum pressure is not applied directly to the scaffold, as in 
the current configuration, but through culture media (or an isotonic liquid in general) within 
which the tubular scaffold is submersed (Figure 2.22). 
 
 
 
 
Figure 2.22  Schematic of a cross-section of the tubular scaffold showing the hydrodynamic forces involved in the 
seeding process with (Right) and without (Left) immersion into a liquid media. 
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In this case, the extraluminal liquid will transmit the vacuum pressure to the scaffold but 
will also eliminate a transmural hydrostatic pressure variation.  Thus, in theory, the transmural 
variation in hydrostatic pressure within and outside the tubular scaffold will cancel one another 
and allow a circumferentially uniform transmural pressure and cell media flow to exist across the 
wall of the tubular scaffold.  Such an approach would have the advantage of obviating the need 
for rotation of the tubular scaffold, or at least significantly diminishing the required rate of 
rotation.    
2.2.6.2 Methods for the empirical validation of the analytical model 
Based on the analytical model presented in Section 2.2.6.1, a dedicated experiment was 
conducted to assess the hypothesis of improved circumferential distribution within immersion 
conditions for the scaffold.  To this end, tubular scaffolds (length = 1 cm, ID = 4 mm, thickness 
= 250 μm, porosity = 90%, pore size range = 20-200 μm, permeability = 2.6x10-13 m2) made of 
TIPS PEUU were seeded with MDSCs via the RVSD with four different seeding conditions 
defined as follow: 
  
1. Rot/Dry: Rotation speed = 150 rpm, Vacuum level = -5 inHg, Flow Rate = 2 mL/min, 
seeding chamber dry (currently used configuration). 
2. Rot/Wet: Rotation speed = 150 rpm, Vacuum level = -5 inHg, Flow Rate = 2 mL/min, 
RVSD chamber filled with saline.  
3. Still/Dry: Rotation speed = 0 rpm, Vacuum level = -5 inHg, Flow Rate = 2 mL/min, 
seeding chamber dry. 
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4. Still/Wet: Rotation speed = 0 rpm, Vacuum level = -5 inHg, Seeding Flow Rate = 2 
mL/min, Seeding chamber filled with saline. 
 
Scaffolds (n = 3 per condition for a total of 12 scaffolds) were seeded with ~8x106 MDSCs each 
released from a single 30 mL syringe loaded with a total of 113 million cells suspended in 28 mL 
of media (i.e., each scaffold was seeded/infused with 2 mL of seeding suspension).  After each 
seeding, the syringe was gently agitated to avoid sedimentation of cells on the bottom of the 
syringe and consequent reduction of seeding suspension cell density. 
Scaffolds were fixed in 4% paraformaldehyde immediately after seeding for 1 hour and 
then washed in PBS. Scaffolds were subsequently processed for cell nuclear imaging as 
previously described in Section 2.2.3.  Seven consecutive pictures for each section were taken at 
40x and digitally reconstructed (Photoshop 7.0) to represent the whole section in one single 
image.  Five reconstructed sections per seeded construct were processed via ImageJ in order to 
quantify the cell density for each seeding condition.  The calculated cell density for each seeding 
condition was obtained dividing the cell number in each section by the total area occupied by the 
scaffold in each section.  To assess cell distribution along the circumferential direction, the 
constructs were initially marked with a line running along the longitudinal extension of the 
scaffold to denote the gravitational axis within experimental groups 3 and 4.  From the 
previously reconstructed sections the four circumferential quadrants (0°-89°, 90°-179°, 180°-
269°, 270°-359°) were identified as described in Section 2.2.3.  Each quadrant of each section 
underwent image-based cell density quantification via a three-step normalization process.  First, 
the cell number in each quadrant of each section (measured as described in Section 2.2.3) was 
normalized by the total number of cells in that entire section to give a percentage (i.e., % of the 
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total cell number incorporated in each quadrant).  This step was performed to take into account 
the possible variability in cell number released within different constructs and variations in 
seeding efficiency.  Second, the area of each quadrant of each section was normalized by the 
total area of that entire section to give a percentage of the total area occupied by each quadrant.  
This was done to consider local variability in seeding due to different wall thickness and, 
therefore, variations in permeability.  Finally, the first two steps were combined to give a 
normalized cell density (i.e., % cell/% area for each quadrant), taking into account errors 
introduced by possible variations in area and initial cell number.   
A reference axis was arbitrarily chosen to identify the four quadrants in the two 
experimental groups using rotation (Rot/Dry and Rot/Wet) and to quantify the circumferential 
variability in cell number.  Moreover, the quadrants were combined (Top = 0°-179°; Bottom = 
180°-359°) in order to show the overall sedimentation effect due to gravity (i.e., bottom versus 
top portion of the scaffold) for the experimental groups.  
2.2.6.3 Results 
According to the cell density assessment, the different experimental conditions affected the 
overall seeding efficiency (percentage of the initial cell number included in the construct after 
seeding).  In particular, group 1 had a statistically higher (p = 0.027) seeding efficiency than any 
of the other groups while no significant differences were detected among the other groups 
(Figure 2.23).  Also, although not statistically significant, group 3 seems to have an increased 
cell density compared to group 2 and 4.  This observation suggests that seeding in dry conditions 
results in a higher seeding efficiency compared to the ones performed in an immersed state.  A 
possible explanation to this phenomenon may be a cell loss from the scaffold while removing it 
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from the seeding device.  In fact, the surrounding liquid media would rapidly rinse the internal 
surface of the scaffold immediately after its disconnection from the two tees.  The pulling of the 
scaffold out of the media, combined with the large concentration gradient (proteins and cells) 
between the dense seeding suspension within the scaffold lumen and wall and the solution inside 
the chamber, might foster such cell loss from the scaffold wall.  The phase immediately 
following seeding is very delicate; the cells are only passively incorporated into the pores 
without cell attachment.  This preliminary observation reinforced the need for a normalization of 
the cells counted in each quadrant of the scaffold (as we will see below) based on the total cell 
number counted in its entire circumferential area.  
 
 
 
 
Figure 2.23  Measured seeding densities for the four different seeding conditions tested (mean ± standard deviation; 
n = 3).  The bars indicate statistical difference with p-values as indicated. 
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Qualitative assessment of cell seeding distribution (Figure 2.24) confirmed the increased 
cell density obtained by seeding with the original configuration (Rot/Dry).  A quantitative 
analysis of cell distribution in the four quadrants is shown in Figure 2.25.  Moreover, the overall 
sedimentation effect due to gravity is shown in Figure 2.26. 
 
 
 
 
Figure 2.24  Representative sections of seeded TIPS PEUU scaffolds within the different seeding conditions: 1) 
Rot/Dry;  2)  Rot/Wet;  3)  Still/Dry;  4)  Still/Wet.  The initial reference point (0°) used for circumferential cell 
seeding quantification is shown.  The arrows indicate the direction of the gravitational axis.  
 
 82 
 Figure 2.25  Normalized cell density in the four circumferential quadrants of the seeded scaffolds (mean ± standard 
deviation; n = 3).  The dashed line indicates the ideal seeding. 
 
 
Figure 2.26  Percentage of total cells for the two circumferential hemi-cylindrical portions of the scaffolds (mean ± 
standard deviation; n = 3).    
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These results show that the rotation is indeed critical to reach a homogeneous 
circumferential distribution as predicted by the analytical model (see Section 2.2.6.1).  The 
results of condition Still/Dry showed a statistically relevant imbalance between measured 
normalized cell densities in the top and bottom portions of the scaffold (p = 0.018) confirming 
the validity of the model and the previously observed gravity effects (see Section 2.1.3 and 
Figure 2.6).  However, the distribution obtained without rotation in immersed conditions 
(Still/Wet) did not agree with the analytical model.  In fact, unexpectedly, the results showed an 
almost statistically significant (p = 0.09) inversion rather than a reduction of the trend noted in 
Still/Dry.  However, a theoretical speculation for the observed increase in cell number in the top 
portion of the scaffold would suggest that the reduced cell sedimentation within the lumen of the 
scaffold observed in the immersed seeding conditions (as explained by the analytic model), 
coupled with the overall reduced cell density observed within the scaffold wall in immersed 
conditions (Figure 2.23), might demonstrate the presence of a stagnant luminal cell suspension 
media with an increased cell density.  Fresh seeding suspension entering the scaffold lumen with 
a stagnant, denser media may tend to float due to a buoyancy effect, resulting in a higher flow 
rate in the top half of the scaffold and, therefore, a higher seeding density.   
These experiments showed that seeding in immersed conditions might introduce 
undesirable effects including lower seeding efficiency, and higher seeding variability (note the 
higher standard deviations observed in the group Still/Wet).  This feature was thus abandoned in 
the future implementations of the RVSD. 
The characteristics of the scaffold would likely affect the seeding distribution.  For 
example, the length-to-diameter (L/ID) ratio of the scaffold more than its absolute dimensions 
provides a relevant geometrical characterization of the scaffold.  This parameter will likely 
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influence the scaffold internal fluid dynamics and therefore, the seeding distribution outcome.  
High values for this ratio (e.g., long tubular constructs with small IDs) will likely generate an 
imbalance between the flow rate exuding through the scaffold in proximity of the tees and that 
exuding through the scaffold within its central portion.  Due to the relatively high permeability of 
the scaffold (which results in a low hydraulic resistance for flows exuding through its wall) the 
resulting distributed pressure loss along the length of the scaffold (after few units of length) 
would be higher than the pressure loss caused by the exudation through the scaffold wall. 
The flow entering the scaffold during the seeding process has two possible pathways: 
either proceeding longitudinally toward the center of the scaffold or exuding radially through the 
scaffold wall.  The flow rate within these two pathways will be inversely proportional to their 
respective hydraulic resistances, with the greater flow favoring the path with the lower resistance 
(radial).  Furthermore, in proximity of the tees the flow has elevated radial components 
(generated to maintain the mass continuity) due to the sudden expansion experienced by the 
fluid.  This creates an additional outflow effect which facilitates the imbalance in longitudinal 
cell distribution.  To test this limitation a simple experiment was performed as a proof-of-
concept.  One TIPS PEUU scaffold (length = 40 mm, ID = 2.2 mm, thickness = 250 µm) was 
seeded with the 10x106 MDSCs suspended in 10 mL of media with seeding parameters 
consistent with what was previously used in Section 2.2.3.  The scaffold size was chosen to 
emphasize the hypothesized longitudinal seeding imbalance with relatively high L/ID ratio of 18.  
Figure 2.27 shows the results obtained and it demonstrates the suspected limitations of the 
RVSD implementation.  Before this seeding device could be utilized in clinically relevant 
applications (where high L/ID ratios are desirable) this severe limitation needed to be addressed.   
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Figure 2.27  Seeding experiment demonstrating the limitation in longitudinal seeding capabilities of the RVSD for 
scaffolds with high L/ID ratios.  Top.  Representative picture taken during the seeding.  Note how the pinkish media 
exudes mostly in proximity of the peripheral regions of the scaffold.  Bottom.  MTT-based cell quantification along 
the longitudinal direction of the scaffold.   
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2.2.7 Flexibility for different materials and applications 
An additional concern mentioned above was the use of scaffolds based on only one type of 
polymeric material (PEUU) and targeting only vascular tissue engineering applications for all the 
seeding tests performed.  To prove the ability of the RVSD to seed any porous material allowing 
for transluminal flow, and at the same time, its suitability for different tissue engineering 
applications, additional biodegradable polymeric scaffolds and cell types originating from 
collaborating laboratories and a Japanese biomaterial company, were tested.  A detailed 
description of these scaffold fabrication techniques and cell types is beyond the scope of this 
dissertation, therefore, only a brief explanation will be provided.   
 First, polycaprolactone (PCL) scaffolds (a generous gift from Dr. Kacey Marra) with 
porosity obtained via salt leaching technique (length = 15 mm, ID = 1 mm, thickness = 500 μm, 
pore size = 35-70 μm), were seeded with 3x106 human Foreskin Fibroblast Cells (hFFCs) (also 
provided by Dr. Marra).  The scaffolds were mounted with tips (recall Figure 2.4) and seeded 
using the same seeding parameters described in Section 2.2.3.  A sample of the scaffold was 
observed via SEM prior to seeding.  Following seeding, the construct was processed for nuclear 
and cytoskeletal staining and observed via fluorescence and confocal microscopy as described in 
Section 2.2.4.   
The scaffold appeared homogeneously integrated with hFFCs throughout the thickness of 
the wall (Figure 2.28-B).  Cytoskeletal staining showed a cellular spreading aspect (Figure 2.28-
C).  
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 Figure 2.28  Utilization of the RVSD for seeding hFFCs in a PCL porous scaffold.  A.  SEM of the unseeded 
scaffold wall.  B.  Nuclear staining of a cross-section of the hFFC-seeded scaffold.  C.  Confocal microscopy of the 
hFFC-seeded scaffold.  The arrows indicate the lumen of the scaffold.  
 
 
 
 Second, a commercially available large-diameter, bi-layered PGA-P(LA/CL) scaffold 
(length = 3 cm, ID = 1.5 cm, thickness  =  600 μm) donated by a Japanese company (Gunze 
LTD, Kyoto, Japan) was seeded with 20x106 rat MDSCs (rMDSCs) and processed for nuclear 
staining with the seeding parameters and technique as described in Section 2.2.3.  Qualitative 
seeding results are shown in Figure 2.29.  
 Finally, Rosa26 mouse hepatocytes (generously provided by Dr. Eric Lagasse) were 
bulk-seeded (cell density: 0.3x106 cells/mm3) into TIPS PEUU scaffolds (ID = 3 mm, length = 
10 mm, thickness = 0.2 mm) and processed for nuclear staining with the seeding parameters and 
technique as described in Section 2.2.3.  The seeding device produced again a uniform 
distribution of cells throughout the thickness of the scaffolds (Figure 2.30-A).  The ability of the 
RVSD to seed the cells without damaging them was again confirmed by the intact cell 
morphology of the delicate hepatocytes (Figure 2.30-B). 
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Figure 2.29  Utilization of the RVSD for seeding large-diameter PGA-P(LA/CL) porous scaffold.  A.  Macroscopic 
appearance of the scaffold immediately following seeding.  B.  Nuclear staining of a cross-section of the rMDSCs-
seeded scaffold. Red = Nuclei.  The arrow indicates the lumen of the scaffold. 
 
 
 
Figure 2.30  Utilization of the RVSD for seeding mouse hepatocytes into a TIPS PEUU scaffold.  A.  Nuclear and 
F-actin staining of a cross-section of the hepatocytes-seeded TIPS PEUU scaffold. Blue = Nuclei, green  =  F-actin, 
dark grey = scaffold.  The arrow indicates the lumen of the scaffold.  B.  Higher magnification.  Picture taken at 
400X.   
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 These additional tests demonstrated the RVSD capability of seeding any type of porous 
tubular scaffolds and any cell types, hence showing its suitability as a platform technology for 
future clinical applications.   
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3.0  SPECIFIC AIM 1, PART 2: SECOND GENERATION OF SEEDING DEVICE 
FOR PRECLINICAL APPLICATIONS: THE S-RVSD 
3.1.1 Modification of the cell seeding system 
Due to the limitation of the RVSD to seed scaffolds of clinically-applicable L/ID ratios (see 
Section 2.2.6.3 and Figure 2.27), some design modifications of the seeding device were 
required.  To deliver cells uniformly along the longitudinal direction of tubular scaffolds, it was 
necessary to create a system that performed successfully, independent of the length of the 
scaffold.  
3.1.1.1 The flow distribution problem and possible solutions  
A problem in hydraulics – commonly referred as the “flow distribution problem” – , is the 
achievement of a uniform distribution of flow rates into lateral branching channels distributed 
along the longitudinal axis of a common central pipe [145].  This problem is analogous to our 
present case; i.e., the scaffold is analogous to the central pipe, and the pores of the scaffold 
represent the branching channels.  A solution to this problem consists of the rationally-guided 
variation of the lumen of the lateral channels to obtain uniform departing flow rates throughout 
the entire length of the central pipe [146].  In particular, lateral branches (or pores) should have 
gradually increasing diameters moving away from the central lumen inflow area resulting in a 
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gradual decrease in the localized pressure losses associated with the lumen restriction 
encountered for each branch.  If properly designed, it is possible to balance the distributed 
(central pipe length) and localized (lateral branches) pressure losses in order to obtain uniform 
flow rates in each lateral branch.   
 Following the analogy of scaffold (central pipe) and pores (lateral branches), this solution 
is not directly applicable to our problem.  In fact, this would imply a modification of the scaffold 
porosity, consisting of a gradual increase in the scaffold pore size along the longitudinal 
direction, which is not desirable for obvious reasons.  However, the same solution could be 
utilized by machining an intermediate custom-made distributor placed coaxially inside the lumen 
of the scaffold.  This components would have a long tubular shape with several radially-oriented 
orifices (with variable diameters as explained), and it would extend throughout the whole length 
of the scaffold providing uniform radial flow rates along its longitudinal direction (Figure 3.1).   
However, the machining of this component should be specific for each scaffold size 
(length), meaning that different distributors should be fabricated to seed different scaffold sizes.  
For example, any different scaffold length would require a specifically-designed component to 
satisfy the condition of equal distribution of flow rate.  Moreover, the described solution is 
intrinsically limited because of the variability in radial velocity for different locations in the 
longitudinal direction of the scaffold (as a direct consequence of consistent flow rates but 
different radial efflux areas).  Different radial flow velocities will likely affect the radial 
distribution of cells within the scaffold wall in different longitudinal locations (possibly this 
limitation affects also the current design of RVSD).  
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 Figure 3.1  Schematic demonstrating the thoughts and rationale behind the custom-made distributor proposed as a 
solution to address the limitations in longitudinal seeding seen with the RVSD. 
 
 
 
Another way to solve this problem would be to globally increase the hydraulic resistance 
provided by the scaffold wall (i.e., to decrease the scaffold permeability).  In this way the 
pressure loss along the longitudinal direction of the scaffold would be negligible compared to 
that in the radial direction, and the radial flow would then be longitudinally uniform.  This 
solution could be implemented in two ways, either by decreasing the scaffold permeability 
directly by altering the scaffold characteristics (e.g., decreasing the pore size), or by applying an 
external, conformal, and slightly water permeable wrap around the scaffold (properly sealed to 
allow only the flow across its wall) in order to produce a reversible increase in overall wall 
permeability.  Neither of these solutions are ideal. The implementation of the first solution would 
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affect the cell-scaffold interaction by significantly reducing the nutrient diffusion into the 
scaffold wall (affecting viability) and by providing incompatible pore sizes to allow for cell 
penetration (as seen for the ES PEUU scaffolds in Section 2.2.4).  The second would introduce a 
user-dependency and risk of contamination due to the manual application of an external wrap.  
Moreover, significantly decreasing the permeability of the scaffold wall may lead to other 
problems, especially for scaffolds with elevated L/ID ratios.  For example this can lead to an 
increase in luminal pressures during seeding, potentially affecting cell viability.   
3.1.1.2 Chosen solution: The Stylet and Diffuser system 
The above considerations led to the idea of a local delivery of cells by means of a mobile internal 
sliding body able to release cells locally in a controllable manner.  This system would include a 
single cell releasing “Diffuser” provided with radial nozzles attached to an arm or “Stylet”.  The 
Stylet has the double function of driving the Diffuser along the axis of the tubular scaffold and 
transporting the cell suspension in its internal lumen.  The sliding Stylet and Diffuser would 
translate along the longitudinal axis of the scaffold while the scaffold is rotating externally on 
around it.  The working principles of such a system are summarized in Figure 3.2.  
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 Figure 3.2  Schematic of the Stylet sliding internally to the rotating scaffold.  
 
 
 
The hypothetical advantage of such a system consists in its possible ability to infuse cells 
locally into the scaffold wall with constant overall flow rate and a uniform radial component of 
the velocity.  The basic principle of the RVSD including the rotation, the vacuum, and the 
infusion of the seeding suspension via a syringe pump would be preserved.  The implementation 
of this new concept would only add a single but fundamental feature to the first generation: the 
sliding internal body.  As such, the second generation of seeding device arose, referred to as the 
sliding-rotational vacuum seeding device (S-RVSD).  One consequence of the implementation of 
this new concept is the adoption of a single cell infusing syringe instead of the two utilized in the 
original design.   
The implementation of the sliding Stylet and Diffuser required several modifications to 
the design of the original RVSD.  The first regarded the achievement of a translational 
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movement for the Stylet/Diffuser component.  To this end, a linear sliding stage with scale and 
vernier (Series A15, Velmex Inc., Bloomfield, NY) was utilized to translate the Stylet and to 
visualize the position of the stage and the subsequent position of the Diffuser inside the scaffold.  
The linear sliding stage converts the rotational movement of its central screw into a translation of 
the stage (Figure 3.3).  The linear sliding stage was fixed to the RVSD base via SS screws with 
careful alignment of its central leading screw to the axis of the RVSD tees.  Custom-made 
components were designed and drew via Solidworks 2005 software (Solidworks Corp., Concord, 
MA). Drawings are shown in APPENDIX A. A custom-made Stylet holder to transmit the 
translational motion from the sliding stage to the Stylet was machined from a single sheet of 
black Delrin® (Figure A.10).  The base of the Stylet holder was mounted on top of the sliding 
stage via two SS socket cap screws (Figure 3.3).  On top of the Stylet holder, a set screw holds 
the Stylet tightly into a bore (Ø = 3.2 mm) running across the full thickness of the component.   
 
 
 
Figure 3.3  Schematic of the linear sliding stage system used to translate the Stylet/Diffuser component during 
seeding with the S-RVSD. 
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The motion control necessary for the movement and positioning of the linear slide stage 
suggested the use of a stepper motor (“Motor 2”) (S57-83, Parker Compumotor, Rohnert Park, 
CA) which was anchored on the RVSD base via an aluminum support (Figure A.11 and Figure 
A.12).  A precision aluminum timing belt pulley (SDP/SI, New Hyde park, NY) was mounted on 
the central screw of the Unislide and driven by a polyurethane/kevlar timing belt (SDP/SI, New 
Hyde park, NY) using an identical pulley mounted on the shaft of the Motor  2.  At this stage of 
the S-RVSD development, it was decided to also control the rotation of the scaffold via another 
stepper motor (“Motor 1”) (S57-83, Parker Compumotor, Rohnert Park, CA) capable of 
delivering a strictly controlled rotational velocity and replacing the original AC motor.  Also 
Motor 1 was anchored to the RVSD base via a custom-made support (Figure A.13 and Figure 
A.14).  The design of an electronic control box for the computer-controlled S-RVSD operations 
will be described in Section 3.1.2. 
The Stylet was fabricated from a thick-walled SS 316L tube (OD = 3.175 mm, ID = 0.98 
mm, length = 25.4 cm).  The Diffuser was machined from a single PTFE cylindrical rod (final 
dimensions: OD = 4.65 mm, length = 5 mm); (Figure A.15).  A central lumen was created 
through 3/4 of its length.  Eight equi-spaced radially-distributed bores (Ø = 0.62 mm) were 
drilled to connect the central lumen of the Diffuser to its cylindrical lateral wall.  Threads on 
both the internal lumen of the Diffuser and the end of the Stylet allow for a firm coupling of the 
two components (Figure 3.4).   
The Driven Tee of the original RVSD (see Figure 2.9) was replaced by a 7 cm-long SS 316L 
tube (OD = 6.35 mm, ID = 5 mm) to allow for a concentric sliding of the Stylet within its 
internal lumen (see Figure 3.3).  Two solid PTFE cylindrical rods (Ø = 5 mm; length = 1.5 cm) 
were pressure fit in the two opposite ends of the new Driven Tee.  A bore (Ø = 3.18 mm) was 
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machined in the center of the two ends in order to re-establish an internal central lumen (Figure 
A.21).  This created a concentric alignment of the Stylet within the Driven Tee and a low-friction 
sleeve bearing allowing for the mutual movement (rotation and translation) of the two 
components. An adapter made of Delrin® was fabricated to reduce the external diameter of the 
Driven Tee from 6.35 mm to 4.7 mm in proximity to the scaffold ligation site (Figure A.22).   
Also the Driving Tee was replaced with a larger and longer tee (Figure A.23). 
 
 
 
 
Figure 3.4  The Diffuser 3D modeling. 
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Two custom-made SS 316-L inline swivel joints (007-10211-ZAT, Rotary Systems, Inc., 
Ramsey, MN) with internal Armoloy plating and Teflon seals were used to replace the rotating 
joints in the RVSD design.  The inline feature of these rotating joints was necessary to allow for 
the sliding of the Stylet across the swivel extension while the Driven Tee was rotated.  The 
mutual movement of the two components would have been otherwise impossible in the previous 
90º rotating joint configuration, in which the bend would not allow for the translation of the rigid 
Stylet within its internal channel.   
The connection between the tees and the new rotating swivel joints were made with SS 
compression fittings (McMaster-Carr) replacing the previous plastic ones.  A SS Yor-Lock 
compression tube fitting (male pipe adapter, McMaster-Carr) was modified (similar to what was 
previously done for the rotating joints crossing the RVSD chamber) by removing its internal 
double-sleeves.  Machining a bore (Ø = 3.2 mm) throughout the main body of the tube fitting to 
remove the internal shoulder (originally designed to stop the fitted tube from further longitudinal 
sliding), enabled its use as a sleeve bearing for the sliding SS Stylet.  The back nut of the 
compression tube fitting was also machined to reduce its overall length.  A fluoroelastomer V-
ring seal (SKF, Göteborg, Sweden) seal was placed between the compression tube fitting and its 
back nut component to create an airtight seal between the translating Stylet and the interior of the 
S-RVSD chamber.  This sealed joint was screwed into the back threaded bore of the inline 
swivel.  A schematic of the assembly is shown in Figure 3.5.  
Two different custom-made supports for the new rotating joints were machined from a 
thick sheet of black Delrin®.  The support for rotating joint connected to the Driving Tee was 
similar in shape with the one of the old rotating joints (Figure A.17), while the rotating joint 
connected to the Driven Tee was re-designed to bridge the sliding stage component with a 
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double base (Figure A.19).  Both supports were provided with caps to hold firmly the rotating 
joints (Figure A.20), and were anchored to the RVSD base via SS socket cap screws.  Two slots 
were made on both support bases (Figure A.16 and Figure A.18) to allow for regulation of the 
distance between the rotating joints and the S-RVSD chamber (i.e., to allow for the regulation of 
the scaffold length) (Figure 3.6).  The Driving Tee side maintained the same basic features as 
that used in the RVSD except for the presence of a three-way stopcock directly attached to a 
polypropylene Luer Lock female port screwed in the back of the rotating joint to close the circuit 
downstream after saline priming just before seeding.  
A detailed overall schematic of the S-RVSD depicting all of its major components as well 
as a photograph of the S-RVSD are shown in Figure 3.7 and Figure 3.8, respectively.   
 
 
 
 
Figure 3.5  3D model of the assembly for the S-RVSD Driven Tee. 
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 Figure 3.6  3D model of the S-RVSD.  Note the regulation of the scaffold length by changing the position of the 
rotating joint supports. 
 
 
Figure 3.7  S-RVSD schematic. 
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Figure 3.8  Actual photograph of the S-RVSD. Inset shows a close-up of the Diffuser. 
 
 
 
3.1.2 Electronic control box 
The introduction of a second motor in the design of the S-RVSD and the adoption of stepper 
motors required the incorporation of electronic drivers to provide the proper motion signal for 
the motors and to control the overall function of the device.  To this end, a control box was built 
to operate the device and the syringe pump in a coordinated fashion.   
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A 20x25 cm electronic enclosure base made of painted steel with 5 cm-tall vertical edges 
was provided with 4 rubber feet on its bottom to allow space for the placement of screws used to 
anchor the internal electronic components.  A power supply (XL-PSU, Parker Compumotor, 
Rohnert Park, CA) was positioned on the base.  This component transforms the 115 V AC 
(60Hz) signal into a stable 24 V DC power supply.  The DC source was used to energize two 
digital micro-stepping drivers (ViX IM250, Parker Compumotor, Rohnert Park, CA).  These 
three components were secured with screws and nuts on the steel base parallel to each other with 
a distance of approximately 2 cm to allow for heat dissipation as per product specifications.  The 
two drivers were connected to each other in a “daisy chain” configuration via a short RJ-45 
cable.  In this configuration, the first driver (“Driver 1”) receives the instructions from a PC via a 
RS-232 communication protocol and transfers the pertinent information to the second driver 
(“Driver 2”) (Figure 3.9).  This configuration also allows for two-way communication among 
motors, drivers, and the computer in case of the future need for implementation of a feedback 
control system such as digital encoders. 
A relay circuit was custom-made to enable the control of the syringe pump.  In particular, 
Driver 1 is provided with a user I/O port (15-Position HD male D-Sub connector).  The internal 
electronics of the driver allows trigger for up to three 24 V output signals upon request.  The 
syringe pump has the option of being remotely controlled.  The basic functions of infuse/refill 
and pump start/stop signals are triggered by the simple opening or closing of two different 
electrical circuits.  To match these two different specifications a relay circuit was custom-made 
on two of the three output pathways available from Driver 1.  
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 Figure 3.9  S-RVSD Electronic Control Box.  Top view.  Back wall is to the right, front wall to the left. 
 
 
 
 Each of the two circuits consisted in a voltage regulator (276-1770, Radioshack Corp., 
Forth Worth, TX) to convert 24 V DC output from the driver into a 5 V DC output followed by a 
5 V DC SPST Reed Relay (275-232, Radioshack Corp., Forth Worth, TX) to control the 
electrical connection mechanism necessary to operate the syringe pump.  These two components 
were connected in a series configuration (Figure 3.10).  
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Figure 3.10  Schematic of the S-RVSD relay circuit utilized to control the syringe pump. 
 
 
 
The power supply was also used to energize a 5x5 cm 24 V cooling fan (514F, ebmpapst, 
Inc., Farmington, CT) mounted on the aluminum back wall (20x10 cm) of the S-RVSD box.  The 
back wall of the electronic box was also provided with a standard panel-mount IEC 320 plug for 
the AC power, an in-line fuse holder, a switch, and a 9-position female D-Sub connector used to 
operate the syringe pump through the aforementioned circuit.  The front aluminum wall (20x10 
cm) was mounted with another 9-position female D-sub connector for the serial communication 
with the PC, and two 6-contacts shielded miniature circular female sockets (series 440, Binder-
USA, LP, Camarillo, CA) for a rapid connection/disconnection with the two stepper motors 
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necessary to operate the S-RVSD.  The box was finally covered with a transparent cast-acrylic, 
vented cover (Figure 3.9). 
 The drivers were controlled via serial communication from a PC.  Software (Easi-V, 
Parker Compumotor, Rohnert Park, CA) converted a specific, proprietary language into 
instructions for the driver.  Examples of common instructions include energizing/de-energizing 
and starting/stopping the motors, defining rotational velocity and acceleration, defining the 
numbers of revolutions before stopping, starting/stopping the syringe pump, etc.  While the 
drivers used are fully themselves programmable (being provided with an internal hardware 
memory allowing for stand-alone operations, without direct connection with a PC), the seeding 
testing and subsequent experiments were conducted in a PC-tethered mode allowing for constant 
control of the operational parameters.  The software allowed for the programming of several 
“buttons” through a graphic interface to respond to basic and more complex commands.  Table 
3-1 shows most of the commands used to operate the S-RVSD before, during, and after the 
seeding procedures.  Most of these commands are a combination of single instructions. 
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 Table 3-1  Commands used to operate the S-RVSD during seeding procedures. 
 
Command Micro-Stepper Instruction 
Energize Motors 0ON;2A100;2V10 
De-Energize Motors 0OFF 
Stop Motors  0K 
Motor 1: Rotation CW 45º 1MI;1A50;1V10;1D3125;1G 
Motor 1: Rotation CCW 45º 1MI;1A50;1V10;1D-3125;1G 
Motor 1: Rotate for Seeding 1MC;1V0.167;1G 
Motor 2: Zero Position 2MA;2W(PA,0);1W(PA,0) 
Motor 2: Forward Step (5mm) 2MI;2D98425;2V100;2G;2TR(MV,=,0);2R(PT) 
Motor 2: Backward Step (5mm) 2MI;2D-98425;2V100;2G;2TR(MV,=,0);2R(PT) 
Motor 2: Go to Zero Position 1MA;1V5;1D0;2MA;2A100;2V5;2D0;1G;2G 
Motor 2: Slide and Seed 2MI;2D-98425;2V0.1;1O(00X);2G;2TR(MV,=,0) 
Syringe Pump: Refill 1O(10X) 
Syringe Pump: Infuse 1O(00X) 
Syringe Pump: Start 1O(X00) 
Syringe Pump: Stop 1O(X01) 
 
 
 
3.1.3 Considerations and calculations for the correct use of the system 
3.1.3.1 Definition of the motion regimen 
The new “sliding” feature of the S-RVSD required some considerations to identify the 
appropriate parameters for its correct operation.  In particular, it was important to identify a 
suitable motion regimen for the Diffuser (i.e., motion type, direction and velocity) and for the 
scaffold (i.e., rotational velocity) in order to yield an optimal seeding.   
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Though very simple to implement with the computer-controlled drivers for the stepper 
motors, a non-steady movement for the Diffuser and scaffold (e.g., multiple passages from the 
same longitudinal location for the Diffuser, periodic rotations of the scaffold, 
accelerations/decelerations,  etc.) might be difficult to model and would require optimization 
studies beyond the scope of this work.  Therefore, a decision was made early on to perform the 
seeding with steady movements of the Diffuser and the scaffold, in which the movement of the 
Diffuser occurs in a single direction with a steady linear velocity and the scaffold rotates with a 
constant rotational velocity during the entire seeding process.  
Once these basic specifications were established, qualitative bench-top testing (no data 
was recorded) suggested several protocol to adopt for the correct use of the device.  When 
considering the Diffuser component, these tests suggested that the “pulling configuration” (i.e., 
with the seeding occurring with the Diffuser initially placed in proximity of the Driving Tee and 
pulled back toward the Driven Tee during the seeding; recall Figure 3.2) was more efficient than 
the opposite “pushing configuration”.  This conclusion was based on the observation that the 
Diffuser, while pushed from the Driven Tee toward the Driving Tee, was causing an increase in 
intraluminal pressure due to the compression of the proximal liquid volume.  This resulted in to 
an increase in the scaffold luminal diameter and a subsequent loss of proximity between the 
Diffuser and the scaffold wall.  The delicate contact between the Diffuser and the scaffold lumen 
was designed to maximize the localization of cells based on the Diffuser position during seeding.  
As a consequence of the pushing configuration, the seeding suspension was partially diffusing 
beyond the Diffuser position, resulting in a loss of seeding precision as observed using colored 
solution during testing.  Conversely, in the pulling configuration, the scaffold wall was in good 
adherence with the Diffuser for the entire duration of seeding.  This contact effect was fostered 
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by the gentle intraluminal suction caused by the retraction of the Diffuser through the lumen of 
the scaffold which induced contact between the two bodies, allowing for localized transmural 
exudation of seeding suspension (in correspondence of the Diffuser nozzles).   
3.1.3.2 Definition of the operational parameters 
Once the type and direction of the Diffuser movement was defined, it was necessary to establish 
the appropriate relationship between the translational and rotational speeds for the Diffuser and 
the scaffold, respectively.  These two parameters are required to be linked based on a specific 
relationship because the cell suspension is released discretely by the 8 radial nozzles.  If the 
Diffuser would release cell suspension without moving and without the external scaffold 
rotation, the seeding pattern within the scaffold cross-section would resemble 8 radially-oriented 
lines crossing the scaffold longitudinal wall corresponding with the 8 cell-releasing nozzles.  If 
the Diffuser would slide without scaffold rotation, this seeding pattern would extend 
longitudinally, resulting in 8 longitudinal “planes” of seeded scaffold.  Finally, if the tangential 
velocity of the scaffold wall (due to the rotation) is significantly slower than the longitudinal 
velocity of the Diffuser, the seeding pattern would be elicoidal with 8 seeded helical cell patterns 
twisting along the length of the scaffold.  Therefore, it is important to slide the Diffuser with a 
speed that allows for circumferential homogeneity throughout the whole length of the scaffold.   
This problem can be solved by considering that the time (tarc) necessary to rotate the 
scaffold for 1/8 of the circumference (arc length included between two adjacent nozzles with the 
assumption that the eight nozzles release the same flow rate of seeding suspension) starting from 
any initial time (t0) has to be at most equal to the time (tnozzle) necessary to remove (during the 
translation of the Diffuser) the extension of the seeding nozzle from the initial longitudinal 
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location of the Diffuser at t0.  That is, tarc  ≤  tnozzle. Performing few calculations (APPENDIX C), 
it is possible to demonstrate that the value of the angular velocity for the scaffold (ωScaffold) has to 
comply with the following expression: 
 
3-1 
 
The angular velocity and velocity of the Diffuser are expressed as rpm and mm/sec, respectively.  
 Once the type of movement for the Diffuser (steady, unidirectional, pulling 
configuration) and a relationship between the rotational velocity of the scaffold and the 
translational velocity of the Diffuser (Equation 3-1) were both established, it was apparent that 
these velocities would be dictated by the overall seeding time.  For example, a long seeding time 
(ts) would require a low vDiffuser in order to cover the length of the scaffold in exactly ts.  
Furthermore, once established ts (and therefore vDiffuser), also ωScaffold results partially defined 
(inferior limit) by Equation 3-1.  One of the design criteria for the original RVSD was the 
rapidity of seeding.  This was achieved, as the seedings using the RVSD took between 1 and 3 
minutes.  Another a priori decision for the design of the S-RVSD was to complete the seeding 
process in 5 minutes.  This set seeding time defined the translational velocity for the Diffuser and 
suggested the rotational velocity of the scaffold.  The translational velocity of the diffuser was 
set to 0.167 mm/sec required to cover the 5 cm of scaffold length in exactly 5 minutes.  The 
rotational speed for the scaffold was set to be 10 rpm in agreement with Equation 3-1, which 
exceeded the minimum required value (~2 rpm) of a factor ~5.  This was decided as a safety 
feature to take into account the possibility that the 8 nozzles of the Diffuser would not release the 
same flow rate (as originally assumed) as a consequence of gravity. 
DiffuserScaffold v≥ 12ω ⋅
 110 
An additional consideration for the S-RVSD regards the direction of rotation for the 
scaffold, which needs to be consistent with the direction in which the Diffuser is screwed on the 
Stylet.  Rotating the scaffold in the opposite direction might cause a disconnection of the 
Diffuser leading to seeding failure.  Additionally, the presence of the sliding feature eliminated 
the possibility of keeping the previous design of using custom-made tips for the scaffold (recall 
Figure 2.4).  Therefore, prior to each seeding, each scaffold needed to be reversibly secured to 
the S-RVSD tees via silk suture ligation. 
3.1.3.3 Definition of the S-RVSD seeding protocol 
 The protocol for seeding with the S-RVSD was defined and described as follows.  The scaffold 
was secured to the device, the tubing, Stylet, Diffuser, scaffold, and Driving Tee circuits were 
primed by infusing Dulbecco’s modified phosphate buffered saline (DPBS) from a priming 
syringe (priming volume = 4.5 mL).  Subsequently, the Stylet, Diffuser and scaffold were primed 
with the seeding suspension to initiate scaffold seeding precisely upon activation of the syringe 
pump.  The Diffuser was positioned in proximity to the Driving Tee and the seeding was 
initiated by applying vacuum to the chamber, starting scaffold rotation, and starting the infusion 
of cell suspension concurrently with the movement of the Stylet (this operation is synchronized 
by the S-RVSD electronic controller).  The seeding was automatically terminated once the 
Diffuser reached the end of the scaffold by synchronously stopping of sliding Stylet and 
Diffuser, the cell infusion, and the rotation of the scaffold. 
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3.1.4 Seeding performance 
3.1.4.1 Qualitative assessment of seeding functionality 
Once the criteria and protocol for seeding the S-RVSD were established, a mock seeding was 
performed using a PTFE porous vascular graft (W. L. Gore & Associates, Inc., Flagstaff, AZ) 
and a bromophenol blue dye (Sigma) to assess the effectiveness of the device qualitatively.  The 
dye was used to mimic the seeding suspension for simplicity, and it also allowed visualizing the 
exuding flow with high contrast to demonstrate the efficacy of the system in terms of local 
delivery of seeding suspension.  The seeding parameters were consistent with those defined in 
Section 3.1.3.    
3.1.4.2 Quantitative assessment of bulk seeding uniformity 
As previously done for the RVSD, a complete quantitative assessment of the bulk seeding 
capabilities of the S-RVSD was performed.  To this end, 5 cm-long, hybrid ES-TIPS PEUU 
scaffolds (n = 3, ID = 4.7 mm; a detailed description of this scaffold type is provided in Chapter 
4) were seeded in order to show the absence of significant differences in cell number along the 
longitudinal, circumferential, and radial directions of the scaffolds, similar to that described in 
Section 2.2.3 for the RVSD.  This analysis also focused on the assessment of apoptosis 
activation to confirm absence of damaging conditions during seeding.  The scaffold ratio (L/ID) 
for these experiments was equal to 11, suitable to demonstrate the ability of the S-RVSD to 
overcome the limitation of the RVSD shown in Figure 2.27. 
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Pig muscle-derived slowly adhering cells (SACs) obtained from a modification of an 
established pre-plating technique [147] were cultured and seeded in DMEM (Sigma) 
supplemented with 20% serum (a detailed description of the isolation technique, and culture 
reagents is provided in Section 7.3).  Three scaffolds were seeded with 30x106 cells suspended 
in 20 mL of media, with a flow rate of 4 mL/min.  The vacuum level was maintained consistent 
with the value, which was that used with the RVSD (-5 inHg), and the translational speed of the 
Diffuser and the rotational velocity of the scaffold were set to 0.167 mm/sec and 10 rpm, 
respectively as previously described (recall Section 3.1.3).   
After seeding, a ring (~ approximately 4 mm in width) was cut from each of the two ends 
of the scaffold   to exclude the portions of scaffold ligated to the tees and not reached by the 
nozzles of the Diffuser from subsequent analysis.  The longitudinal cell distribution was assessed 
via MTT assay (as previously described in Section 2.2.3) performed on scaffold segments (~4 
mm) taken from 9 longitudinal portions (i.e., L1-L9 in Figure 3.11).  The MTT absorbance was 
normalized by the actual length of each portion to account for cut length variations.  The 
circumferential distribution was assessed (as previously described in Section 2.2.3) from 3 
longitudinal sections of the scaffold (~3 mm); namely from a proximal (in proximity of the 
Driven Tee), medial, and distal locations (in proximity of the Driving Tee) of the scaffold (see 
Figure 3.11).  A portion (~ 1 mm in length) of each of these three segments was dedicated to 
histology (H&E) for both qualitative circumferential assessment and quantitative (radial) 
analysis.  Briefly, the radial distribution was assessed by creating a rectangular mask, split in 
three equal areas by two perpendicular segments along its long edge, using Rhinoceros 3.0 
(Robert McNeel & Associates, Seattle, WA).  Five random nuclear staining images previously 
used to quantify the circumferential distribution from each of the three seeded scaffolds were 
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imported in PowerPoint 2003 (Microsoft Corp.).  The mask was superimposed onto each image 
and manually rotated and scaled to be perpendicular to and fit to a portion of cross-section.  In 
this manner, the mask compartmentalized three regions of interests across the scaffold radius 
(i.e., luminal, medial, and abluminal).  The cell number in each of the three radial regions was 
counted manually and recorded on a spreadsheet.  The same operation was repeated three times 
for three different, random, locations within each image.  
 
 
 
 
Figure 3.11  Schematic of serial cut on the scaffold for the quantitative assessment of the S-RVSD seeding 
uniformity.  
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3.1.4.3 Quantitative assessment of apoptosis 
Apoptosis, which is an early marker of cell injury, was quantified from the same three frozen 
sections dedicated to circumferential and radial cell distribution analysis using the In Situ Cell 
Death Kit (Roche Applied Science, Indianapolis, IN).  This assay utilizes the fluorescein-based 
TUNEL method to identify cleavages in the genomic DNA produced as a consequence of 
apoptosis.  Briefly, frozen cross-sections were dried at 37˚C for 30 minutes, and rehydrated in 
PBS for 30 minutes.  Samples were then incubated at room temperature for 10 minutes each in 
10μg/ml Proteinase K followed by a freshly prepared solution of 0.1% Triton X-100 and 0.1% 
sodium citrate for permeabilization of cell membranes.  DNA strand breaks were identified by 
incubation at 37˚C for one hour with Terminal deoxynucleotidyl transferase and fluorescein 
labeled dUTP (both provided in the kit from Roche).  Nuclei were counterstained with DAPI. 
 A section from each slide was treated with 100 U/ml of DNase I to serve as positive 
controls each time the assay was performed to ensure efficacy of the kit.  All sample preparation 
parameters including incubation times, temperatures, and reagent concentrations were optimized 
using DNase I treated positive controls.  Negative controls were incubated with labeled dUTP 
without the transferase enzyme.  All slides were mounted in gelvatol and imaged at 200X using a 
Nikon Eclipse E800 epifluorescent microscope and Spot image acquisition software.  For each 
scaffold in the three described locations (Prox., Med., and Dist.), 5 images at 200x were 
quantified from at least 3 sections.  Quantification of the number of TUNEL positive cells was 
performed by manual counting, while the total number of cells per image was counted via 
ImageJ softwar (as previously described in Section 2.2.3).  The percentage of positive cells was 
obtained by dividing the manually-counted positive cells by the total cell number in each image. 
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3.1.4.4 Statistical analysis 
All statistical analyses of the quantitative cell distribution measurements were performed with 
SPSS v.13 (SPSS Inc., Chicago, IL) software.  All the datasets were tested for normality via the 
Kolmogorov-Smirnov test.  Comparison for different groups was performed using one-way 
ANOVA.  Results are given as mean ± standard deviation.  A confidence interval greater than 
95% (p<0.05) was considered significant.  
3.1.4.5 Results 
The initial qualitative mock seeding test using the blue dye demonstrated that the device was 
inducing a localized exudation of dye along with the position of the Diffuser, as expected 
(Figure 3.12). 
The MTT assay results (both qualitative and quantitative) for the longitudinal distribution 
of cells are shown in Figure 3.13.  Statistical analysis showed no significant differences in the 
longitudinal distribution of cells (p = 0.77).  
The quantification of the circumferential cell distribution revealed no statistical 
differences in the four quadrants of the scaffolds, neither among the three different locations 
along the longitudinal direction of the scaffolds (Figure 3.14), nor among the whole scaffolds in 
general (Figure 3.15).    
Radial distribution was homogeneous, showing no significant differences among the 
three radial portions of the scaffold wall (Figure 3.16).   
The percentage of apoptotic cells following seeding via the S-RVSD was 5.0±7.1%.  A 
qualitative assessment of apoptosis is shown in Figure 3.17. 
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Figure 3.12  Mock seeding sequence (1-9) of the S-RVSD demonstrating the functioning of the device.  A 
commercially available vascular graft and a blue ink were used for this purpose.  The arrows indicate the current 
position of the internal Diffuser.  The overall seeding time was 5 min. The frames of the sequence are spaced 
approximately 40 sec from each other.  
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Figure 3.13  Longitudinal distribution of cells seeded via the S-RVSD.  Top.  Qualitative assessment of MTT signal 
for the three scaffolds seeded in the 9 longitudinal positions.  Center.  Representative sections stained for nuclear 
staining. Blue = nuclei, red = scaffold.  The arrows indicate the lumen of the scaffold.  Bottom.  Quantification of 
the MTT assay (mean ± standard deviation; n = 3).  The dashed line shows the ideal case of perfect distribution 
correspondent to the 11.11% of the total cell number included in each longitudinal location of the scaffold.  
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Figure 3.14  Local circumferential cell distribution after seeding via S-RVSD.  Top.  Representative H&E sections 
of the three locations used to quantify the circumferential distribution valid as a qualitative assessment.  Bottom.  
Normalized cell density in the four circumferential quadrants of the scaffolds (mean ± standard deviation; n = 3).  
Note that the value 1.0 (dashed line) corresponds to the ideal seeding in which the cells are perfectly equi-distributed 
around the circumferential direction. 
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 Figure 3.15  Global circumferential cell distribution after seeding via the S-RVSD (mean ± standard deviation; n = 
3).  Note that the value 1.0 (dashed line) corresponds to the ideal seeding in which the cells are perfectly equi-
distributed around the circumferential direction. 
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Figure 3.16  Radial cell distribution after seeding via the S-RVSD.  Top.  Representative H&E showing the mask 
used to quantify the cell number.  The arrow indicates the lumen of the scaffold.  Bottom.  Quantification of radial 
cell distribution (mean ± standard deviation; n = 3).  The dashed line indicates the ideal 33% corresponding to a 
perfectly uniform radial distribution of cells. 
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 Figure 3.17  Apoptosis detection after S-RVSD seeding testing.  Left Column.  Representative images of the three 
scaffolds seeded.  Right Column.   Representative pictures of the three positive controls used. Blue = Nuclei. Purple 
= Apoptotic nuclei. Arrows indicate the lumen of the scaffolds. Pictures were taken at 200X. 
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3.1.5 Discussion and limitations 
The new internal sliding, local cell delivery feature implemented in the S-RVSD has proven to 
overcome the previous seeding length limitations seen with the RVSD.  The modified device was 
able to deliver cells uniformly throughout the length of 5 cm scaffolds with L/ID ratio of 
approximately 11 (Figure 3.13), whereas the original device failed to do this for scaffolds with 
L/ID > 5 (Figure 2.27).  In fact, the length of the scaffold used in the S-RVSD assessment was 
only limited by the dimension of the chamber.  In theory, with properly scaled chamber and 
Stylet, there is no limit for the scaffold length.  The device has also shown to provide uniform 
circumferential distribution of cells along the circumferential direction of the scaffold (recall 
Figure 3.15). 
Additionally, these series of tests of the S-RVSD has also proven to deliver cells in a 
uniform manner across the radial direction of the scaffolds (recall Figure 3.16).  The radial 
distribution is likely affected by the flow rate of cell seeding suspension. No study has been 
performed to understand the role of the flow rate in the radial cell distribution, as that was 
beyond the scope of this work.  However, showing the ability to control cell distribution might 
be critical for future applications, where different layers of cells could be serially deposited 
across the thickness of the scaffold to mimic the cell components present in the arterial 
vasculature (e.g., fibroblasts in the adventitia, smooth muscle cells in the media, and endothelial 
cells in the intima). 
 The low level of apoptosis detected supported the hypothesis of the absence of cell 
injury following seeding (see Figure 3.17).  There was initial concern that the shear stress, to 
which the cells would be exposed within the S-RVSD could be high enough to adversely affect 
cell viability.  In particular, the flow within the Stylet central lumen is likely to generate the 
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highest shear stress due to the small caliber of the lumen (~0.9 mm) and the high flow rate. The 
pores of the scaffold, though much smaller, receive a reduced flow rate due to the permeation of 
flow across a very high numbers of pores.  The shear stress within the Stylet lumen was 
estimated using Equation 2-6  in Section 2.2.2.1 to be 9.6 dynes/cm2  (APPENDIX D), 
confirming the physiologic magnitude of the forces involved with the seeding process of the S-
RVSD.   
Another important improvement of the S-RVSD was the implementation of computer-
controlled motors and syringe pump.  This feature increased the precision of the seeding process 
with strict control of the scaffold rotation and translation of the Diffuser while reducing the 
human interactions and therefore, improving upon the reproducibility of the seeding outcomes.       
In summary, the S-RVSD developed here appears to have ideal features to seed porous 
tubular scaffolds for preclinical applications of a TEVG.  One such application will be 
extensively explored in Chapter 7 in which a large animal model (pig) will be the recipient of a 
TEVG seeded with the S-RVSD.  The S-RVSD may represent a technology suitable for future 
clinical applications as well.  However, the current prototype needs modifications to be 
compliant with the requirements of a medical device.  In Section 8.4.1.2 one possible 
modification is proposed, along with a description of a prototype of a disposable “product” that 
can be utilized in the system for future clinical applications. 
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4.0  SPECIFIC AIM 2: DEVELOPMENT OF A NOVEL SCAFFOLD FOR 
VASCULAR TISSUE ENGINEERING APPLICATIONS  
The scaffold is one of the most critical components in tissue engineering, as it should provide a 
temporary structure and milieu for regeneration, i.e., gradual replacement of the scaffold with 
native-like tissue.  Furthermore, the scaffold should provide mechanical support to withstand 
physiologic conditions over an extended period of time.  The matching of mechanical properties 
with those of native vessels is a critical requirement for any small-diameter vascular graft, as 
mechanical mismatch has been associated with perturbation in the local hemodynamics, 
establishing the basis for restenosis and graft failure [148].   
Throughout the last two decades many endeavors have been made to develop a 
mechanically and functionally sound TEVG to replace or bypass arterial segments.  Extensive 
research has been dedicated, in particular, to the development of scaffolds with the right 
combination and compromise of mechanical, structural, and biological properties suitable for 
cardiovascular applications.  Different approaches have been explored for this purpose, spanning 
from biological materials [31, 66, 149], to completely synthetic materials with [150, 151] or 
without [45, 46] surface modifications, to approaches [152].  Biological scaffolds (e.g., collagen 
and fibrin gels) can exhibit an intrinsic capacity for biocompatibility and bioactivity; however, 
they have also been associated with suboptimal mechanical properties [67] and have the potential 
for disease transmission and immunogenicity.  Decellularized biological tissues tend to offer 
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improved mechanical properties, however, incomplete removal of exogenous materials has been 
attributed to severe immunological reactions in early human clinical trials [153] and thus these 
scaffolds, while clearly promising, require significant care in their preparation and 
characterization.  Moreover, the seeding of these scaffolds is not feasible, owing to their low 
porosity.  Synthetic scaffolds have the capacity of exhibiting tunable and reproducible properties.   
However, the most commonly used aliphatic polyesters such as poly(glycolic acid), poly(L-lactic 
acid), and their copolymers are generally much stiffer than native soft tissues and can, under 
some conditions, induce a transient or chronic inflammatory response due to the acidity of their 
degradation products  [43].  Another common challenge in tissue engineering is the difficulty of 
obtaining highly bulk-cellularized scaffolds due to intrinsic scaffold limitations such as 
insufficient pore size or interconnectivity, or to inadequate seeding techniques [112].Critical to 
the majority of vascular tissue engineering approaches is the scaffold component [40], which 
provides, as a temporary 3-D template, structural, mechanical and possibly biological support 
and guidance throughout the tissue formation and remodeling processes.  Foremost, the scaffold 
should allow for cell infiltration, adhesion, and proliferation, followed by cell-mediated 
remodeling leading to ECM deposition [154].  Other requirements for the scaffold include 
mechanical strength, compliance, and suture retention strength comparable to physiologic values 
[35].  Moreover, the scaffold should not possess significant plastic behavior since this could lead 
to aneurysm formation upon chronic implantation.  Additionally, toward a more “biomimetic” 
approach the scaffold should hypothetically possess anisotropic structural and mechanical 
properties similar to native blood vessels [155, 156].   
 
 126 
4.1 PEUU: AN ELASTOMERIC POLYMER FOR VASCULAR TISSUE 
ENGINEERING 
The PEUU represents a valid candidate as a scaffold for TEVG scaffold due to its elasticity and 
tunable mechanical and degradation properties [51, 52].  This polymeric material is 
cytocompatible and processable into scaffolds via several techniques.  A TIPS process, for 
example, has been used to fabricate highly porous scaffolds [53] able to promote efficient cell 
integration, cell attachment, and diffusion of nutrients in vitro [54, 55].  The same polymer was 
electrospun to obtain similar nanofibrous architecture and mechanical properties to those of 
native, structural soft tissues [56, 57].   
Due to the promising properties and flexibilities for different processing techniques, the 
PEUU was defined as a scaffold of choice for our approach. 
4.1.1 The use of TIPS PEUU for TEVG applications 
Initial studies toward the creation of a TEVG were performed using the TIPS PEUU as the 
scaffold of choice [54, 55].  This scaffold has been previously described and characterized in the 
form of tubular scaffolds with a wall thickness of approximately 2.0 mm [53].  Tubular scaffolds 
with reduced wall thickness (obtained by modifying the size of the mold used) were used for the 
testing and validation of the initial vacuum seeding device (Section 2.1.2), the bulk seeding 
testing of the RVSD (recall Section 2.2.3, [55]), in vitro testing of cell proliferation,  spreading, 
and phenotype within the scaffold both immediately following seeding with the RVSD and after 
several days of dynamic culture (this characterization will be properly described in Section 5.1 
[54]), and finally the initial in vivo testing as an aortic interposition graft in a rat model 
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(described in Chapter 6).  The chronology of the mentioned studies did not follow the order of 
this dissertation since most of the testing was performed within overlapping time frames and not 
following a rigid sequential structure.  A comprehensive description of this scaffold fabrication 
technique, morphology, and mechanical properties has been provided in the literature and 
therefore, is beyond the scope of the current dissertation.  However, a mechanical 
characterization of the material will be described in Section 4.2.5 in comparison to the newly 
developed scaffold (ES-TIPS PEUU) and to native arteries.  Furthermore, an indirect 
characterization of the TIPS scaffold will be provided as a part of the composite ES-TIPS 
scaffold.  
 The use of TIPS PEUU was discontinued when, during in vivo testing, significant 
evidence of scaffold dilation, leading to aneurysm formation, emerged (this will be properly 
described in Chapter 6).  An initial heat treatment was performed to increase the strength of the 
material but was not enough to lead to in vivo scaffold stability.        
4.1.2 The use of ES PEUU for TEVG applications 
The ES PEUU has remarkable mechanical features due to its fibrous structural nature, which 
replicates the anisotropic properties of native soft tissues [56].  The use of the ES PEUU scaffold 
was limited in our approach due to its small pore size, not allowing for the desired bulk cell 
seeding and integration.  However, the material was used to successfully test the surface seeding 
capabilities of the RVSD (recall Section 2.2.4).  Furthermore, the ES PEUU scaffold has been 
utilized to test the response to shear stress of` rMDSCs surface-seeded onto the luminal surface 
of scaffolds and subjected to media flow perfusion by a perfusion bioreactor system (see 
APPENDIX E).   
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Small ES PEUU scaffolds (length = 10 mm, ID = 1 mm) were also used to evaluate their 
in vivo performance as an aortic interposition graft in a rat model.  Different configurations were 
attempted in this model, including unseeded scaffolds, scaffold luminally coated with a 
covalently bound hydrophilic layer (MPC), and scaffold surface seeding with rMDSCs.  These 
first two acellular approaches are the subject of a publication in preparation and are certainly 
beyond the subject of the current dissertation due to their lack of stem cell-based features.   
As for the TIPS PEUU scaffold, no special characterization or description will be 
dedicated to the ES PEUU scaffolds since this appear elsewhere [57], however the mechanical 
properties of this scaffold were measured in comparison with the newly developed ES-TIPS 
PEUU scaffolds and a morphological characterization was performed as part of the composite 
ES-TIPS PEUU scaffold as described in the following section. 
4.2 ES-TIPS PEUU: A NOVEL SCAFFOLD FOR VASCULAR TISSUE 
ENGINEERING APPLICATIONS 
To match the scaffold requirements of seedability and sound mechanical properties, a novel 
PEUU-based scaffold was developed and tested.  Both TIPS and ES processing were applied 
sequentially to obtain a composite (i.e., bi-layered) tubular conduit scaffold, integrating the 
positive features of both scaffolds.  In particular, the desirable microstructural and mechanical 
characteristics yielded by TIPS and ES, respectively, were rationally integrated for the purpose 
of creating a novel scaffold for small-diameter vascular tissue engineering applications.  A 
thorough morphological and mechanical characterization was performed to test compatibility of 
the scaffold relative to the native vasculature.  The scaffolds were then seeded with adult muscle-
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derived stem cells, via the RVSD to assess the efficiency of cell inclusion within a short seeding 
duration time.   
4.2.1 PEUU polymer synthesis 
Most of the reagents utilized for the synthesis of the PEUU polymer were processed prior to their 
use.  In particular, solvents dimethyl sulfoxide (DMSO) and N,N-dimethylformamide (DMF) 
were dried over 4-A molecular sieves.  Polycaprolactone diol (PCL, Aldrich, MW ¼ 2000) was 
dried under vacuum for 48 hours at 50°C.  Putrescine (Sigma) and 1,4-diisocyanatobutane (BDI, 
Fluka) were distilled under vacuum.  Stannous octoate (Sigma) catalyst and 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP, Oakwood) solvent were used as received.  Biodegradable and 
biocompatible PEUU was synthesized from BDI and PCL with putrescine chain extension using 
a two-step solution polymerization as described previously [51].  Briefly, 250 ml roundbottom 
flask under dry nitrogen with reactant stoichiometry of 2:1:1 BDI:PCL:putrescine molar ratio 
were used.   BDI at 15wt% in DMSO was continuously stirred with 25wt% PCL in DMSO 
followed by stannous octoate addition.  The reaction was allowed to proceed for 3 h at 80ºC 
followed by cooling at room temperature.  Putrescine was then added drop wise with stirring and 
the reaction was continued at room temperature for 18 h.  The resulting PEUU solution was 
precipitated in distilled water, the wet polymer was immersed for 24 h in isopropanol to remove 
unreacted monomers, and the polymer was dried under vacuum at 50°C for 24 h.  
 130 
4.2.2 Scaffold preparation 
Two different small-diameter sizes of composite scaffolds were made, both a larger diameter 
(ID-4.7: length = 30 mm, ID = 4.7 mm), and a smaller diameter (ID-1.3: length = 10 mm, ID = 
1.3 mm).  The rationale behind the choice of these two sizes was their relevance for planned 
preclinical studies in rats (abdominal aorta) (Chapter 6) and pigs (carotid artery and internal 
jugular vein)   (Sections 7.6 and 7.7).  The ID-4.7 scaffold was also used for testing the S-
RVSD as described in Section 3.1.4.   
The internal layer (i.e., intima/media equivalent) of the composite scaffolds consisted of 
porous PEUU, obtained via TIPS as previously described [157].  Briefly, PEUU solutions in 
DMSO (10% w/v) were poured at 80°C into custom-made molds, accordingly dimensioned for 
the two different scaffold sizes.  Each mold consisted of an internal SS (for the ID-4.7 mold) or 
tungsten carbide mandrel (for the ID-1.3 mold) covered by PTFE tubing.  The mandrels were 
concentrically aligned into a tubular glass sheath via two custom-machined PTFE sealing 
stoppers (Figure 4.1).  The molds were filled with hot polymer solution and then rapidly cooled 
to -80°C for 3 hours, inducing the separation of the phases (solvent/polymer). The molds were 
subsequently uncapped and immersed in ethanol for 1-2 weeks at 4°C to allow the solid solvent 
crystals to completely dissolve, yielding an interconnected pore structure.  The scaffolds were 
washed for 48 hours in demineralized water to remove residual solvent, and freeze-dried for an 
additional 48 hours.  
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 Figure 4.1  Custom made molds used for creating the internal TIPS PEUU layer of the ES-TIPS scaffolds. 
 
 
 
The TIPS conduits were subsequently coated by ES of PEUU using an apparatus and technique 
previously described [57].  Briefly, the TIPS conduits were slipped onto mandrels (diameters: 4.0 
mm, 1.0 mm) in conjunction with an intermediate thin sleeve made of PTFE tubing to facilitate 
insertion and removal.  PEUU solution in HFIP (8% w/w) was prepared and loaded into 10 mL 
syringes connected via plastic tubing to a steel capillary (ID = 1.2 mm), which was suspended 7 
cm over the target TIPS tubular scaffold/mandrel.   
The mandrels were rotated at 250 rpm and simultaneously translated on an x-y stage 
(Velmex Inc., Bloomfield, NY) along the longitudinal direction of the mandrels in a cyclic 
manner (translational speed = 6 cm/s, amplitude = 8 cm, frequency = 0.4 Hz).  The mandrels 
were charged with -3 kV, while the capillary was charged with 10 kV.  High voltage was 
supplied for each component using a combination of two high voltage generators (Gamma High 
Voltage Research, Ormond Beach, FL).  The polymer solution was infused via a precision 
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syringe pump (Harvard Apparatus, Holliston, MA) at 1 mL/hr.  The ES time for the ID-4.7 
scaffold was 1 hour while for the ID-1.3 was 15 minutes. 
A schematic of the entire process is shown in Figure 4.2.  At the end of the process, 
electrospun polymer deposited beyond the extension of the underlying TIPS scaffold was 
removed with a razor.  The scaffolds were dried within a vacuum chamber for 24 hours.  
Sterilization was performed by immersing the scaffolds in 70% ethanol solution for 24 hours 
followed by multiple washes with sterile DPBS. 
4.2.3 Statistical methods 
All statistical analysis was performed using SPSS v.15 software (SPSS Inc., Chicago, IL). All 
datasets were tested for normality via the Shapiro-Wilk test. Comparison of the mean values of 
the data sets was performed using one-way ANOVA. Post hoc analysis was performed via 
Bonferroni test. Student’s t-test was used to determine significant differences between different 
set of data. All measures are presented as mean ± standard deviation. A confidence interval 
greater than 95% was considered significant (p<0.05).  
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 Figure 4.2  ES-TIPS PEUU scaffold fabrication.  A.  The inner layer of the compound scaffold is obtained by 
pouring hot polymer solution into a custom-made mold and rapidly freezing it to induce solvent-polymer phase 
separation (TIPS).  B.  After freeze drying, the resulting tubular scaffolds are mounted onto a mandrel in order to 
deposit an external micro-fibrous PEUU layer via electrospinning (ES).  An intermediate sleeve between the TIPS 
scaffold and the mandrel is used to facilitate removal of the ES-TIPS scaffold at the end of the procedure.   
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 4.2.4 Morphological assessment 
4.2.4.1 Methods 
ES-TIPS PEUU scaffolds were immersed in liquid nitrogen and rapidly cut with a cold razor to 
generate a sharp fracture, exposing a cross-section with preserved structural features.  The 
specimens were mounted dry on aluminium stubs with a double adhesive copper tape and sputter 
coated with a 3.5 nm thick layer of gold/palladium (Sputter Coater 108 auto, Cressington 
Scientific Instruments Inc., Cranberry Twp., PA).  The cross-sections were imaged by field 
emission SEM (JSM-6330F, JEOL ltd. Tokyo, Japan).  Image-based analysis (ImageJ) was used 
to measure the thickness of the two layers, the dimension of the pores, and the thickness of the 
ES nanofibers.  A total of 10 to 30 measurements were used for each scaffold analyzed (n = 3).  
Pore size was measured as the maximum diameter of all void spaces visible in the image.  
4.2.4.2 Results 
ES-TIPS PEUU scaffolds appeared macroscopically smooth and without any gross defects 
(Figure 4.3-A).  Observed under SEM, the scaffolds exhibited a morphology characterized by 
two distinct layers: a highly porous internal layer (TIPS) and a fibrous external layer (ES) 
(Figure 4.3-Figure 4.4).  The measured thickness of the TIPS layer in the ID-1.3 and the ID-4.7 
scaffolds was 345±55 μm and 481±74 μm, respectively.  No statistical difference in thickness 
was detected for the TIPS scaffolds before and after ES (p = 0.79), demonstrating absence of a 
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significant compression effect due to the ES process.The external ES layer in the ID-1.3 and the 
ID-4.7 scaffolds had a thickness of 73±26 μm and 253±60 μm, respectively.  The two layers 
appeared to be firmly adhered to each other with no grossly visible delaminations (i.e., 
disconnections larger than the average TIPS pore size; see, e.g., Figure 4.3-C).   
The observed adherence between the layers was presumably due to the combined effects 
of the many localized fusions of the ES nanofibers with the pore walls of the TIPS scaffolds 
(Figure 4.3-D).  The TIPS layers of the ID-1.3 scaffolds had pore sizes measuring 5.1±3.2 μm 
while for the ID-4.7 scaffolds the pore size was 123±20 μm.  The pore size of the ES layer (for 
both scaffold sizes) was 5.1±3.2 μm while the diameter of the ES nanofibers was 743±201 nm.   
A summary of morphological properties is shown in Table 4-1. 
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Figure 4.3  Representative morphological assessment of the ID-4.7 ES-TIPS PEUU scaffold.  A.  Macroscopic 
appearance after electrospinning.  B.  Micrograph representing a cross-sectional portion of the compound scaffold. 
The arrow indicates the lumen.  C.  Interface between the two layers of the scaffold.  D.  Adhesion points (indicated 
by black arrow heads) in which electrospun fibers are fused with the pore structures of the TIPS. 
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Figure 4.4  Representative morphological assessment of the ID-1.3 ES-TIPS PEUU scaffold.  A.  Micrograph of the 
whole cross-section.  B.  Magnification of the boxed area in A.  The arrow indicates the lumen of the scaffold. 
 
 
 
Table 4-1  Summary of morphological properties of the ES-TIPS PEUU scaffolds. 
 
N Mean Standard deviation
Thickness of Uncoated Small TIPS Scaffolds (μm) 3 389.9 48.9
Thickness of Uncoated Large TIPS Scaffolds (μm) 3 489.3 45.1
Thickness of TIPS Layer for Small Scaffolds (μm) 3 345.8 55.1
Thickness of TIPS Layer for Large Scaffolds (μm) 3 481.4 74.4
Thickness of ES Layer for Small Scaffolds (μm) 3 73.9 26.8
Thickness of ES Layer for Large Scaffolds (μm) 3 253.2 60.1
Pore Size of TIPS Layer for Small Scaffolds (μm) 3 50.8 3.1
Pore Size of TIPS Layer for Large Scaffolds (μm) 3 123.3 20.1
Pore Size for ES Layer (μm) 3 5.1 3.2
Diameter of ES Fibers (nm) 3 743.2 201.7  
 
 138 
4.2.5 Mechanical properties 
Mechanical testing was performed only on the ID-4.7 ES-TIPS conduits due to size limitations 
of the ID-1.3 scaffolds (~3 mm for the circumferential direction), which did not allow for a 
complete characterization.  In addition, a batch of ID-4.7 TIPS PEUU and ES PEUU was tested 
to assess uniaxial mechanical properties in order to assess the mechanical contribution of each 
component of the ES-TIPS Scaffolds.  Additionally, human saphenous veins (hSVs) and porcine 
internal mammary arteries (pIMAs) (generously provided by Dr. Marco Zenati) were obtained 
from remaining portions of vein grafts used in CABGs procedures and from animals used for 
unrelated acute surgical studies, respectively.  These native vessels were assessed to compare the 
mechanical properties of the ES-TIPS PEUU scaffolds with those of native vessels and 
determine the suitability of the scaffold for in vivo applications.   
4.2.5.1 Uniaxial tensile testing 
To measure uniaxial material properties of the scaffold conduits, a tensile tester (Tytron TM250, 
MTS System Corp., Minneapolis, MN) mounted with a 10 lb force transducer (Model 661.11B-
02, MTS System Corp., Minneapolis, MN) was used.  Dry scaffolds were cut into strips (width 
~2 mm, length ~15 mm) along their circumferential or longitudinal directions.  Adjacent samples 
were paraffin embedded and sectioned to retrieve accurate thickness measurements of each 
specimen via image-based techniques.   
To ensure a firm but delicate retention of the scaffold within the metal tensile system 
clamps, each specimen was mounted via a sandwich of thin cardboard and hot glue [158].  
Specimen length and width were measured with a digital caliper (Thermo Fisher Scientific, 
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Waltham, MA).  The specimens from each direction were pulled at 10 mm/min crosshead speed 
until rupture following 10 cycles of preconditioning to 20% strain.  Load–displacement curves 
were computed to obtain stress–strain relationships according to current length and cross-
sectional area with the assumption of incompressibility [58].  This assumption implies that the 
measurable initial volume of the tested specimen remains constant throughout testing.  
Therefore, knowing the stretch λ = L/L0 (ratio between the current, deformed specimen length 
(L) and the initial length (L0)) of the tested strip, it is possible to retrieve the deformed cross-
sectional area as: A = A0/ λ.  The Cauchy stress is then calculated as σ = F/A (load/deformed 
cross-sectional area).  The strain was conventionally calculated as: ε = λ – 1.   
Ultimate tensile stress (UTS) and strain to failure (STF) were considered, respectively as 
the maximum stress value before failure and its corresponding value of strain.  Elastic modulus 
was estimated by calculating the slope of the stress-strain curves using a linear regression fitting 
curve for levels of circumferential strain measured while pressurizing (see the experimental setup 
description in Section 4.2.5.5) the scaffolds from physiologic diastolic to systolic values of 
arterial pressure (80-120 mmHg). 
4.2.5.2 Ring testing 
Native vessels were tested uniaxially only in the circumferential direction following a 
slightly different experimental setup (ring strength [159]).  This was due to size limitation of the 
native vessels and to the difficulty in establishing a firm grip of the wet and slippery native tissue 
as done for the dry scaffolds.  In particular, to measure ring strength, an ATS uniaxial tensile 
tester (10 mm/min crosshead speed according to ASTM D638-98 until sample failure) mounted 
with a 10 lb force transducer (SM-10, Interface) was modified to surround the two clamps with a 
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custom-fabricated sealed chamber filled with saline.  A recirculation circuit composed of a roller 
pump, PVC tubing, and heat exchanger was constructed in order to maintain a constant 
temperature of 37ºC during the tests (Figure 4.5).   
 
 
 
 
Figure 4.5  Custom-made ring test setup provided with recirculation saline chamber. 
 
 
 
A ring of each vessel was cut (1-2 mm length) and diameter, thickness, and width was 
measured with a dial caliper.  The rings were inserted with two custom made stainless steel flat 
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hooks that were subsequently attached to the clamps of the testing device.  All specimens were 
preconditioned prior to testing with 10 cycles at 5% circumferential stretch.  Load-displacement 
curves were computed to obtain stress-strain relationships according to initial length and current 
cross-sectional area with the assumption of incompressibility, as previously described.  The 
stress-strain relationships were derived to calculate the instantaneous elastic modulus.  A 
schematic of the ring testing procedure is shown in Figure 4.6. 
 
 
 
 
Figure 4.6  Ring test schematic. Image from [58]. 
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4.2.5.3 Burst testing 
Burst pressure was measured by pressurizing the scaffolds and the native vessels with a controlled 
flow of compressed air within a simple closed circuit (Figure 4.7).  Scaffolds were loaded 
internally with high viscosity freezing medium (TBS, Triangle Biomedical Sciences) 
immediately prior to testing in order to clog the pores avoiding transluminal flow for complete 
pressure retention [58].  This gel has no significant mechanical properties as evidenced by a 
simple mechanical testing experiment in which the pressure required to burst a bubble of gel was 
measured to be smaller than 4 mmHg.  Air was infused at 100 mL/min as recommended by 
previous work [156].  Pressure was measured via a high pressure gauge (pressure range = 0-60 
PSI, Noshok, Berea, OH) after clamping the downstream line (Figure 4.7).  The maximum 
pressure before rupture was taken as the burst pressure.  
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 Figure 4.7  Burst test setup.  
 
 
 
4.2.5.4 Suture retention testing 
Suture retention testing was performed according to American National Standard Institute-
Association for the Advancement of Medical Instruments (ANSI/AAMI) VP20 standards [32] 
using the same testing apparatus as for the uniaxial testing.  Briefly, each tubular scaffold and 
native tissue was cut to obtain rectangular strips (n = 4, length = 10 mm, width = 4 mm).  The 
short edge of each specimen belonged to the circumference of the original tubular scaffold to 
replicate the direction of the actual pulling force involved in an end-to-end anastomosis.  A 
single 5-0 PDS™ (Ethicon, Inc.) loop was created 2 mm from the short edge of each sample and 
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secured to a hook connected to the clamp of the testing device.  An extension rate of 2 mm/sec 
was used to pull the suture.  Suture retention force was considered to be the maximum force 
recorded prior to pull–through of the suture.  Suture retention strength was obtained by 
normalizing the suture retention force to the thickness of each scaffold.  
4.2.5.5 Compliance and β stiffness testing 
Dynamic compliance and β stiffness measurements were performed via a previously described 
vascular perfusion system [160].  The flow loop was filled with saline at room temperature, and 
delivered physiologic, arterial, pulsatile intraluminal pressure (120/80 mmHg) and flow (100 
mL/min).  Briefly, a pulsatile centrifugal pump (Biomedicus 520D, Medtronic, Minneapolis, 
MN) was used to provide a sinusoidal pulsatile flow to tees enclosed into a testing chamber.  
Two pressure transducers (Model TJE, Honeywell – Sensotec Co., Columbus, OH) placed 
equidistant upstream and downstream of the vessel central point were used to measure 
intraluminal pressure.  The pressure in the center of the vessel was then calculated as the average 
between the proximal and distal pressure transducer measurements.  The outer diameter of the 
pressurized scaffolds was measured with a He-Ne laser micrometer (Beta LaserMike, Dayton, 
OH).  Both pressure and diameter signals were automatically recorded at 30 Hz for 1 minute 
every hour over 24 hours via an acquisition card connected to a personal computer.  Compliance, 
C, was calculated from recordings of pressure, P and inner diameter, IDp as:   
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The inner diameter at a given pressure P, IDp, was estimated via an assumption of 
incompressibility from the cross sectional area, A, of the scaffold (measured from histological 
sections of the same construct using ImageJ software), and the outer diameter ODp of the 
scaffold (measured via a laser micrometer) by the expression:   
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Recordings of ODp for each time point were also used to calculate the percentage of scaffold 
dilation over time (ΔOD%) to quantify possible plastic deformations due to creep.  This value 
was calculated by dividing the average pressurized external diameter at each time point by the 
initial average pressurized external diameter for each tested scaffold.   
Native vessels were tested also for static compliance; briefly, the constructs were 
subjected to a pressure ramp (0-200 mmHg) by means of a syringe pump (Harvard Apparatus), 
and the circuit was clamped downstream while the pump infused saline at a constant rate (4 
mL/min).   
 Pressure-diameter relationships during compliance measurements were also used to 
compute the dimensionless stiffness index, β, via: 
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deformations of the scaffolds, which could possibly lead to dilations during sustained exposure 
to pulsatile arterial pressures. 
4.2.5.6 Results 
All scaffolds exhibited anisotropy for supra-physiologic values of distension reached throughout 
the uniaxial testing.  The circumferential properties were generally characterized by a lower 
slope (stiffness) and lower UTS compared to the longitudinal properties for all three scaffolds.  
In particular, TIPS and ES PEUU scaffolds exhibited very different uniaxial properties with 
different shapes of the stress-strain curve.  The TIPS curve had an almost linear behavior (Figure 
4.8) while the ES curve had an exponential trend more similar to native tissues (Figure 4.9), as 
expected.  The uniaxial curve for the ES-TIPS PEUU scaffolds revealed a behavior that was in 
between that for the TIPS and ES alone, suggesting a balanced contribution of the two 
components (Figure 4.10 and Figure 4.11).   
A comparison of the three different scaffolds is shown in Figure 4.12.  
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 Figure 4.8  TIPS PEUU uniaxial mechanical properties within a physiologically-relevant range of strain (mean ± 
standard deviation; n = 3). 
 
 
Figure 4.9  ES PEUU uniaxial mechanical properties within a physiologically-relevant range of strain (mean ± 
standard deviation; n = 5). 
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 Figure 4.10  ES-TIPS uniaxial mechanical properties within a physiologically-relevant level of strain (mean ± 
standard deviation; n = 3). 
 
 
Figure 4.11  Circumferential and longitudinal uniaxial tensile properties of ID-4.7 scaffolds (mean ± standard 
deviation; n = 3) along the complete testing range.  The scaffold shows significant anisotropy (p<0.05; n = 3) with 
stiffer and stronger mechanical properties in the longitudinal direction.  The level of strain to failure is comparable 
in the two directions. 
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 Figure 4.12   Comparison of uniaxial properties of the three scaffolds.  Note how the ES-TIPS material properties 
fall between those of its two individual components, as expected. (TIPS PEUU: n = 3; ES PEUU: n = 5; ES-TIPS 
PEUU: n = 3) 
 
 
 
The circumferential and longitudinal UTSs for the TIPS scaffolds were statistically 
different (p = 0.038) with values of 0.4±0.1 MPa and 0.7±0.2 MPa, respectively; while this 
values were not statistically different (p = 0.21) for the ES scaffolds UTSs, with values of 
14.0±2.9 MPa and 17.2±5.7 MPa, respectively.  For the ES-TIPS, the circumferential UTS was 
statistically weaker (8.3±1.7 MPa; p 0.013) than the longitudinal UTS (21.1±4.8 MPa).  The ES 
and ES-TIPS scaffolds were significantly stronger (p < 0.001) than the TIPS PEUU, regardless 
of the direction.  Figure 4.13 summarize the strength comparison among the three different 
scaffolds.  The circumferential UTS of the hSVs and pIMAs were 3.7±2.0 MPa and 10.4±7.1 
MPa, respectively (Figure 4.14).  
 
 150 
 Figure 4.13  Comparison of strength among the three different scaffolds.  The bars indicate the absence of statistical 
significance between two groups; all the other comparisons are statistically significant (p < 0.05).  (TIPS PEUU: n = 
3; ES PEUU: n = 5; ES-TIPS PEUU: n = 3).  
 
 
Figure 4.14  Comparison in circumferential UTS between ES-TIPS PEUU scaffolds and native vessels.  The bar 
indicates statistically significant difference (p < 0.05) between two groups; all the other comparisons are not 
statistically significant.  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
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The STF of the TIPS scaffolds was not statistically different in the two directions (p = 
0.59) with circumferential and longitudinal values of 1.0±0.1 and 1.3±0.4, respectively.  
Similarly, the ES PEUU STF was not statistically different in the circumferential and 
longitudinal directions (p = 0.35) with values of 2.8±0.3 and 2.5±0.5, respectively.  The ES-TIPS 
scaffolds were significantly more distensible (i.e., greater STF; p < 0.05) than the two other 
scaffolds with no significant differences in the two directions (circumferential STF = 5.3±0.5, 
longitudinal STF = 5.6±0.7; p = 0.56) (Figure 4.15).  The circumferential STF for the hSVs and 
pIMAs were 1.7±0.7 and 1.5±0.2, respectively (Figure 4.16).   
 
 
 
 
Figure 4.15  Strain to failure results from uniaxial tensile tests for the three different scaffolds.  The bars indicate 
the absence of statistical significance between two groups; all the other comparisons are statistically significant (p < 
0.05).  (TIPS PEUU: n = 3; ES PEUU: n = 5; ES-TIPS PEUU: n = 3). 
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 Figure 4.16  Comparison in circumferential STF between ES-TIPS PEUU scaffolds and native vessels.  The bar 
indicates absence of statistically significant difference between two groups; all the other comparisons are 
statistically significant (p < 0.05).  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6) 
 
 
 
 
The approximated elastic modulus was not significantly different in the two directions for 
TIPS (p = 0.41) and ES-TIPS (p = 0.23) scaffolds, while the ES PEUU scaffolds exhibited 
statistically different moduli (p = 0.0008) (TIPS: circumferential = 0.4±0.03 MPa, longitudinal = 
0.76±0.1 MPa; ES: circumferential = 2.9±0.3 MPa, longitudinal = 4.7±0.5 MPa; ES-TIPS: 
circumferential = 1.4±0.4 MPa, longitudinal = 1.8±0.3 MPa) (Figure 4.17).  The circumferential 
elastic modulus for the hSVs and pIMAs was 2.3±1.3 MPa and 0.4±0.2 MPa (Figure 4.18).  A 
summary of the uniaxial properties for ES and TIPS PEUU is shown in Table 4-2. 
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 Figure 4.17  Approximated elastic modulus for the three different scaffolds.  The bars indicate absence of 
statistically significant difference between two groups; all the other comparisons are statistically significant (p < 
0.05).  (TIPS PEUU: n = 3; ES PEUU: n = 5; ES-TIPS PEUU: n = 3). 
 
 
Figure 4.18  Comparison in approximated circumferential elastic between the ES-TIPS scaffolds and the native 
vessels.  The bar indicates absence of statistically significant difference between two groups; all the other 
comparisons are statistically significant (p < 0.05).  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
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 Table 4-2  Summary of uniaxial tensile properties for the two single components of the ES-TIPS PEUU scaffolds. 
 
N Mean Standard deviation
ES PEUU Circumferential ultimate tensile stress (MPa) 5 14.5 2.2
TIPS PEUU Circumferential ultimate tensile stress (MPa) 3 0.4 0.1
ES PEUU Longitudinal ultimate tensile stress (MPa) 5 17.2 5.7
TIPS PEUU Longitudinal ultimate tensile stress (MPa) 3 0.7 0.2
ES PEUU Circumferential strain to failure 5 2.8 0.3
TIPS PEUU Circumferential strain to failure 3 1.2 0.2
ES PEUU Longitudinal strain to failure 5 2.5 0.5
TIPS PEUU Longitudinal strain to failure 3 1.3 0.4
ES PEUU Circumferential elastic modulus (MPa) 5 2.9 0.3
TIPS PEUU Circumferential elastic modulus (MPa) 3 0.4 0.1
ES PEUU Longitudinal elastic modulus (MPa) 5 4.6 0.4
TIPS PEUU Longitudinal elastic modulus (MPa) 3 0.7 0.2  
 
 
 
The burst pressure for the ID-4.7 ES-TIPS PEUU scaffolds was 2292±599 mmHg.  The 
burst strength for hSVs and pIMAs was 1267±569 mmHg and 2146±263 mmHg, respectively 
(Figure 4.19).  Suture retention force for the ES-TIPS scaffold was 3.4±0.3 N, while the suture 
retention tension was 5.1±0.4x103 N/m.  The suture retention force for the hSVs and pIMAs was 
2.6±0.8 N and 1.0±0.3 N (Figure 4.20), while the suture retention tension was 6.2±2.4x103 N/m 
and 4.3±1.9x103 N/m, respectively (Figure 4.21).  
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 Figure 4.19  Comparison in burst pressure between ES-TIPS PEUU scaffolds and native vessels.  The bar indicates 
statistically significant difference between two groups (p < 0.05); all the other comparisons are not statistically 
significant.  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
 
 
Figure 4.20  Comparison in suture retention force between the ES-TIPS PEUU and native vessels.  The bar 
indicates absence of statistically significant difference (p < 0.05) between two groups; all the other comparisons are 
statistically significant.  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
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 Figure 4.21  Comparison in suture retention strength between ES-TIPS PEUU and native vessels.  None of the 
differences are statistically significant.  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
 
 
 
Comparison of the pressure-diameter (P-D) relationships for the ES-TIPS PEUU 
scaffolds before (Figure 4.22) and after (data not shown) 24 hours of perfusion, showed no 
significant differences.  P-D curve for the ES-TIPS scaffolds were compared to those obtained 
with the native vessels (Figure 4.23).  The dynamic compliance for the hSVs and pIMAs was 
3.4±2.0x10-4 mmHg-1 and 11.2±6.0 x10-4 mmHg-1, respectively.   
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 Figure 4.22  Pressure-diameter relationship under physiologic pulse pressures for the ID-4.7 scaffolds at the 
beginning of the 24 hour perfusion. The curve is a second-order polynomial interpolation of the data points from n = 
3 tested scaffolds.  
 
 
Figure 4.23  Comparison of P-D curves between ES-PEUU scaffolds and native vessels.  The results are presented 
as Average ± SEM.  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
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Recordings of the percentage of variation of the initial average OD over 24 hours of 
perfusion, detected a non-significant increase in average diameter (Figure 4.24). 
 
 
 
 
Figure 4.24  Percent variation of average external diameter for the ID-4.7 scaffold over the pulse during 24 hours of 
arterial perfusion ex vivo (mean ± standard deviation; n = 3).  No significant differences were noted between any 
time points over 24 hours of cyclic pressure 
 
 
 
Though a slight, non-significant dilation occurred (<1% over 24 hrs), the diameter at the 
end of the 24 hours was not statistically different from that recorded at the beginning.  
Compliance also did not change significantly over 24 hours from its initial value of 4.6±0.5x10-4 
mmHg-1 (Figure 4.25).  The compliance for the hSVs and pIMAs were 3.4±2.0x10-4 and 
11.2±6.0x10-4 mmHg-1, respectively (Figure 4.26). 
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Figure 4.25  Dynamic compliance of the ID-4.7 scaffold measured over 24 hours of mechanical training under 
arterial physiologic pulsatile pressure (mean ± standard deviation; n = 3).  No significant differences were detected 
between any time points. 
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 Figure 4.26  Comparison in dynamic compliance between ES-TIPS PEUU scaffolds and native vessels.  The bar 
indicates statistically significant difference between two groups; all the other comparisons are not statistically 
significant (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6). 
 
 
 
Similarly, the dimensionless stiffness index β did not change significantly over the 24 
hour perfusion, with an initial value of 21.6±2.9 (Figure 4.27).  The stiffness index for the hSVs 
and pIMAs were 46.0±11.9 and 14.0±11.9, respectively. 
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 Figure 4.27  β stiffness of the ID-4.7 scaffold measured over 24 hours of mechanical training under arterial 
physiologic pulsatile pressure (mean ± standard deviation; n = 3).  No significant differences were detected between 
any time points. 
 
Figure 4.28  Comparison in β stiffness between the ES-TIPS PEUU scaffolds and the native vessels.  The bar 
indicates absence of statistically significant difference between two groups; all the other comparisons are 
statistically significant (p < 0.05).  (ES-TIPS PEUU: n = 3; hSV: n = 4; pIMA: n = 6).  
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 A summary of biomechanical values measured for the ES-TIPS PEUU scaffolds and for 
the native vessels is shown in Table 4-3 and Table 4-4. 
 
 
 
Table 4-3  Summary of biomechanical properties of the ES-TIPS PEUU scaffolds. 
 
N Mean Standard deviation
Circumferential ultimate tensile stress (MPa) 3 8.3 1.7
Longitudinal ultimate tensile stress (MPa) 3 21.1 4.8
Circumferential strain to failure 3 5.3 0.5
Longitudinal strain to failure 3 5.6 0.7
Circumferential elastic modulus (MPa) 3 1.4 0.4
Longitudinal elastic modulus (MPa) 3 1.8 0.3
Burst pressure (mmHg) 3 2292 599
Suture retention force (N) 4 3.4 0.3
Suture retention tension (N/m)x103 4 5.1 0.4
Dynamic compliance (mmHg-1)x10-4 3 4.6 0.5
Stiffness index 3 22.2 3.1  
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 Table 4-4  Summary of biomechanical properties of native hSVs and pIMAs. 
 
N Average Standard Deviation
hSV thickness (μm) 4 436 121
pIMA thickness (μm) 6 231 38
hSV circumferential UTS (MPa) 4 3.7 2.0
pIMA circumferential UTS (MPa) 6 10.4 7.1
hSV circumferential STF 4 1.7 0.7
pIMA circumferential STF 6 1.4 0.2
hSV circumferential E (MPa) 4 2.3 1.3
pIMA circumferential E (MPa) 6 0.4 0.2
hSV burst pressure  (mmHg) 4 1267 569
pIMA burst pressure  (mmHg) 6 2146 263
hSV suture retention force (Newton) 6 2.6 0.8
pIMA suture retention force (Newton) 6 1.0 0.3
hSV suture retention tension (Newton/m) 6 6.2 2.4
pIMA suture retention tension (Newton/m) 6 4.3 1.9
hSV dynamic compliance (mmHg-1)x10-4 4 3.4 2.0
pIMA dynamic compliance (mmHg-1)x10-4 6 11.2 6.0
hSV β stiffness index 4 46.0 11.9
pIMA β stiffness index 6 15.0 10.0  
 
 
 
4.2.6 Cell seeding capabilities 
The ES-TIPS PEUU scaffolds were bulk-seeded via the RVSD with rMDSCs, obtained and 
cultured as previously described for the murine MDSCs in Section 2.2.3.  To avoid longitudinal 
distribution issues (recall Figure 2.27), the ID-4.7 scaffolds were cut to a length of 2 cm prior to 
seeding.  Both scaffold sizes were seeded using custom made tee adapters with 3x106 (ID-1.3) or 
30x106 (ID-4.7) rMDSCs (corresponding to an equivalent seeding density of approximately 
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1.5x105 cells/mm3).  The seeding parameters were: a vacuum of -5 inHg, an infusion rate of 2.5 
mL/min and a rotational speed of 150 rpm (for the ID-1.3 scaffolds), or an infusion rate of 4 
mL/min and a rotation speed of 10 rpm (for the ID-4.7 scaffolds).   Immediately after the seeding 
of each sample, the media exuded through the scaffold into the RVSD chamber was collected 
and used for cell counting via a hemocytometer to calculate seeding efficiency (percentage of 
initial cell number entrapped within the scaffolds).  Subsequently, the scaffolds were placed in 
static culture in Petri dishes for two hours and then processed for fluorescence-based cytoskeletal 
and nuclear staining and imaging as shown in Section 2.2.3.  The scaffolds were visualized with 
high exposure times (~10 sec) under a TRITC filter. 
After two hours of culture, following seeding, fluorescent staining showed high cellular 
density inside the internal TIPS layer for both the ID-1.3 and ID-4.7 constructs (Figure 4.29).  
Cell distribution was qualitatively uniform across the entire thickness (radial direction) of the 
internal layer of the TEVG, and throughout the circumferential and longitudinal direction.  An 
extensive quantitative analysis of seeding uniformity was beyond the scope of this exercise.  
However, this type of analysis has been shown for the ID-4.7 scaffolds seeded with the S-RSVD 
in Section 3.1.4.  The external ES layer did not exhibit the presence of any cells, as expected, 
due to its small, restrictive pore size, not allowing passive cell penetration.  Cell seeding 
efficiency in the ID-4.7 and ID-1.3 scaffolds was 91.3±1.6% and 93.2±1.7%, respectively.  The 
seeding procedure took 1.5 min for the ID-1.3 scaffolds and 5 min for the ID-4.7. 
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 Figure 4.29  Representative cell density into the TIPS layer of the ES-TIPS PEUU scaffolds 2 hours after seeding (n 
= 3).  A.  ID-4.7 scaffolds.  B.  ID-1.3 scaffolds.  The arrows indicate the luminal surface. Blue = nuclei, green = F-
actin, red = scaffold. Magnification = 100X. 
 
 
 
4.2.7 Discussion and limitations of ES-TIPS scaffold  
We developed and tested a PEUU-based scaffold for vascular tissue engineering obtained by 
combining two previously developed PEUU-processing techniques: TIPS [53] and ES [57].  The 
biocompatibility, cell attachment, and tunability of degradation rate and mechanical properties 
for the PEUU were previously demonstrated [51].  Moreover, recent in vivo studies showed how 
the same material did not produce detrimental host inflammatory response due to its degradation 
products but rather fostered remodeling [161, 162].  Morphologically, the scaffold was 
biomimetic, presenting two concentric layers with the highly cellularized, porous TIPS layer 
mimicking the functional tunica media and the fibrous, external ES layer acting as the adventitial 
layer providing mechanical support (see Figure 4.3 and Figure 4.4).  We speculate that these 
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features might be able to guide the process of neo-tissue formation toward native-like features 
upon remodeling in vivo.  In Chapter 6 we will address this point in detail. 
Mechanically, the ES-TIPS PEUU scaffolds showed a predictable compromise between 
the mechanical properties of its two single components (TIPS PEUU and ES PEUU), leading to 
ideal mechanical properties for arterial vascular applications.  In particular, the ES-TIPS values 
of UTS (Figure 4.14), elastic modulus (Figure 4.18), dynamic compliance (Figure 4.26), and β 
stiffness (Figure 4.28) were between those of hSVs and pIMAs.  The ES-TIPS PEUU had 
physiologically-compatible values of burst pressure (Figure 4.19) and suture retention strength 
(Figure 4.20 and Figure 4.21).  When compared with previously described mechanical 
properties of human arteries, the ES-TIPS PEUU scaffolds showed comparable burst strength 
and suture retention force values (burst pressure = 2031-4225 mmHg, suture retention force = 
2.0±1.1 N) [32].  Furthermore, the ES-TIPS PEUU scaffold exhibited compliance, β stiffness, 
and elastic modulus similar to those measured for healthy human coronary arteries (compliance 
= 14.1±5.9x10-4 mmHg-1, β stiffness = 16.9±7.1, elastic modulus = 1.4±0.7 MPa) [163].  These 
characteristics suggest that the ES-TIPS PEUU scaffold may represent an ideal substitute for 
matching the mechanical properties of native arteries.  Indeed, in light of the previously 
demonstrated ability to reproducibly control the anisotropy of ES PEUU by varying the 
rotational speed of the mandrel [56], it is expected that a similar degree of control will be 
possible in the context of ES-TIPS PEUU scaffolds, thus potentially allowing for TEVG 
anisotropy to be tailored to that of the particular vessel targeted for replacement.  However, a 
comprehensive study toward the optimization of mechanical properties and anisotropy of the ES-
TIPS scaffold was beyond the scope of this dissertation and, therefore, was not performed.   
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The ES-TIPS PEUU scaffolds maintained their geometry and mechanical properties over 
time while perfused ex vivo for 24 hours with physiologic, pulsatile pressure waveforms (see 
Section 4.2.5.5).  This feature may be critical for the in vivo applications of the scaffold as a 
TEVG.  Aneurysm formation, for example, is a possible drawback of TEVGs and may be due to 
the intrinsic viscoelastic behavior of thermoplastic polymers (creep) and weakening associated 
with degradation kinetics.  The relatively slow in vitro degradation previously reported for 
PEUU [51] would likely help the host remodeling mechanisms to gradually replace the scaffold 
with native tissue while the scaffold provides mechanical integrity over an extended period of 
time.  In vivo studies for extended implant periods will address this concern in Chapter 6. 
The seeding via the RVSD yielded high cell density (~1.5x105 cells/mm3) in both the ID-
1.3 and the ID-4.7 scaffold sizes (Figure 4.29) within a few minutes of seeding procedures and 
with high seeding efficiencies (>92%).  These features are critical for the future clinical 
translation of TEVGs, where rapid turn-around time is desired, and any amount of donor cells 
wasted due to inefficient seeding could be unacceptable.  Chapter 5 will present longer-term 
biological endpoints regarding the incorporation of cells into TIPS PEUU [54] and ES-TIPS 
PEUU scaffolds following seeding and in vitro culture.  These endpoints include cell viability, 
proliferation, phenotype and ECM deposition.  The assessment of these endpoints is clearly 
important prior to pre-clinical animal studies.  The scope of the cell seeding studies conducted 
herein had only the aim of demonstrating feasibility, with the primary focus being the 
mechanical characterization of the construct.  
While the ES-TIPS PEUU scaffold exhibited material properties similar to native arteries, 
these results were limited to some of the tests performed in a dry state at room temperature and 
without cellular components for ease of testing.  These testing conditions are different from those 
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that the scaffold would experience when implanted in vivo, where the material would be 
hydrated, infiltrated with cells, at body temperature, and in contact with a complex biological 
milieu.  It has been shown that the material properties of synthetic scaffolds might vary 
depending on the hydration conditions of the scaffold [164].  The reported differences in 
mechanical properties between dry and wet samples were within the same order of magnitude.  
Therefore, testing in simplified environmental conditions might not significantly affect the 
mechanical properties of the scaffold reported here.  Once implanted, the scaffold will undergo 
degradation and remodeling which will affect the mechanical properties over time.  In Chapter 6 
we will quantify the performance of these scaffolds following in vivo remodeling.
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5.0  SPECIFIC AIM 3: IN VITRO STUDIES TO UNDERSTAND CELL-SCAFFOLD 
INTERACTIONS AND “MATURATION” OF THE TEVG 
5.1 BIOLOGICAL ANALYSIS OF MURINE MDSCS INCORPORATED INTO TIPS 
PEUU SCAFFOLDS AND CULTURED IN VITRO 
5.1.1 Initial considerations toward the development of a stem cell-based TEVG 
The development of the first generation seeding device (RVSD, see Section 2.1) – which 
allowed for an effective, fast, and reproducible cell integration within porous, tubular scaffolds 
(i.e., the fabrication of a TEVG) – initiated a series of subsequent studies investigating the 
culture and maturation of cells into a 3D porous tubular matrix.  The purpose of these studies, 
described in this chapter, was to assess the cell/scaffold interactions over a defined period of 
culture time within different culture conditions in preparation for the in vivo studies.   
As described in Section 1.9, time is a critical factor for the future clinical translation of a 
TEVG, and it is a recurrent key consideration throughout this work.  Short fabrication times are 
essential to propose future products compatible with the standard clinical practice for two basic 
reasons:  first, a long fabrication time is likely to translate into expensive production processes, 
which might be also prone to issues or failure.  Second, from the clinical perspective, it is 
important to allow a consistent percentage of patients among elective and emergent cases to 
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benefit from a TEVG approach.  This group of patients might not be able to wait extended 
periods of time for a TEVG.  Normal histogenesis processes produced in vitro can demand very 
extensive time frames (several months) to produce a native-like ECM structure “mature” enough 
to withstand in vivo implantation with a basic functionality [30].  Therefore, when deciding “how 
good is good enough?” for undergoing implantation of a tissue engineered construct, it is 
necessary to accept or define a compromise between functionality and fabrication time [165].   
As described in Section 4.2, a novel scaffold for vascular applications was developed and 
tested (ES-TIPS PEUU) with the purpose of mimicking the mechanical and structural features of 
native vessels.  The extensive mechanical characterization performed, suggests its suitability to 
withstand the demanding arterial mechanical environment and to match the elastic behavior of 
the native arterial wall.  Behind the development of the biodegradable scaffold was the goal of 
providing a synthetic substrate, which was mechanically suitable for immediate implantation, 
without requiring extended culture time.   
The development of the RVSD was also oriented toward a rapid fabrication time, and 
implantation readiness.  Upon incorporation of cells within the scaffold via the RVSD, it is 
critical to allow cells to settle into the pores, attach, spread, and proliferate before substantial 
mechanical perturbation (such as that experienced with in vivo implantation) can be applied.  
This necessity was realized early on in this work by performing in vitro perfusion experiments of 
the TEVG constructs (data not shown).   
The cells represent the second critical part of our TEVG paradigm and should allow for 
antithrombogenicity once implanted in vivo.  In theory, cells should contribute to the remodeling 
of the TEVG, leading to native-like structural and functional features upon degradation and 
remodeling in vivo.  Progenitor cells show great potential for use in tissue engineering 
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applications and may circumvent many of the shortcomings associated with other options in cell 
sourcing (see Section 1.5).  Progenitor cells are easier to harvest than terminally differentiated 
cells for vascular applications where a muscle biopsy, a bone marrow aspirate or a blood aspirate 
are usually preferable to a blood vessel biopsy to collect endothelial or smooth muscle cells.  
Stem cells also usually display a rapid, almost limitless expansion capability.  The skeletal 
muscle is a valid source of stem cells for tissue and genetic engineering applications.  MDSCs 
are a population of long-term proliferating cells, expressing hematopoietic stem cell markers.  
They have previously shown the ability to retain their phenotype for more than 30 passages with 
normal karyotype and were able to differentiate into muscle, neural, and endothelial lineages 
both in vivo and in vitro [99-101].  MDSCs are a unique population of multipotential cells 
distinct from the well-studied satellite cells, and characterized by more plasticity when compared 
with the satellite cell.  It has been hypothesized that MDSCs could actually be a precursor of the 
satellite cell itself [101].  MDSCs have also been shown to have both a strong self-renewal 
capacity and have proved to be useful in myogenic regeneration models [101, 166, 167].  
MDSCs are SCA-1+, CD34+, and they represent a promising alternative for vascular tissue 
engineering applications [99].  For these reasons MDSCs were used as the cell source of choice 
for our approach.           
The goals of the studies described in this section were to evaluate the interaction of 
MDSCs with the PEUU scaffold, and to identify suitable culture criteria to allow for MDSCs 
proliferation and possibly ECM deposition within the scaffolds prior to implantation within 
scaffolds.      
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5.1.2 Dynamic culture of a MDSC-based TEVG in spinner flasks 
5.1.2.1 Methods 
The first experiments were performed to evaluate the behavior of murine MDSCs in TIPS PEUU 
scaffolds.  The rationale behind the use of mouse cells relied essentially on their extensive 
phenotypic and behavioral characterization, which allowed detecting variations induced by the 
TEVG approach proposed here.   
The synthesis of the polymer was consistent with that previously described in Section 
4.2.1.  That is, the obtained PEUU polymer solution was injected into a cylindrical mold 
consisting of an outer glass tube (ID = 5.5 mm) and an inner PTFE mandrel (OD = 4.5 mm), 
coaxially fixed by two rubber stoppers.  The mold filled with hot PEUU solution underwent 
TIPS processing as described in Section 4.2.2 to obtain porous tubular scaffolds.  Scaffold 
length, ID, and wall thickness were measured with a digital caliper and were nominally 2 cm, 4 
mm, and 300 µm, respectively.  
 Mouse MDSCs were isolated via an established pre-plating technique [99].  Cells were 
then plated at low density (200 cells/cm2) on 175 cm2 flasks and cultured at 37 ºC and 5% CO2 
with complete DMEM media (described in Section 2.2.3).  Cells were expanded to the desired 
number and were only used between passages 10 and 15.  Media changes were performed every 
48 h during culture.  Before use, MDSC monolayers were washed three times in DPBS and then 
incubated with 0.1% trypsin for 5 min to detach them from the flasks.  MDSCs were then 
centrifuged at 1200 rpm for 5 min to form a pellet, and resuspended in DMEM to the desired 
concentration in preparation for seeding.   
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MDSCs were incorporated into the fabricated TIPS PEUU scaffolds (total cell number = 
10x106 cells, seeding suspension density = 2x106 cell/mL) via the RVSD.  Seeding parameters 
were consistent with what was previously described in Section 2.2.3, except for the seeding flow 
rate, which was 5 mL/min.  The constructs (n = 12) were then flushed with 5 mL of plain 
DMEM in order to wash residual cells from the lumen of the scaffolds, and were then removed 
and incubated in a Petri dish for 1 h.  After seeding, the TEVGs were placed in 500 mL spinner 
flasks (196580575, Bellco Glass Inc., NJ) with 100 mL of culture media, supplemented with 50 
mg/mL of ascorbic acid, and stirred at 15 rpm for 7 days.  Control constructs were cultured either 
within the spinner flasks without ascorbic acid or in static culture in a Petri dish. 
To assess cell spreading and distribution, ring segments for different areas of each 
construct were fixed, processed, and imaged for F-actin and nuclear staining as previously 
described in Section 2.2.3.  To assess collagen production and TEVG histology, separate ring 
segments were fixed in 10% neutral buffered formalin for 1 hour.  They were then embedded in 
paraffin blocks and 5 µm sections were cut using a microtome (Thermo Shandon Inc., 
Pittsburgh, PA).  Sections were mounted on slides, stained with H&E and Masson’s trichrome 
and viewed under bright light optics using a Nikon Eclipse E600 microscope. Collagen 
production was qualitatively assessed on acquired images using Adobe Photoshop (v. 7.0, Adobe 
Systems Inc., USA). 
To assess proliferation and viability within the constructs, samples were analyzed with 
MTT mitochondrial activity assay at days 1, 3 and 7 [168].  Briefly, before the TEVG was fixed, 
three rings of approximately equal size (normalized by weight) were randomly sectioned from 
each construct and placed in the wells of a 96-well plate with 200 µl of serum free a-MEM and 
20 μl of MTT solution (Sigma Aldrich, St. Louis, MO) and processed as described in Section 
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2.2.3.  The number of contained cells was estimated by using a standard curve previously 
generated for known cell concentrations and by transforming absorbance to cell number using 
the equation generated by the slope of the curve.  The average reading of the three rings was 
used as the result for each construct.  Comparisons between groups (ascorbic acid supplemented 
and nonsupplemented constructs) were made by a two-tailed paired t-test and results were 
expressed as difference in cell number.  Population doubling time (PDT) and number of 
population doublings (PD) were calculated from those values as: PD = log (cell number at day 
3/cell number at day 1), PDT = time/PD. 
Cells were characterized at day 0 (prior to seeding) and after 7 days of TEVG culture by 
flow cytometry for CD34 and Sca-1 expression.  Briefly, TEVGs were incubated with 0.1% 
trypsin for 5 min to remove MDSCs from the scaffolds.  The cells were then pelleted and 
blocked with 10% mouse serum for 15 min.  Some cells were then labelled with rat anti-mouse 
Sca-1 (phycoerythrin (PE) anti-mouse Ly6A, 1 ml stock, 553336, Pharmingen, USA) and CD34 
(biotinylated, 1 ml stock Purified Rat Anti-Mouse CD 34(1HC)) monoclonal antibodies for 15 
min.  The same proportion of cells were treated with equivalent amounts of isotype control 
antibodies PE-Mouse IgG 2b (33805X, Pharmingen, USA) and biotin purified Rat IgG (11021D, 
Pharmingen, USA).  Both fractions were then washed with PBS and labelled with streptavidin–
allophycocyanin (APC, 1:300, 13049A, Pharmingen, USA), 7-Amino-actinomycin D (7-ascorbic 
acid D), or Via-Probe (555816, Pharmingen, USA) to exclude non-viable cells from the analysis.  
Appropriate gating was performed to determine Sca-1 and CD34 expression via flow cytometry 
with a FACS Aria (Becton Dickinson, San Jose, CA).  Cells at day 0 were processed following 
the same protocol, but without the need for removal from the scaffold.   
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Immunofluorescence was performed to corroborate Sca-1 expression and to assess 
myotube formation (fusion) by myosin heavy chain (MHC) expression.  Briefly, frozen sections 
were obtained as described above and incubated with 0.1% Triton-X 100 in PBS for 10 min.  
Non-specific binding of antibodies was blocked by incubating the samples for 45 min with 5% 
normal donkey serum in PBS with 0.5% bovine serum albumin (Fraction V, Sigma-Aldrich, St. 
Louis, MO) and 0.15% glycine (Sigma- Aldrich, St. Louis, MO).  Following this, the sections 
were incubated at room temperature with the primary antibodies (Sca-1 (1:500) and MHC 
(1:500) Sigma-Aldrich, St. Louis, MO) diluted in blocking solution for 60 min.  Unbound 
primary antibody was removed by subsequent washes in PBS.  Next, the samples were incubated 
with a Cy3-conjugated (Sigma-Aldrich, St. Louis, MO) secondary antibody (1:500) for 1 h at 
room temperature and then rinsed three times for 15 min with PBS.  For nuclear visualization, 
cells were counter-stained with DAPI.  The samples were then mounted in gelvatol and viewed 
under confocal microscopy using an Olympus F1000 confocal microscope.  Positive controls 
were MDSCs cultured at high density for 7 days with low serum. Under these conditions, 
MDSCs undergo myogenic differentiation readily [169].  
Uniaxial mechanical characterization and suture retention tests were performed on the 
seeded scaffolds following the same protocols described in Section 4.2.5.2.  
5.1.2.2 Results 
Immediately after seeding, nuclear staining showed a high number of cells inside the constructs.  
Distribution was qualitatively even along the length and across the entire thickness of the TEVG 
(Figure 5.1-A), confirming the results previously shown in Section 2.2.3.   After 3 days of static 
culture, cells appeared to migrate from the center of the wall toward the inner and outer edges 
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during this timeframe (Figure 5.1-B).  In contrast, the TEVGs cultured in dynamic conditions 
appeared completely populated with cells that were clearly spread throughout the scaffolds 
(Figure 5.1-C).  Macroscopically, the scaffolds appeared to have a tissue-like aspect and texture 
(Figure 5.2).  
 
 
 
 
Figure 5.1  Representative microscopic aspect of MDSC-seeded TEVG.  A.  The constructs showed uniform 
transmural cellular distribution immediately after seeding.  B.  Appearance after 3 days of static culture showing cell 
accumulation at the edges of the polymer.  C.  Appearance after 3 days of culture in spinner flasks showing cell 
spreading throughout the wall thickness.  Green = F-actin, blue = nuclei.  The arrows, indicate the scaffold lumen.  
Image adapted from [54]. 
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 Figure 5.2  Representative macroscopic aspect of the TEVG after 3 days of dynamic culture.  Image adapted from 
[54]. 
 
 
 
 Proliferation analysis showed that the cells within the constructs supplemented with 
ascorbic acid in spinner flask culture exhibited a rapid proliferation, starting from 116±76x103 
cells/mg (cell number per weight of construct) at day 0 and reaching 491±145x103 cells/mg at 
day 3 (n = 3) (Figure 5.3 and Figure 5.4).   
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 Figure 5.3  Representative nuclear/f-actin and H&E staining images showing cell proliferation over three days of 
dynamic culture.  A-B.  Immediately after seeding.  C-D.  After 24 hours of dynamic culture.  E-F.  After 48 hours 
of dynamic culture.  G-H.  After 72 hours of dynamic culture.  Note how the constructs are now completely 
populated with cells.  The arrows indicate the lumen of the scaffolds. 
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Figure 5.4  Quantification of cell proliferation following culture in spinner flasks.  The bars indicate statistically 
significant difference between two groups (p < 0.05; Day 0: n = 5; Day 1: n = 3; Day 3: n = 5).  Image adapted from 
[54]. 
 
 
 
The calculated number of PD was 2.1 while the PDT was 35 hours.  A significant 
difference in proliferation was detected between the constructs supplemented with ascorbic acid 
and the non-supplemented controls.  At day 1 the TEVGs supplemented with ascorbic acid had 
174±30x103 more cells/mg than those not supplemented (p<0.05; n = 3), and at day 3 the 
difference was 121±75x103 cells/mg (p<0.05; n = 5) (Figure 5.5). The ascorbic acid 
supplemented TEVGs exhibited collagen production by day 7, while the non-supplemented 
constructs did not show any collagen production (Figure 5.6).  
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 Figure 5.5  Quantification of effect of AA on cell proliferation following culture in spinner flasks.  The values 
represent the differences in cell number between constructs supplemented with ascorbic acid and non-supplemented 
controls. The bars indicate statistically significant difference between two groups (p < 0.05; Day 0: n = 5; Day 1: n = 
3; Day 3: n = 5).  Image adapted from [54]. 
 
 
Figure 5.6  TEVG histology with Masson’s trichrome. After 7 days, the constructs supplemented with ascorbic acid 
(A) had visible collagen deposition, differently from the controls (B) with no ascorbic acid.  Blue = collagen, 
arrowheads indicate the lumen.  Image adapted from [54]. 
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 The stem cell characterization at day 7 showed no significant difference in positive 
expression of Sca-1 in MDSCs compared to that at day 0 (77±20% compared to 66±6%, 
respectively; p < 0.05; n = 3).  Initial CD34 expression level was 61±10%, while at 7 days it was 
19±12% (p < 0.011; n = 3) (Figure 5.7-A/B).  Sca-1 positive expression by immunofluorescence 
was consistent with the flow cytometry analysis (Figure 5.7-C).  MHC expression was only 
scarcely noted in MDSCs after 7 days of culture (Figure 5.7-D). 
Suture retention strength was measured to be 1.32±0.30 N (n = 5). 
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 Figure 5.7  Stem cell characterization.  A.  Sca-1 and CD34 expression measured by flow cytometry.  B.  Sca-1 
remained high and unchanged while CD34 expression was decreased (p = 0.011; n = 3) after 7 days in culture.  C.  
Sca-1 expression was confirmed by immunofluorescence. Red = Sca-1, blue = nuclei, scale bar = 10 μm.  D.  MHC 
expression was scarce, suggesting a low incidence of fusion and myotube formation.  Positive control (inset) shows 
myotube formation of monolayer MDSCs. Red = MHC, blue = nuclei.  Image adapted from [54]. 
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5.1.2.3 Discussion 
In this acute (3-7 days) assessment of cell-scaffold interactions, it was demonstrated that 
following seeding via the RVSD, cells were able to proliferate and populate the polymer scaffold 
while in dynamic culture (Figure 5.1), retaining their stem cell features (Figure 5.7) and 
producing collagen when stimulated with ascorbic acid (Figure 5.6).  The seeding procedure was 
completed in minutes and the scaffolds were fully populated with healthy-looking cells within 3 
days (Figure 5.4).  Collagen deposits were evidenced after 7 days (Figure 5.6), demonstrating 
initial secretion of ECM.  With these premises, this approach, as opposed to a completely 
cellular-based approach requiring months to obtain an implantable engineered blood vessel [32], 
would allow the TEVG to be implanted shortly after seeding, provided that the cells are 
incorporated successfully and that the scaffold is mechanically sound to withstand arterial 
circulation.   
 While the mechanical properties of the TIPS PEUU scaffolds, are in some aspects similar 
to those of native arterial vessels (e.g., STF (Figure 4.15), elastic modulus (Figure 4.17), and 
suture retention (Figure 4.20)), the strength of the material might not be ideal for vascular 
applications as seen in Figure 4.13.  This concern was confirmed by the initial in vivo studies in 
which the TIPS PEUU scaffolds were associated with aneurysm formation and failure (this will 
be described in detail in Chapter 6).  However, the high porosity and pore interconnectivity of 
the TIPS PEUU scaffolds are believed to play an important role in the observed cellular 
proliferation and spreading, and might constitute a critical feature for the development of a 
TEVG.  The development of the ES-TIPS scaffold (Section 4.2) was highly driven by these 
considerations.  
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The behavior of the MDSCs incorporated into the PEUU scaffolds was consistent with 
the high proliferative features described in 2D culture [167].  The values for Sca-1 and CD34 
expression in monolayer are similar to previous reports [99, 169, 170].  However, this is the first 
report to characterize the cells for their expression of CD34 and Sca-1 in a 3D environment.  The 
observation that MDSCs maintain Sca-1 (Figure 5.7) suggests that these cells maintain their 
stem cell phenotype throughout the seeding and culture process.  CD34 is a surface glycoprotein 
which functions in hematopoiesis and hematopoietic cell adhesion [171, 172].  The role of CD34 
expression in MDSC function has not been fully elucidated [167, 173], although this marker is 
routinely used to characterize MDSCs [174, 175].  A possible speculation regarding the loss of 
CD34 expression (Figure 5.7-B) following cell incorporation in a TEVG could be related to a 
change in the cell adhesion characteristics due to a 3D environment (scaffold pores).  
Furthermore, in another type of muscle stem cell, it has been shown that CD34 varies with the 
activation state of the cell [176].  The scarce expression of MHC noted after 7 days (Figure 5.7-
D) suggests that cells are not forming myotubes, as shown in the positive controls, indicating that 
spontaneous differentiation to myogenic lineage is not occurring.  Maintaining the stem cell 
phenotype during culture is desired in order to profit from the compelling regenerative 
capabilities of the cells when exposed to the actual vascular environment upon implantation.  
The performance of MDSCs within the TIPS PEUU scaffolds described in this section adds to 
their previously reported potential in cell transplantation, making them an attractive source for 
vascular tissue engineering and confirming them as a cell type of choice for our approach.   
It is widely accepted that a successful TEVG will require dymanic culture conditions [40, 
177] due to the need for increased nutrient transfer inside the walls of the scaffold compared to 
static culture.  Indeed, this possibly explains the cell migration toward the edges, which was 
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observed in the controls of the current study (Figure 5.1-B).  Several studies have utilized 
perfusion bioreactors to overcome this problem and to provide the TEVG with a more realistic 
mechanical environment, which is also thought to be important to drive the cells into the desired 
phenotypic lineage [75, 127, 128, 178].  We have demonstrated in this section that spinner flask 
culture has the ability to increase nutrient transfer inside a 2-cm long TEVG while maintaining 
the simplicity of a standard culture method, making it more attractive for clinical applications, 
where the set-up of a complex bioreactor might represent a limiting factor.  However, this simple 
bioreactor setup might not be suitable for longer constructs, where the need for a coherent media 
flow inside the lumen of the TEVG is necessary to provide uniform nutrient transport.  
Therefore, longer scaffolds will require a modification of the culture system in order to achieve 
the same nutrient transfer observed in the experiments described in this section.  The 
development and testing of such system will be described in Section 5.3. 
5.2 BIOLOGICAL ANALYSIS OF RAT MDSCS INCORPORATED INTO ES-TIPS 
PEUU SCAFFOLDS AND CULTURED IN VITRO 
5.2.1 Considerations toward species-specific in vitro studies in preparation for animal 
studies 
In the previous section an extensive in vitro characterization of cell/scaffold interaction was 
provided for murine MDSCs.  These studies were designed to test a spectrum of endpoints 
comprehensively including viability, proliferation, matrix deposition, and phenotype for a well 
characterized type of MDSCs such as the murine one.  In order to translate the performed 
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analysis toward in vivo studies (Chapter 6), it was necessary to replicate part of the endpoints 
performed for murine cells with species-specific cells for each model of interest.  Providing a 
phenotypic analysis before and after a very short in vitro culture period was considered to be 
beyond the scope of the current dissertation.  Therefore, it was decided, for the sake of time and 
feasibility, to focus on the most critical aspects of cell/scaffold interactions:  first, the capacity of 
species-specific cell incorporation into the designated scaffold of interest, and second, the ability 
of the incorporated cells to proliferate and populate the matrix in a short amount of time.  A 
densely cellularized scaffold was considered the premise for implantation. 
5.2.2 Incorporation and dynamic culture of rat MDSCs into ES-TIPS scaffolds 
5.2.2.1 Methods 
MDSCs were isolated from striated muscle biopsies of Lewis rats by means of a previously 
described pre-plating technique [99].  The cells were then transfected with the LacZ reporter 
gene following a previously described method [100].  Briefly, a plasmid encoding for the β-
galactosidase (LacZ), minidystrophin and the neomycin resistance gene was transfected for 24 
hours using the lipofectamine reagent (GIBCO BRL) according to the manufacturer’s 
instructions.  The transfection was made to be consistent with the future in vivo implantation in 
Lewis rats (see Section 6.1.1) ruling out the possibility of a cell behavioral change as a result of 
the transfection.  Cells were then plated, cultured, and expanded (as described in Section 5.1.2).  
Before seeding, rat MDSCs were trypsinized and put in suspension as described in Section 5.1.2 
and prepared to the desired concentration in preparation for seeding.   
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The cells were seeded into ID-1.3 ES-TIPS PEUU scaffolds (length = 1 cm) prepared as 
previously described in Section 4.2.2.  The number of cells and seeding parameters used were 
consistent with that previously described in Section 4.2.6.  Briefly, 3x106 LacZ+ rat MDSCs 
suspended in 5 mL of complete culture media (as described in Section 2.2.3) were seeded into 
each scaffold via the RVSD (a total of 9 ES-TIPS PEUU scaffolds were seeded).   
Immediately after seeding, TEVGs were cultured in static conditions at 37°C in standard 
incubators for 2 hours and then placed into spinner flasks at 15 rpm for 7 days.  Three constructs 
were fixed and processed for F-actin and nuclear staining (as explained in Section 2.2.3) 
immediately after the 2 hours of static culture.  An additional three constructs were removed 
from spinner flask after 3 days of dynamic culture and processed identically.  Finally the last 
three constructs were processed in the same manner after 7 days.  The cell density, proliferation, 
and spreading into the ES-TIPS scaffold were quantified via an image-based technique.  In 
particular, nuclear staining images were taken at 10x and processed with the ImageJ software.  
Grayscale images were thresholded and subsequently processed with a watershed filter to 
indentify and separate overlapping nuclei.  The number of nuclei was automatically counted with 
a particle count function.  The cell density was obtained by dividing the measured scaffold area 
by the counted number of nuclei.  Cell spreading was quantified by measuring the area of F-actin 
staining and dividing it by the number of counted nuclei in each image.  The F-actin area was 
obtained by threshholding images obtained with the FITC filter and by measuring the resulting 
total area.  Merged images were used to evaluate the results qualitatively at each time point.  
Statistical analysis was performed consistently with that described in Section 4.2.3. 
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5.2.2.2 Results and discussion 
The 1.3-ID ES-TIPS scaffolds were highly cellularized immediately after seeding (Figure 5.8-
A), confirming the results previously obtained with the same cell type and scaffold (Figure 4.29-
B).  After 3 days of dynamic culture, the constructs had a significant reduction in cell number 
followed by a non-significant variation at 7 days (Figure 5.8-B/C, and Figure 5.9).  After 3 and 
7 days it was possible to notice, in some luminal areas, multilayered accumulations of cells, 
eventually detaching from the TEVGs during dynamic culture (Figure 5.8-C).  These results 
provide insights about the reduction in cell number detected after the achievement of cell 
confluency into the scaffolds, suggesting cell migration toward areas with higher nutrient 
concentration (e.g., the lumen).   
A set of experiments was performed to understand the role of the initial seeding density 
on the maturation time of the TEVG (data not shown).  In those experiments it was noted that by 
increasing the initial cell number during the seeding process, the time required for obtaining cell 
confluency was reduced (Note: the concept of confluency in a 3D environment is here intended 
as complete cell coverage detected retrospectively with any cytoskeletal markers within 
histological assessment; an example of 3D scaffold confluency is shown in Figure 5.3-G/H).  
Upon achievement of confluency, cells migrated toward areas of increased nutrient concentration 
(likely due to nutrient competition) and ultimately fell off the constructs, leading to reduced cell 
densities.  Based on those results is was concluded that using 3 million cells as the initial 
concentration and a period of three days of dynamic culture exceeded the ideal “maturation” time 
leading to cellular loss.  Therefore, it was established that the ideal in vitro culture period prior to 
in vivo implantation (see Section 6.1.1), when seeding 3x106 into 1.3-ID ES-TIPS scaffolds 
should have been less than 3 days (e.g., 24-48 hours following seeding).   
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The spreading quantification over 7 days of dynamic culture showed a positive trend, 
though not significant (Figure 5.10).  This result is consistent with cell adhesion and partial 
spreading into the 3D pores of the scaffold.  An important insight learned from this and some 
unrelated experiments (data not shown) was that the TIPS PEUU porous structure is supportive 
of proliferation, as seen extensively in Section 5.1.2, but it might hamper the free cell 
rearrangement including full spreading, and more importantly cell alignment.  This is caused by 
the spongy-like, though interconnected, porous matrix of the TIPS PEUU scaffolds, which 
results in the presence of physical polymer walls between pores, avoiding cell penetration.  
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 Figure 5.8  Representative qualitative results of rat MDSC-incorporated ES-TIPS PEUU scaffolds.  A.  Results after 
2 hours of static culture.  B.  Results after 3 days of dynamic culture.  C.  Results after 7 days of dynamic culture.  
The arrows indicate the luminal surface. Blue = nuclei, green = F-actin, red = scaffold.  Images taken at 100X.     
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 Figure 5.9  Quantification of rat MDSC density into ES-TIPS PEUU scaffolds at different time points.  The bar 
indicates statistically significant difference between two groups (p < 0.05; n = 3); all the other comparisons are not 
statistically significant. 
 
 
Figure 5.10  Cell spreading (intended as average area positive for F-actin for each cell) at different time points.  
None of the differences are statistically significant (n = 3). 
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 5.3 DEVELOPMENT OF A NOVEL BIOREACTOR FOR TISSUE-ENGINEERED 
TUBULAR CONSTRUCTS: THE PERFUSER 
Described in Sections 5.1.2 and 5.2.2 was the dynamic culture of TEVGs using spinner flask 
bioreactors in order to improve nutrient transport to the constructs via convection.  With this 
technique, cells were able to spread and populate the constructs within three days without 
compromising their stem cell phenotype.  However, these culture conditions are likely to be 
suitable only for small L/ID ratios (L/ID for the TEVGs described in Section 5.1.2 was 
approximately 5, while that for those described in Section 5.2.2 was approximately equal to 6).  
Longer constructs (L/ID > 8) are likely to receive a poor amount of nutrients in their central 
region compared to the end regions, and this could lead to inhomogeneous tissue development.  
This potential issue is confounded by the folding of the tubular scaffolds following placement in 
the rotational fluid dynamic field of the spinner flask.  Therefore, media has little chance of 
reaching the entire lumen during culture in spinner flasks.  With this in mind, a novel, cost-
effective bioreactor was designed in order to homogeneously perfuse tubular constructs by 
creating a continuous flow of media into their lumen.  
5.3.1 Design principles 
The main design specification for the bioreactor was the creation of a controllable, continuous 
flow into tubular scaffolds without generation of relevant intraluminal pressures.  This feature 
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was required to create a continuous turnover of nutrients along the entire length of the scaffolds, 
which is paramount to cell survival, attachment, and proliferation in the delicate phase 
immediately following cell seeding.  Upon incorporation of cells into the scaffolds via the 
seeding devices (see Chapters 2 and 3), cells are essentially passively suspended in culture 
media within the scaffold pores, and it is necessary to provide nutrient transport without 
generating forces that could flush them away from the scaffold before an initial attachment can 
be achieved.  Another design specification was the compatibility in size with a standard 
incubator.  This specification allows for a considerable reduction in complexity and variability 
compared to a need for temperature and pH control by simply being exposed to the incubator 
environment.  Finally, another important feature being sought was cost-effectiveness.  Complex 
bioreactors for vascular applications usually require very expensive components to perfuse 
tubular structures (e.g., centrifugal or roller pumps) and measure and control the flow rate (e.g., 
ultrasonic flowmeters and resistors) which are incompatible with easy clinical translation.  The 
device should also allow for independent experiments by separating completely the culture 
environment for each TEVG, and have a limited culture media volume to reduce the costs 
associated with the use of expensive culture reagents.  
To meet these requirements a modification of the simple spinner flask design was 
proposed, utilizing the concept of a wind sock in an inverted fashion.  Wind socks are normally 
used in aviation to detect wind direction and strength by allowing a tapered fabric tube to rotate 
on a hinge and spontaneously align with the direction of the wind.  The tapered shape is used to 
enhance the inlet flow rate (by increasing the inflow area) and to progressively increase the 
internal air velocity proceeding further into the conical geometry until the outlet (in which it 
reaches the maximum air flow velocity).  This phenomenon allows for a horizontal placement 
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(lifting effect) of the sock against the gravity due to a net reduction of the internal pressure 
(induced by the increased internal velocity according to Bernoulli’s law).   
If the relative velocity of the two components (wind and wind sock) is inverted (i.e., 
moving the sock against a static volume of fluid) the result will be intuitively the same: the sock 
will have an internal fluid flow and will undergo the same lifting effect (Figure 5.11).  We can 
utilize this concept by connecting a tubular conduit (TEVG) at the end of the sock and moving 
the system with a linear velocity v within the liquid (cell culture media).  The resulting internal 
flow generated by the movement of the sock will have an inflow velocity of approximately v as 
well, and it will continue its path inside the downstream conduit, “perfusing” the conduit itself .  
This is the basic concept utilized in the design of the Perfuser.   
The natural following step was to eliminate the space-requirement from this design 
principle involving the need of continuous, linear movement into a fluid.  This could be 
accomplished by making the movement itself periodical (i.e., rotational).  The simple spinner 
flask design is suitable to serve this purpose by performing some simple modifications 
(described in Section 5.3.2).  Spinner flasks are ideal bioreactors for a number of applications 
due to their simplicity, cost-effectiveness, low-maintenance, and functionality, and they are an 
ideal candidate to comply with the required design specifications of this project. Spinner flasks 
are also ideal for performing independent experiments (more flasks can be used contemporarily), 
and require a limited amount of cell culture media for their functioning.    
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 Figure 5.11  Analogy of the Perfuser principle (right) to the wind sock (left).  VIn represents the velocity of the wind 
entering the wind sock.  VOut is the outflow velocity (increased by the tapered shape of the wind sock).  If the 
Perfuser is moved with velocity VMov = Vin in a static environment filled with air, the resulting outflow velocity 
should be the same as VOut.   
 
 
 
A system able to create the wind sock effect by taking advantage of the rotation provided 
by the internal rotating body of a spinner flask was the key concept in the design of the Perfuser.  
However, one important aspect to consider while utilizing a rotational velocity around a pivot 
was the relative velocity.  This conceptual system, rotating inside an enclosed space such as the 
spinner flask, will likely create a circular, whirpool motion of the surrounding fluid, reducing the 
relative velocity between the wind sock and the rotating fluid leading to reduction/loss of relative 
velocity and thus net effective flow inside the sock.  Therefore, it was important to design the 
rotating body in a hydrodynamically-efficient fashion to reduce the perturbation of the flow 
created by the rotating components, while maximizing the internal perfusion.  The presence of a 
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neck in the spinner flask glass containers suggested the design of a geometrically-variable 
system able to retract while being inserted through the neck of the bottle and expand in a 
controllable fashion once needed.  It was also necessary to provide each spinner flask with the 
capability of perfusing two TEVGs at the same time instead of one.  This was implemented to 
allow the culture of each TEVG with a backup construct for the prospective large animal studies 
planned (Chapter 7). 
 
5.3.2 Fabrication of the device 
Commercially available 500 mL spinner flasks (196580575, Bellco Glass Inc, NJ) were 
completely unmounted in their basic components including a glass bottle, a central vertical PTFE 
stem with internal glass tube, a PTFE-coated magnetic bar and, a PTFE paddlewheel.  An 
assembly (Perfuser system) formed by five components was fabricated for each spinner flask 
used (Figure 5.12).  Custom-made components were designed and drawn via Solidworks 2005 
software (Solidworks Corp., Concord, MA).  Drawings are included in APPENDIX A. 
In particular, the Perfuser system consisted of a cylindrical cuff made of Delrin® (external 
diameter = 3 cm, internal diameter = 1.6 cm, thickness = 1 cm, Figure A.24) allowing for a 
connection with the spinner flask stem, two arms, and two plugs acting as wind socks.  The cuff 
was provided with two opposite rectangular slots to host foldable arms.  Each arm (length = 2.5 
cm, width = 1 cm, thickness = 3 mm, Figure A.25) was made of Delrin® and was provided with 
hydrodynamically-efficient lateral profiles (rounded) on their long edges, designed to avoid fluid 
perturbation while rotating within the fluid.  Each arm was coupled with the cuff via SS pins 
(hinges) allowing for variable angle orientation between the arms and the cuff.  Both hinges were 
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provided with small custom-made SS hinge springs working in a self-opening configuration (i.e., 
when unconstrained, both arms extend fully, reaching a mutual angle of 180º).  On top of the two 
hinges, two small SS screws were inserted vertically through the wall of the cuff reaching the 
wall of each arm.  By modifying the depth of each screw it was possible to regulate precisely the 
maximum angle of the arm with respect to the cuff by defining the upper limit for the extension 
of the arm induced by the spring.   
Distally from the cuff, each arm was connected via a hinge to a Delrin® plug designed to 
take advantage of the wind sock effect (Figure A.26).  Each plug was made from a solid cylinder 
of material, and oriented in order to generate internal flow by rotating in a clockwise direction.  
A conical cavity (maximum internal diameter = 1 cm) was machined throughout its longitudinal 
axis and a bore was drilled to create a channel (ID = 3 mm) in the distal end of the plug.  All 
edges were made rounded and smooth, again for minimizing the creation of a rotational flow 
inside the flask.  On the back of the external wall of the plug, some material was removed via a 
lathe until an attachment tee with external diameter of 4.7 mm was created.  The tee was 
provided with several circumferential grooves to allow for a secure ligation of the TEVG.   
The Perfuser assembly was then connected to the PTFE vertical stem of the spinner flask 
by sliding the cuff onto the stem and tightening a SS set screw to secure the cuff at the desired 
height (~ 6 cm from the bottom of the stem; Figure 5.12).  The original Teflon-coated stirrer bar 
was replaced with a longer one (Fisher Scientific) (shape = octagonal, diameter = 1 cm, length = 
5.4 cm) to increase the torque transmitted to the rotating body inside the spinner flask.  The 
original paddlewheel was discarded as its use would tend to generate rotational velocity in the 
fluid field.   
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Figure 5.12  3D model of the Perfuser illustrating the major components of the device. 
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The rotating Teflon and glass stem is reconnected to the cap of the spinner flask and the 
assembly inserted into the spinner flask glass container.  To insert the assembly, the arms and 
plugs are temporarily retracted, reducing the angle between the arms and the stem, thereby 
reducing the radial dimension of the assembly.  The angle between the arm and the stem was set 
in order to have the plug positioned at approximately 2 mm (i.e., minimum geometrical clearance 
to allow unconstrained rotation) from the interior wall of the glass.  As a result, the radial 
distance between the centerline of the central PTFE stem and the longitudinal axis of the 
Perfuser plug was approximately 2.9 cm.  The rotation of the Perfuser internal rotor was obtained 
by a precision multi-plate magnetic stirrer platform (D2005 Stirrer, BELLCO Biotechnology) 
which communicates the torque via magnets across the glass container of the spinner flask. 
 
5.3.3 Performance and flow visualization 
Once the Perfuser prototype was developed, it was necessary to demonstrate the consistency 
between the expected behavior of the Perfuser and the actual one via a validation process.  To 
this end, a series of experiments was performed to show effective functioning of the device and 
to characterize the fluid dynamics inside the spinner chamber and the forces involved with the 
operation of the device.   
The first experiment was designed to verify the absence of issues related to the movement 
of the internal rotating system with the attached TEVG scaffolds.  Two 5 cm-long ID-4.7 TIPS 
PEUU scaffolds were ligated with a single 4-0 silk suture to the tees of the Perfuser.  The system 
was then filled with 250 mL of water and put in rotation at different rotational speeds.  The 
system was able to rotate smoothly over a range of rotational speeds between 8 and 200 rpm.  
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Slower rates were characterized by loss of fluidity in the movement while higher speeds caused 
the rotating body to freeze, falling out of phase with the underneath driving rotating magnet.  The 
scaffold followed the curvature of the internal glass wall while rotating, as expected.  No kinks 
or entanglements were detected in the scaffolds. 
The second experiment was performed to demonstrate flow inside the tubular scaffolds 
during the Perfuser operation.  To this end, the rotating body, including the PTFE stem and the 
Perfuser assembly, was coupled with an ink reservoir formed by a 1.6 microcentrifuge tube (with 
the cap-end cut off) and a capillary tube (see Figure 5.13-A).  The reservoir was connected via 
transparent tape to the PTFE stem approximately 2 cm higher than the Perfuser cuff, and about 
5.5 cm higher than the centerline of the plug.  On the bottom of the tube a small hole was drilled 
and a small polypropylene capillary tube (Intramedic) was pressure fit into it by pulling a silk 
suture previously knotted to the tube.  The capillary tube was aligned with the rounded edge of 
the Perfuser arm and secured to it with transparent tape in order to cross the centerline of the 
underneath Perfuser plug.  The capillary tube was cut slightly before the center of the plug to 
allow for release of dye just in front of the plug.  Two PTFE vascular grafts (length = 6 cm, ID = 
6 mm ID, L/ID = 10) (W. L. Gore & Associates, Inc., Flagstaff, AZ) were connected to the 
Perfuser plugs for the purposes of flow visualization testing (Figure 5.13-A).  The hydrophilic 
nature of the PEUU scaffolds was not ideal for testing purposes due to a consistent absorption of 
ink (data not shown) causing loss of the contrast necessary for testing.   
The reservoir was filled with a CDI tissue marking dye (Cancer Diagnostics, Inc., 
Birmingham, MI) and the rotating portion of the Perfuser was rapidly inserted into the glass 
container of the spinner flask and rotated at 12 rpm.  A sequence of pictures was taken with a 
SLR camera (Canon 40D) provided with a macro lens (28 mm USM Canon) at the rate of 6 
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pictures per second and with a shutter speed of 1/2500 sec and an aperture of 4.5 to capture 
qualitatively the ink released by entering the plug and leaving the scaffold.   
The images clearly show the path of the dye entering the Perfuser plug (Figure 5.13-B), 
and exiting the scaffold (Figure 5.13-C), confirming the generation of flow inside the conduit.  
After interruption of the rotation the dye was again released, but this time it fell vertically to the 
bottom of the glass container (Figure 5.13-B).  Figure 5.14 shows a photo sequence capturing a 
half of a revolution during the Perfuser testing.  
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Figure 5.13  Testing of the Perfuser.  A.  Modification of the Perfuser by an ink releasing system 
composed by a small cylindrical reservoir and a capillary tube slowly infusing dye in the center of the 
Perfuser plug.  B.  Image demonstrating flow within the inlet of the plug (dashed box) while spinning at 12 
rpm and after the rotation was halted (inset).  C.  Image of the distal tip of a conduit showing outflow of ink 
(dashed square) confirming the establishment of flow inside the tubular scaffold.  
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 Figure 5.14  Perfuser testing: photo-sequence of the dye release over approximately a half of a revolution.   
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After this qualitative assessment of flow was completed, some additional testing was 
performed to quantify the flow performance of the system.  To this end, a machine vision system 
– comprising of a high/resolution camera (A504K, Basler AG, Ahrensburg, Germany) mounted 
with a Telecentric 55 mm lens and a 2x converter (Computar TEC-M55, CBC (AMERICA)
Corp., Commack, NY), and a XCap acquisition board and software (Epix, Inc., Buffalo Grove, 
IL) – was used with a high-performance machine (System: XP 64, Processor: Intel Xeon, 
memory: 6 Gb). 
High-speed (500 fps), high-resolution (1280x1024 pixels) videos of the Perfuser were 
acquired at different rotational speeds using the same dye releasing system and dye described 
above.  The exposure time for each frame was 2 msec, and the aperture of the lens was set to 2.8.  
The camera was oriented perpendicularly to the glass container and was focused on the 
centerline of the rotating plug to capture the tangential component of velocity of the released dye 
into the plug during rotations at different rotational speeds (12, 20, 43, 62, and 83 rpm).  The 
system was illuminated by two opposite Fiber-Lite high intensity illuminators (Dolan-Jenner 
Industries, Boxborough, MA).  A sheet of white paper was placed between each light source and 
the glass container to increase the diffusion of the light avoiding glass reflections.  Each video 
was processed with the Xcap software to retrieve two snap shots depicting arbitrary initial and 
final positions of the plug during its motion.  The pair of images for each rotational velocity were 
stored and processed with ImageJ to measure the horizontal distance between an arbitrary, 
recognizable feature in the dye flow (i.e., a curl) and the edge of the plug inlet (Figure 5.15).   
The measure of distance was corrected taking into account the error introduced by the 
phenomenon of parallax.  This effect is defined as an apparent change in an object's position (in 
this case the measured distance) due to a change in the observer's position, or equivalently due to 
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a movement of the observed object.  In this case the camera was the observer, while the plug and 
dye were the observed objects changing positions.  The nontrivial model used to perform this 
optical correction is described in APPENDIX F. By measuring the number of frames between 
the initial and the final snap shot and by measuring the variation in corrected distance between 
the moving plug and the released dye, it was possible to quantify the relative velocity between 
the dye and the plug.  The measured relative velocity was used to quantify the flow rate entering 
into the front cone of the plug (and therefore the perfused conduit) by simply multiplying the 
measured velocity by the known inlet area of the plug.  This method is justified also in the case 
of a rotational velocity field such as the one generated into the Perfuser.  In fact, a rotational field 
with rotational velocity (ω) is characterized by linearly increasing tangential velocities (v) 
moving distally from the center of rotation along the radial direction (r) (according to v = ω r).  
The velocity measures were taken in the centerline of the Perfuser plug, therefore, the measures 
reflected the average flow velocity over the entire area of the plug opening.  The inner hemi-
portion of the plug was naturally exposed to lower tangential flow velocities but it was balanced 
by the outer hemi-portion, which was perfused with higher tangential flow velocities.  
Additionally, a measurement error for each rotational velocity acquisition was calculated.  This 
error reflected the discrepancy in value between the angular velocity of the plug defined 
according to the spinner flask platform setup and the correspondent angular velocity measured 
via machine vision calculations.  The error value was obtained by dividing the nominal rotational 
velocities tested by the respective values obtained from high-speed measurements and provided 
an indication of the possible variability of the results.  The measurement error calculated for all 
the rotational velocities used was 12.5±6.3% (n = 5). 
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Figure 5.15  Sample pair of images used in the Perfuser flow visualization.  A.  The initial snapshot taken for the 
flow quantification at 12 rpm.  The horizontal distance between a selected curl in the dye and the edge of the 
perfuser plug is indicated.  B.  The paired snapshot shows the reduction in distance following a known time frame.  
Each pair of images (initial and final shot) was scaled by measuring the know length of the plug.   
 
 
 
The flow rates calculated for each angular velocity of the Perfuser are shown in Figure 
5.16.  A second order polynomial fit was made via Excel showing a good agreement with the 
experimental data (R2 = 0.97).  Using the measured tangential velocities and Equation 2-6, it 
was possible to calculate the wall shear stress inside the lumen of ID-4.7 scaffolds for different 
rotational speeds (Figure 5.17).  Also in this case a second order polynomial curve showed a 
good fit (R2 = 0.97).   
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 Figure 5.16  Perfuser flow rates measured for different rotational velocities via a flow visualization technique.  The 
solid line represents a second order polynomial fit of the data. Given as measure ± error; n = 1.  Note that the “error” 
is 12.51% of the measure as described above.  
 
 
Figure 5.17  Shear stresses generated into a 4.7-ID scaffold while connected to the Perfuser rotating at different rpm 
levels.  The solid line represents a second order polynomial fit of the data.  Given as measure ± error; n = 1. 
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A summary of the values obtained for each rotational velocity is shown in Table 5-1. 
 
 
 
Table 5-1  Summary of flow visualization analysis. 
Rotational speed (rpm) 12 20 43 62 83
Relative tangential velocity of the dye (cm/sec) 0.94 1.14 2.64 3.63 3.59
Flow rate into the scaffold (mL/sec) 0.66 0.80 1.85 2.55 2.52
Wall shear stress into a 4.7-ID scaffold (dynes/cm2) 0.57 0.70 1.62 2.22 2.20
Tangential velocity of the plug (cm/sec) 3.65 6.09 13.09 18.87 25.26
Ideal flow rate (mL/sec) 2.56 4.27 9.19 13.25 17.73
Fluid dynamic efficiency 25.66% 18.75% 20.19% 19.22% 14.20%  
 
 
 
5.3.4 Discussion 
The results obtained with the Perfuser indicated the achievement of controllable and 
physiologically relevant values of flow rate and shear stress in the TEVG by varying the 
rotational velocity of the system.  The flow rate and the related shear stress increased with the 
rotational velocity, apparently reaching an asymptomatic value after 83 rpm.  Flow visualization 
results demonstrated that the rotating components of the Perfuser indeed created a rotational 
velocity field in the fluid.  This effect was clearly due to the drag force exerted on the fluid by 
the rotating components.  This phenomenon generated a reduction in the overall fluid dynamic 
efficiency of the Perfuser.  In fact, if the plug would spin into a fluid media completely and 
permanently static, the resulting flow and shear stresses would be greatly enhanced by the 
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increased net relative velocity entering the Perfuser plug.  Calculating the ratio between the ideal 
(corresponding to a Perfuser plug moving within a static fluid) and measured flow rates, it was 
possible to quantify the fluid dynamic efficiency of the system, which was equal to 19.6±4.1% 
(i.e., the system with its defined geometrical features and working principles, at the current status 
of development, was able to perfuse the scaffolds with about 20% of its physical potential based 
on the aforementioned concept of the wind sock).  It was observed that the efficiency was 
generally decreasing for higher angular velocities (Table 5-1).  This data was consistent with the 
observed asymptotic behavior of the flow rate (Figure 5.16).  By performing more complex CFD 
optimization studies of the profiles of the rotating components it should be possible to increase 
the overall fluid dynamic efficiency of the Perfuser.  However, this subject was beyond the scope 
of this work and it was, therefore not further addressed.  
The results that were obtained suggested that the Perfuser might represent an ideal tool 
for the temporary dynamic culture of TEVGs or any tissue engineering tubular constructs 
(TETCs) due to its simplicity, cost-effectiveness, and functionality.  Mass transport, in fact, is 
widely believed to be primary limiting factor in tissue engineering [179], which often requires 
dynamic conditions to allow for culture of cells in a 3D environment.  The Perfuser was able to 
provide intraluminal perfusion of nutrients in long TETCs, thus presumably enhancing mass 
transport.  It was also able to provide physiologically relevant levels of shear stress with very 
limited resources.  A variety of costly and complex bioreactors were previously described [180], 
however, since time is an important factor in the development of a TEVG, a device such as the 
Perfuser appears to be an ideal candidate to serve the purpose of a short, inexpensive, and 
effective period of dynamic culture required before in vivo implantation in a large animal model.   
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In the following section an additional validation of the performance of the Perfuser 
involving actual TEVG culture is described.   
5.4 BIOLOGICAL ANALYSIS OF PIG SLOWLY ADHERING CELLS INTO ES-
TIPS PEUU SCAFFOLDS CULTURE IN VITRO 
In summary of the work to this point, the development of the RVSD (Chapter 2) opened the 
possibility to incorporate efficiently and without damage cells into porous tubular scaffolds to be 
used as TEVGs.  The initial investigations toward a characterization of the device (Section 2.2.3) 
and the following comprehensive in vitro culture (Section 5.1) used murine cells due to their 
extensive characterization [99-101, 166, 167, 169].  A basic phenotypic assessment following 
seeding with the RVSD and subsequent acute dynamic culture in a spinner flask was performed 
to understand the influence of these processes in the maintenance of stem cell phenotypic 
markers.   
In preparation for small animal in vivo studies (Chapter 6), rat cells were used to test the 
capacity of the RVSD to incorporate efficiently cells originating from a different species into the 
ES-TIPS PEUU scaffold, and the spreading and proliferation of those cells into the scaffolds 
(Section 5.2.2).  The phenotypic characterization of rat MDSCs and their modification as a result 
of the seeding procedure and/or dynamic culture was considered beyond the scope of the work 
due to the poor characterization available in literature for rMDSCs and therefore, the lack of 
comparative standards.   
In preparation for a large animal in vivo study in pigs (Chapter 7) autologous slowly 
adhering cells (SACs) were isolated and characterized for their morphology and proliferation 
 211 
kinetics (Sections 7.3 and 7.4) and used to test the functionality of the newly developed S-RVSD 
(Section 3.1.4).  Those studies served two the purposes; providing a quantitative demonstration 
of the seeding uniformity along the three cylindrical directions of the scaffolds (longitudinal, 
circumferential, and radial), and demonstrating the ability for pig late SACs to be incorporated 
with a high density into the pores of the ES-TIPS PEUU scaffolds.  Furthermore, the TUNEL 
assay showed the absence of significant apoptosis following seeding, providing additional 
evidence of cell viability.     
  The remaining step toward in vivo implantation in pigs was to test the proliferation of 
pig SACs within ES-TIPS PEUU scaffolds following dynamic culture in the newly developed 
Perfuser bioreactor.  
5.4.1 Pig SACs-containing scaffold cultured in dynamic conditions via the Perfuser 
Pig SACs were cultured to confluency in 175 cm2 flasks (a detailed description of the isolation 
technique, cell characterization, and culture reagents is provided in Sections 7.3 and 7.4), 
trypsinized, counted, and suspended in 20 mL of complete culture media.  Cells were then 
seeded into 5 cm long ID-4.7 ES-TIPS PEUU scaffolds (see Section 4.2) via the S-RVSD.  Each 
scaffold was seeded with 15x106 pig SACs (n = 3) using seeding parameters consistent with 
those described in Section 3.1.4.  Briefly, the feed rate for the seeding suspension was 4 mL/min, 
the rotational speed of the scaffold was 10 rpm, the translational velocity of the Diffuser was 
0.167 mm/sec, and the vacuum was set to -5 inHg.   
Immediately after seeding, the scaffolds were placed into 50 mL conical tubes filled with 
40 mL of media and were cultured statically for 2 hours in a standard incubator.  The cap was 
left untightened to allow for gas exchange in the incubator’s 5% CO2 atmosphere.  Following 
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static culture, a ring of each scaffold (~8 mm in width) was cut with a scalpel blade and split into 
four smaller rings (~2 mm in width).  Three from each scaffold were processed for MTT (3 
repeated measurements per sample) with the same protocol described in Section 2.2.3.  The 
fourth ring was processed for histology (H&E) as previously described in Section 2.2.3.   
Each scaffold was then aseptically mounted on a dedicated Perfuser (to perform 
independent experiments), ligated with 4-0 silk and cultured for 48 hours while rotating at 20 
rpm in standard incubators.  At 24 and 48 hours additional rings from each scaffold were again 
harvested, split, and processed for histology and MTT. 
Immediately after seeding, the scaffolds appeared homogeneously populated with pig 
SACs with a relatively low density and the usual spherical shape (Figure 5.18-A).  After 24 
hours of dynamic culture, the scaffold appeared densely populated with spread cells (Figure 
5.18-B).  After 48 hours of dynamic culture into the Perfuser, the histology showed an elevated 
number of cells into the TIPS layer of the scaffold but a generalized loss of cell spreading 
(Figure 5.18-C).  The MTT results showed a significant 3-fold increase in cell number (Figure 
5.19) after 24 hours, confirming the qualitative histological results.  There was no significant 
difference detected in cell number between the 24 and 48 hour time points.   
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 Figure 5.18  Qualitative assessment of pig SACs culture within the Perfuser.  A.  Representative results after 2 
hours of static culture immediately following seeding.  B.  Representative results after 24 hours of dynamic culture 
within the Perfuser.  C.  Representative results after 48 hours of dynamic culture within the Perfuser.  The arrows 
indicate the lumen of the ES-TIPS PEUU scaffolds. 
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 Figure 5.19  Proliferation analysis of SACs cell within ES-TIPS PEUU scaffolds following dynamic culture in the 
Perfuser. 
 
 
 
This experiment confirmed the capability of the S-RVSD to incorporate effectively pig 
SACs into ES-TIPS scaffolds.  It also demonstrated SACs proliferation within the scaffolds 
scaffolds following dynamic culture in the Perfuser.  According to what was established in 
Section 5.2.1 these two characteristics represent critical requirements to perform in vivo studies.    
While the subject would deserve further investigations (in particular a better 
understanding of the lack loss of additional cell spreading observed after 48 hours, and an 
analysis of different initial cell densities, time points, and rotational velocities for the Perfuser), 
additional related studies were not performed in this dissertation work.  This was mostly due to a 
very limited availability of pig cells as well as time and budget constraints, which did not allow 
for performing additional, complementary studies.  As mentioned in the Section 1.10 this work 
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is not free of limitations due to its deep interdisciplinary features, and this is just another 
example.  
In the next Chapter the lessons learned from seeding device validation, scaffold 
development and testing, and acute in vitro dynamic culture experiments were directly applied 
toward preclinical translation with in vivo experiments both in small and a large animal models.     
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6.0  SPECIFIC AIM 4, PART 1: SMALL ANIMAL ALLOGENEIC TEVG STUDY 
6.1 INITIAL CONSIDERATIONS ON IN VIVO STUDIES 
Several accomplishments contributed to the initiation of the in vivo studies of the TEVG in a 
small animal model and, subsequently in a large animal model as well.  As mentioned, the actual 
order of experiments did not follow the rigid structure of this dissertation.  In particular, the first 
implantations in Lewis rats were performed using TIPS PEUU scaffolds seeded with rat MDSCs.  
This was possible following the development and testing of the RVSD (Section 2.1).  Thorough 
in vitro testing using murine MDSCs within dynamic culture conditions (Section 5.1.2), and 
some validation studies to reproduce the results using rat MDSCs and TIPS PEUU scaffolds 
(Figure 6.1-B) were then performed.  As explained in Section 5.2.1 the established criteria for 
implantation were the achievement of a densely and uniformly cellularized scaffold in a short 
amount of time.  The goal was to provide a viable, stem cell-based TEVG with the potential to 
remodel and regenerate in vivo into a functional native-like artery.  
To corroborate the validity of the established criteria for implantation, it is useful to refer 
to another approach led by Dr. Toshiharu Shin’oka.  This group used similar basic requirements 
for implantation, and obtained successful results in both preclinical and clinical studies.  In these 
studies, autologous BMPCs were harvested and isolated in the operating room.  A cell 
suspension was prepared using BMPCs and autologous plasma, and was manually seeded, 
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intraoperatively, on a commercially available, medical grade, biodegradable scaffold just prior to 
implantation [38, 39, 96, 115].  The resulting conduit was tested in large-caliber applications 
such as an inferior vena cava interposition graft, or the cavopulmonary connection.  These 
applications are characterized by a less demanding mechanical environment than that in the 
systemic arterial tree, and therefore a reduced occlusive rate due to neo-intimal tissue formation 
compared to those of small-diameter arteries.   
While the technique described by Shin’oka et al. seems ideal from the clinical standpoint 
due to its off-the-shelf availability and promising results, their cell seeding efficiency was very 
poor.  The seeding and culture protocols described in this dissertation (seeding via the RVSD and 
the acute dynamic culture of the scaffold, leading to cell attachment, proliferation, and 
spreading) might add value to it.  In particular, the advantages of having an efficient, cost-
effective, rapid, and reproducible seeding method has been widely speculated in Section 1.6, and 
the need for a transient, acute, and delicate period of dynamic culture has been demonstrated in 
Chapter 5.  For example, when comparing our results immediately after seeding with those 
published by Shin’oka et al. (Figure 6.1), the potential benefit of our approach is apparent.  Not 
only does the seeding density and the seeding uniformity across the scaffold wall appear higher 
in our approach, but also the seeding efficiency.  It is likely that the manual nature of the seeding 
technique described by Shin’oka et al. will lead to less efficient incorporation of cells (i.e., many 
available cells are likely wasted).  Furthermore, in both approaches, cells have a spheroidal shape 
immediately after seeding, denoting poor or no attachment to the scaffold pores.  In these 
conditions, an abrupt exposure to physiological levels of pressures and flow might lead to cell 
loss.  Therefore, a short period of culture within delicate dynamic conditions, such as the one 
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described in this approach, might contribute to a more effective cell retention and functionality 
upon implantation.   
 
 
 
 
Figure 6.1  Comparison of cellular density between the seeding the approach described by Shin’oka et al.[115] (A – 
left and right panels), and a TIPS PEUU scaffold seeded with rat MDSCs via the RVSD (B). The arrow in the 
bottom image indicates the luminal surface. Blue = nuclei, green = F-actin, red = scaffold. Image taken at 200x.  
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Within this framework, the animal studies were initiated as a natural subsequent step in 
our translational approach.   
In the following sections a comprehensive analysis of the in vivo studies will be provided. 
6.1.1 Preparation of allogeneic TEVGs for in vivo studies 
To test the working hypothesis of this dissertation work (recall Section 1.10), the in vivo 
remodeling of porous biodegradable elastomeric scaffolds (initially TIPS PEUU, and 
subsequently ES-TIPS PEUU) seeded with allogeneic rMDSCs in a rat model for a period of 8 
weeks was evaluated.  
Lewis rat MDSCs were isolated and transfected with the LacZ reporter gene as described 
in Section 5.2.2.  Cells were then plated, cultured, and expanded as described in Section 5.1.2.  
Before use, rMDSC monolayers were detached from the culture flasks between passages 10 and 
15, counted, and then resuspended in culture media to the desired concentration in preparation 
for seeding as described in Section 5.1.2.  Each seeding bolus consisted of 5 mL of complete 
media and 3x106 rMDSCs.  
ID-1.3 TIPS PEUU (length = 1 cm, ID = 1.3 mm, thickness = 350 μm) and ES-TIPS 
PEUU (length = 1 cm, ID = 1.3 mm, thickness = 420 μm) scaffolds were fabricated as described 
in Section 4.2.2.  Each scaffold was provided with a pair of tips (recall Figure 2.4), and 
sterilized in 70% ethanol solution for 24 hours, in preparation for seeding.  Each scaffold was 
then rinsed multiple times in sterile Dulbecco-modified phosphate-buffered saline (DBPS), to 
remove residual ethanol solution, and stored in cold DPBS in 15 mL tubes until use.  Prior to 
seeding, each scaffold was warmed to 37°C in a water bath. 
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Each scaffold was seeded via the RVSD as described in Section 4.2.6.  Briefly, each 
scaffold was mounted into the RVSD via simple pressure fitting of the scaffold tips onto the 
RVSD tees.  The RVSD fluid circuit was de-aired and primed by the injection of warm DPBS.  
The prepared seeding suspensions were fed equally into two 3 mL syringes.  Both syringes were 
then connected to the RVSD and mounted on the rack of a syringe pump to begin the seeding 
process.  The seeding parameters consisted of a feed rate of 2.5 mL/min, a rotational speed of 
150 rpm, and a vacuum level of -5 inHg.  The constructs were then flushed with 5 ml of plain 
DMEM to seed the residual cells from the tubing and the lumen of the scaffolds.  
Immediately after seeding, the constructs were removed and incubated in a Petri dish for 
1 hour with the tips still attached to prevent cell loss from the scaffold during handling.  After 
this short period of static culture, the plastic tips and a small portion of overlapping scaffold were 
carefully removed.  Constructs were then placed in 500 mL spinner flasks (Bellco Glass) with 
100 mL of culture media and stirred at 15 rpm for 48 hours before implantation. 
6.1.2 In vivo small-animal study design 
The rat is an established model for vascular disease and has been extensively studied.  This 
model has the advantage of being available at low-cost, and having a rapid and reproducible 
vascular response to injury [181].  Due to its characteristics, the rat is usually used as an initial 
model to test the effects of novel vascular therapeutic approaches, including those leading to 
migration and proliferation of smooth muscle cells and the formation of neointima in vivo [181].  
In particular, the infrarenal portion of the rat aorta has been used in a number of small-diameter 
vascular studies due to its relatively easy access, and the low number of lateral branches.  These 
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studies include the testing of TEVGs [69, 182], synthetic vascular grafts [183, 184], or surgical 
techniques [185, 186].  
The Lewis rat is an inbred, albino strain, normally used for transplantation and 
endocrinology studies [187].  This rat strain was chosen for its suitability for transplantation due 
to its inbred feature, which could potentially result in immune-tolerance to recipient of an 
allogeneic cell source, not requiring immune suppression.  
Adult Lewis rats (n = 42; weight ~ 300 g; (Charles River Laboratories, Inc., Boston, MA) 
received aortic interposition grafts as described in Section 6.1.3, and were divided in 4 groups. 
The first group (rG-1; n = 15) received TIPS PEUU scaffolds seeded with rMDSCs. The second 
group (rG-2; n = 17) received ES-TIPS PEUU scaffolds seeded with rMDSCs.  The third group 
(rG-3; n = 10) received either an acellular TIPS PEUU scaffold as a control for rG-1 (n = 5), or 
an acellular ES-TIPS (n = 5) as a control for rG-2.   
Animals were electively sacrificed at 8 weeks or euthanized earlier if ambulatory 
impairment or distress was evident due to construct occlusion or thromboembolic events.  
Following euthanasia, a comprehensive set of endpoints were evaluated to assess the 
performance and the remodeling of the scaffolds, including fluoroscopy, gross pathology, 
histology, SEM, and immunohistochemistry. 
6.1.3 Infrarenal aortic interposition graft in rats 
All animal procedures and treatments were performed in compliance with the Institutional 
Animal Care and Use Committee (IACUC) of the University of Pittsburgh guidelines.  
Animals were anesthetized in a 2% isofluorane in pure oxygen atmosphere (induction 
chamber) followed by a single dose of 50 mg/kg ketamine, injected interperitoneally.  Animals 
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were then placed on a warming pad (40-45°C) in supine position and ventilated with 1% 
isofluorane in pure oxygen administered via a rat-sized rubber cone positioned on the animal’s 
nose.  
Surgeries were performed using aseptic techniques and sterile instruments.  The skin of 
the anterior abdomen was aseptically prepped, without previous fur shaving, with povidone-
iodine solution.  A midline laparotomy incision was made through the skin and abdominal 
muscles.  The wound and viscera were retracted and held in place by a small screw retractor.  
The abdominal aorta was exposed below the renal arteries and carefully separated from the 
inferior vena cava.  Sodium heparin (40 IU) was given intravenous through a tributary vein of 
the inferior vena cava.  Two micro-vascular clamps, held by a microapproximator, were applied 
to the infrarenal aorta proximally (5-8 mm downstream to the renal arteries) and distally (about 
15 mm from the first clamp), and the aorta was sectioned in between the clamps creating a gap of 
approximately 1 cm, due to the relief of the physiological longitudinal vascular tension.  The 
TEVG was trimmed on both edges to obtain a 1 cm-long construct and then sutured in place to 
the native aorta, in an end-to-end, interrupted anastomotic pattern with 10-0 polyamide 
monofilament (Arosurgical, Newport Beach, CA).  An average of 6 stitches per anastomosis was 
required.  The trimmed edges of each TEVG were fixed in 4% paraformaldehyde and processed 
for cytoskeletal and nuclear staining as described in Section 4.2.6 to assess the pre-implantation 
cell density.  
After the graft was anastomosed, the clamps were released and patency was verified by 
direct observation.  Clamping time was approximately 25-35 minutes.  Finally, the muscle layer 
and skin were closed with 3-0 polyglactin absorbable suture (VICRYL, Ethicon, Inc.), and a 
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povidone-iodine ointment was applied on the sutured abdominal incision to prevent post-
operative infections.     
The rats were observed in the surgical suite until fully recovered from the anesthesia and 
then returned to the housing area.  Standard analgesic and antibiotic therapy was administered 
following the surgery.  In particular, for the first 3 days after surgery, buprenorphine (0.5 mg/kg 
twice a day) and cefuroxime (100 mg/kg twice a day) were administered subcutaneously.  
Antiaggregation therapy was started after the surgery with aspirin and dypiridamole (200 mg via 
mouth daily during the first week and 100 mg via mouth daily after the first week until elective 
sacrifice). 
A schematic of the surgical procedure is shown in Figure 6.2.  
6.1.4 Performance after 8 weeks in vivo 
6.1.4.1 Patency 
After 8 weeks, animals were anesthetized with 5 % isofluorane in pure oxygen, anticoagulated 
and concurrently euthanized with a lethal intracardiac injection of heparin/KCl (40 IU of heparin 
in 5 ml of KCl).  Following euthanasia, the thoracic descending aorta was exposed via median 
sternotomy and by displacement of the heart and lungs, and then cannulated with a 22 G 
Angiocath (BD, Sandy, UT) secured with a 4-0 silk ligation.  The animals were placed under a 
dynamic angiography system (OEC 9800 Plus, GE Healthcare, Piscataway, NJ) and iodine 
constrast media (Renografin-60, Bracco Diagnostics, Princeton, NJ) was manually infused 
through the angiocath during irradiation and acquisition to assess graft patency.  Patency rate 
was calculated as the ratio between the number of animals with positive contrast flow through 
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the construct and the total number of animals within each experimental group.  Statistical 
differences in patency rate between groups were detected via an exact Fisher test for non-
parametric variables.  Mechanical failure was assumed when obvious dilation could be observed 
at the time of fluoroscopy.   
 
 
 
 
Figure 6.2  Rat infrarenal aortic interposition graft surgery.  A.  Schematic showing the location of the TEVG as an 
interposition graft in the abdomen of the animal.  B.  Close-up showing the graft at the end of one representative 
vascular procedure.  The arrows indicate the 10-0 stitches used to anastomose the graft to the native aorta.  Note the 
good size matching.  
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6.1.4.2 Gross macroscopic appearance 
After angiography, a midline laparotomy was performed and the constructs were dissected, 
explanted from the animal along with approximately 5 mm of native aorta within each 
anastomosis and stored in saline until processing.  All of the specimens were initially observed at 
10x under a zoom stereomicroscope (SMZ660, Nikon Instruments Inc., Melville, NY), in order 
to detect gross macroscopic remodeling, signs of infections, abscess formation, presence of 
intraluminal thrombus and vessel wall thickening.  The TEVGs were subsequently cut in several 
longitudinal portions for the various other endpoints.    
6.1.4.3 Histology 
For histological assessment, separate ring segments were fixed in 10% formalin for 1-2 hours 
and immersed in 30% sucrose solution overnight at 4°C, before standard paraffin embedding and 
sectioning (section thickness = 5 μm) via microtome (Thermo Shandon Inc., Pittsburgh, PA).  
Hematoxylin and eosin and Masson’s trichrome were performed following standard histological 
protocols.  Histological slides were observed and imaged within bright field microscopy via an 
Eclipse E600 microscope (Nikon Instruments Inc., Melville, NY) provided with a digital color 
CCD camera (Model 2.3.1, Diagnostic Instruments Inc., Sterling Heights, MI). 
Phenotypic assessment of newly formed tissue was assessed via immunofluorescence 
using a previously described protocol (see Section 5.1.2).  Briefly, dedicated sections were 
incubated for 60 minutes at room temperature with the following primary antibodies: smooth 
muscle alpha-actin (1:500) (Sigma-Aldrich, St. Louis, MO), calponin (1:200), (Sigma-Aldrich, 
St. Louis, MO), myosin heavy chain (1:500) (Sigma-Aldrich, St. Louis, MO) and Von 
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Willebrand Factor (vWF) (1:100) (Dako).  Unbound primary antibody was removed by 
subsequent washes in PBS.  The samples were then incubated with a Cy3-conjugated (Sigma-
Aldrich, St. Louis, MO) secondary antibody (1:500) for 1 hour at room temperature and 
subsequently rinsed 3 times for 15 minutes each with PBS.  For nuclear visualization, cells were 
counter-stained with DAPI.  The samples were then mounted in gelvatol and viewed and imaged 
with the aforementioned microscope and camera.  
Cell tracking, using the LacZ reporter, was performed on 5 μm frozen sections fixed in 
2% glutaraldehyde, according to a previously described protocol (recall Section 5.2.2) using the 
X-gal stain overnight and eosin counterstain where blue nuclei was only found in LacZ+ cells.  
The luminal surface of the explanted constructs was examined by SEM. Dedicated 
samples were processed as described in Section 2.2.4. 
6.1.4.4 Results 
After 48 hours of dynamic culture, the constructs of rG-1 (rMDSC-seeded TIPS PEUU scaffold) 
and rG-2 (r-MDSC-seeded ES-TIPS PEUU scaffold) appeared completely populated with cells 
that were spread inside the scaffolds (Figure 6.3). 
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 Figure 6.3  Pre-implantation microscopic aspect of the TEVG for small animal studies.  A.  rMDSC-seeded TIPS 
PEUU scaffold.  B. rMDSC-seeded ES-TIPS PEUU scaffold.  The arrows indicate the luminal surface. Blue = 
nuclei, green = F-actin, red = scaffold. 
 
 
 
Surgical implantation was feasible in all cases and no differences were noted between the 
groups in the surgical features of the constructs (i.e., tissue handling and suturability).  Upon 
implantation, all TEVGs clearly appeared to have strong pulsatility, with no oozing or leaking of 
blood.  All animals recovered well from surgery and showed no signs of distress immediately 
post-operatively.  In rG-1, two animals showed signs of lower limb impairment, absence of 
pulses, and lower limb necrosis within the first 72 hours, requiring early sacrifice.  Another 
animal had an aneurysmatic rupture leading to the death at day 4.  In rG-2, three animals were 
sacrificed before 8 weeks due to ischemia of the lower limbs.  In rG3, five animals showed 
evidence of lower limb ischemia, which required early sacrifice within the first week.  All 
remaining animals were electively sacrificed at 8 weeks with no need of premature euthanasia.  
Four animals (two in rG-1, and two in rG-2) that had a self-limited necrotic plaque in the 
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medial/distal part of the tail but positive femoral pulses, were treated with a partial resection of 
the tail following standard amputation techniques, and were electively sacrificed after 8 weeks.  
The angiograms performed to evaluate patency rate showed that in rG-1, eight out of 
fifteen animals (53.3%) had an open construct with no signs of stenosis.  However, four of these 
animals showed aneurysmatic dilation (50%) of the TEVG (Figure 6.4-A).  In rG-2, eleven out 
of seventeen animals (64.7%) were patent with no signs of stricture, dilations, or mechanical 
failure (Figure 6.4-C).  In contrast, only one out of ten animals (10%) in the combined rG-3 was 
patent while the remainder showed a complete obstruction of the graft (Figure 6.4-E).  There 
were no significant differences in patency rate between rG-1 and rG-2 (p = 0.22), but when 
compared to the acellular controls in rG-3, both groups had a significant difference (p = 0.03 for 
rG-1 vs rG-3, p = 0.007 for rG-2 vs rG-3). 
All patent constructs in rG-1 and rG-2 showed a tissue-like appearance with clear 
remodeling of the scaffold without signs of scar tissue at the level of the anastomoses (Figure 
6.4-B/D).  No signs of infection or abscess formation were detected in any of the explants, 
regardless of patency outcome.  Non-patent constructs in these groups had white organized tissue 
in the lumen, mainly at the anastomoses level, suggestive of intimal hyperplasia formation.  In 
rG-3, all constructs but one, showed clear intraluminal thrombus formation with little or no 
remodeling of the scaffold (Figure 6.4-F).   
SEM analysis for the explanted TEVG in rG-1 and rG-2 revealed no signs of stricture at 
the anastomosis level in the patent constructs (Figure 6.5-A/B), and a clear integration between 
the native vessel wall and the implanted polymer (Figure 6.5-B.  In rG-1 and rG-2 groups, an 
endothelial-like layer was observed on the luminal surface, with a smooth transition from the 
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native endothelium to the tissue engineered graft (Figure 6.5-C).  The luminal surface in rG-3 
constructs was completely covered by adherent platelets (Figure 6.5-D). 
Histological analysis of rG-1 and rG-2 showed formation of an external collagenous 
capsule, as well as an internal tissue layer with collagen and cellular components characteristic 
of smooth muscle cells (Figure 6.6-A/B).  The scaffold showed a good remodeling in the TIPS 
layer in both groups and less remodeling in the electrospun layer in rG-2 group (Figure 6.6-B).  
There was evidence of giant cells, characteristic of a foreign body response, together with a 
population of mononuclear cells inside the scaffold, suggesting an active degradation process.  
Although not quantified, the cell density inside the polymer appeared to be lower than the pre-
implant analysis suggesting cell migration out of the scaffolds.  In rG-3, there were almost no 
cellular components inside the scaffold with scarce remodeling and a clear organized fibrin 
structure in the lumen, characteristic of thrombus formation.   
X-gal staining of the sections from the rG-1 and rG-2 groups showed LacZ+ cells that 
participated in the remodeling, corroborating the remaining presence of the implanted cells at 8 
weeks (Figure 6.7).  
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Figure 6.4  Fluoroscopy and gross pathology after 8 weeks in vivo.  Representative fluoroscopy and gross 
pathology, respectively, of rG-1 (A, B), rG-2 (C, D), and rG-3 (E, F).  The arrows in the left panels indicate the 
position of the TEVG.  Note aneuryrism formation of the TIPS scaffold (A) and complete occlusion of acellular 
scaffolds (E). 
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Figure 6.5  SEM of the luminal surface of the TEVG following 8 weeks in vivo.  A.  Representative micrograph of a 
patent TEVG from rG-1.  The black arrow indicates the anastomosis between the aorta (Ao) and TEVG.  B.  
Representative micrograph of a patent TEVG from rG-2.  The white arrows indicate the two layers of the ES-TIPS 
PEUU scaffold.  C.  Representative close-up on the lumen of a patent TEVG from rG-2.  The image is also 
representative for rG-1 TEVGs.  D.  Representative micrograph of the lumen of the scaffold from rG-3. 
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Figure 6.6  Histological analysis following in vivo remodeling.  Representative Masson’s trichrome results for rG-1 
(A), rG-2 (B), and rG-3 (C) groups.  The arrows indicate the lumen of the TEVG. 
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 Figure 6.7  Representative X-Gal staining after in vivo remodeling revealing LacZ+ cells in rG-1 (A), and rG-2 (B) 
groups. B.  Representative results of rG-2.  The inset in B is a different region (same scale) showing LacZ+ cells 
participating in capillary formation in the rG-2 group.  The arrows indicate the lumen of the TEVGs.   
 
 
 
The immunohistochemical analysis showed that the inner tissue layer noted in rG-1 and 
rG-2 was positive for smooth-muscle alpha actin and calponin, suggesting a smooth muscle cell 
phenotype. The cell layer lining the luminal surface stained positive for vWF, corroborating the 
presence of endothelial cells.  No differences were noted between rG-1 and rG-2 groups.  
Myosin heavy chain was negative in all of the samples. 
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 Figure 6.8  Immunohistochemistry after in vivo remodeling in rG1 (left column) and rG-2 (right column).  A-B.  
α-SMA (green) and cell nuclei (blue).  C-D.  Calponin (red) and cells (blue).  E-F.  vWF (green) and cell nuclei 
(blue).  The arrows indicate the lumen of the TEVGs.  
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6.1.5 Discussion  
The remodeling of rMDSC-based TEVGs in vivo has been investigated in this section and 
compared to the behavior of acellular scaffolds.  Marked differences in patency rates were 
detected between cellular and acellular constructs, suggesting antithrombotic properties of the 
seeded cells, leading to maintenance of patency.  LacZ+ seeded cells (LacZ+) were detected in 
the TEVGs after 8 weeks in vivo (Figure 6.7), demonstrating the role of MDSCs in the 
remodeling process.  The presence of the seeded cells in the scaffold after 8 weeks also supports 
the utility of acute dynamic culture to allow for cell retention, attachment, and spreading.   
The presence of neo-tissue formation within the TIPS layer of the scaffolds, characterized 
by densely cellularized, collagenous tissue (Figure 6.6), and positive markers for smooth muscle 
cells (α-SMA and calponin; Figure 6.8), and for endothelial cells (vWF; Figure 6.8) suggests 
the remodeling of the TEVG toward an artery-like structure.  
The TIPS PEUU scaffold proved to be mechanically inadequate for arterial applications 
as evidenced by the high dilation/failure rate (50%) leading to aneurysm formation and, in one 
case, to rupture.  Conversely, the compound ES-TIPS PEUU scaffold demonstrated suitability 
for arterial applications.  The combination of the two PEUU processing techniques in the ES-
TIPS scaffolds provides the necessary porosity for cell support and tissue ingrowth, while 
providing the mechanical properties to withstand systemic circulation at least for a period of 8 
weeks.  Moreover, the absence of detectable differences in remodeling within the TIPS layers of 
rG-1 and rG-2 suggests that the electrospun layer does not affect either the cellular activity or 
diffusion of nutrients.    
The engraftment of MDSCs in TEVGs after 8 weeks (Figure 6.7) provides only initial 
evidence to suggest the role of the seeded cells in the remodeling process in vivo.  Direct 
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comparison between histology and LacZ+ images did not allow for the establishment of a direct 
relationship between the engrafted cells and the new tissue formation.  Follow-up co-localization 
studies, molecular endpoints, and functional tests are necessary to elucidate the mechanisms of 
action by which the cells prevent thrombosis of the grafts and contribute toward the detected 
presence of vascular cell phenotypes.  However, it is possible that the signaling released by the 
implanted cells plays a key role in the remodeling and recruitment of host endothelial cells.   
The use of allogeneic cells without immune suppression represents another limitation of 
this study.  Though Lewis rats are inbred, thus limiting the chances of a strong immune response, 
this might have caused the sub-optimal patency rate detected.  A careful investigation, assessing 
macrophage infiltration, and other markers denoting the immune response, should be performed 
in additional studies.  
The rat model represents another intrinsic limitation of this study.  Unless genetically-
modified to develop a particular condition, the rat is normally more resistant to cardiovascular 
disease than humans [188].  Therefore, while this study may have suffered an underestimation of 
the patency rate due to the allogeneic cell source, it may have overestimated patency rate due to 
the intrinsic resistance of rats to vascular disease.   
Another limitation of this study is the amount of polymer degradation noticed in the long 
term endpoint at 8 weeks.  Although the TIPS portion appears heavily remodeled and infiltrated, 
supporting the hypothesis that TIPS PEUU degradation occurs concurrently with tissue 
deposition and regeneration, the ES layer remains intact with no visible degradation after 8 
weeks.  This evidence did not allow for the assessment of whether the TEVG is supportive of a 
conservative remodeling as a whole (i.e., the degradation kinetics are comparable with the 
deposition of structurally- and mechanically-sound native ECM leading to a stable TEVG until 
 237 
complete scaffold degradation occurred), and hence did not allow for proving its suitability as an 
arterial substitute.  We have observed in a separate study (data not shown) that electrospun 
constructs implanted as an arterial vascular graft can resist in vivo degradation for more than six 
months, without failing mechanically.  While it is possible that, by that time, the TIPS layer 
would be sufficiently remodeled and the newly formed tissue would be strong enough to 
withstand systemic circulation, concerns arose regarding the degradation properties of the ES 
PEUU material.  Therefore, a comprehensive study to describe and optimize the degradation 
kinetics of the ES PEUU, and longer-term in vivo studies to test the resulting TEVG as a vascular 
substitute, are required, but was beyond the scope of this dissertation.  
Most of the previously described cellular approaches for vascular tissue engineering have 
relied on a long-term culture period to reach the desired cell density and mechanical strength.  It 
has been shown in this work that the combination of an effective seeding technique (Chapter 2) 
followed by a short term in vitro culture period in a dynamic environment (Chapter 5) 
effectively yields a TEVG suitable for arterial applications within a clinically relevant period of 
time, without adversely affecting the phenotype of the seeded stem cells.  In this in vivo study 
within the rat model, some evidence has been provided that such an approach is a suitable 
alternative to obtain an arterial vascular substitute. 
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7.0  SPECIFIC AIM 4, PART 2: LARGE ANIMAL AUTOLOGOUS TEVG STUDIES 
The allogeneic, small animal study described in the previous sections showed very promising 
results.  Moreover, it answered critical questions demonstrating most of the articulated 
hypothesis of this work (recall Section 1.10).  However, the rat model, though inexpensive and 
practical, might be significantly distant in pathophysiology from the human model [181].  
Therefore, a more complex model was subsequently used to bring the approach a step further 
toward clinical translation.  To this end, an autologous study was designed and performed in a 
clinically relevant, large animal model using pigs.  
The domestic pig model has the advantage of having better cardiovascular anatomic and 
phenotypic similarities with humans than rodents.  It is cost-effective and readily available [189].  
Domestic pigs have been used for a variety of vascular grafting approaches, including several 
TEVG studies both for small- [190, 191], and large-diameter [192] applications, and synthetic 
vascular graft studies [193, 194].   
Since time is a key factor to consider when designing a clinically viable approach for 
tissue engineering, all of the techniques in this work have been designed to take place in a short 
amount of time.  Indeed, the seeding process takes only minutes, the scaffold is readily available 
off-the-shelf because it can be produced and in stock well ahead of time, and the acute culture 
within a spinner flask or the Perfuser requires 1 to 3 days to populate the scaffolds with spread 
cells.  The limiting factor, when translating the allogeneic study performed in rats into a fully 
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autologous approach in pigs, is represented by the cell source.  The striated muscle is a valid 
source of adult stem cells [166], and was chosen for the approach presented.  (recall Section 
5.1.1).  However, the isolation of MDSCs using the preplating technique as previously described 
[99], is time consuming, requiring approximately 6 days to extract the PP6 fraction of cells 
(MDSCs) as a small percentage of the total cell number available, before the expansion process 
can be initiated.   While the possibility of MDSC isolation and characterization utilizing more 
complex methods, such as the fluorescence-activated cell sorting, is certainly an ideal option to 
obtain the stem cell fraction rapidly [54], due to limited funding and the preclinical nature of 
these studies, a period of 2 weeks for the stem cell isolation via the preplating technique and their 
expansion was chosen.   
The validity of this approach and time frame was tested in prior pilot studies, which 
demonstrated its feasibility, and allowed time to troubleshoot a number of issues related to the 
initial study design (APPENDIX G). Specifically, the autologous cell isolation/expansion and 
scaffold fabrication protocols were modified to accommodate requirements learned during the 
course of the pilot study.  
7.1 STUDY DESIGN 
Once the amount of time dedicated to obtain cells was established, the design and the time frame 
of the study were designed accordingly.  In particular, the study entailed a muscle biopsy 
performed on each animal the first day (Day 0) to isolate autologous stem cells.  The following 2 
weeks were used to isolate (Days 0-5), and expand and transfect (Days 6-13) the cells with the 
LacZ promoter for in vivo tracking purposes.  On Day 14, cells were seeded into ES-TIPS PEUU 
 240 
scaffolds (recall Section 4.2) via S-RVSD (recall Chapter 3).  After a short period of static 
culture, the seeded scaffold was transferred in the Perfuser (Section 5.3), and cultured 
dynamically for a 24 hour period prior to implantation on Day 15.   
The seeded scaffolds were then implanted either as a carotid interposition graft (CIG) or 
as an arteriovenous (vascular access) graft (AVG) in a carotid-to-internal jugular vein 
configuration.  The implantation side was randomly selected for each animal.  The contralateral 
side was implanted in a paired-control fashion with a carotid sham for the CIG animals or with a 
PTFE graft for the AVG animals.  The study can thus be divided in three different experimental 
groups.  The first group (pG-1) consisted of animals receiving an autologous TEVG as a CIG for 
1 month (n = 5).  The second group (pG-2) was animals receiving a CIG for 3 months (n = 4), 
and the last group (pG-3) was animals receiving a TEVG as an AVG for 1 month (n = 2).  It 
important to note that in the pilot studies (APPENDIX G), an additional 9 pigs were used;  7 pigs 
in pG-1, one pig in pG-2, and another pig in pG-3.  These animal could not be included in the 
final study since they required the variation of several study parameters to address a number of 
issues encountered during the course of the study.  Furthermore, the pilot study did not entail the 
use of the Perfuser bioreactor (recall Section 5.3), but rather a simple culture in spinner flask, as 
described for the small animal study (Section 6.1.1), was utilized.   
 Recall that the rat study demonstrated very poor patency rates for the unseeded scaffolds 
(Section 6.1.4), suggesting a role of seeded stem cells in the maintenance of patency.  For this 
reason, no unseeded scaffolds were used as controls in this study due to the high cost of the pig 
model and the apparent lack of usefulness of the unseeded scaffold.  Instead, more clinically-
relevant controls (i.e., the carotid sham and the PTFE graft) were used.  The carotid sham control 
was used to test the pathogenic effect of the surgical access and manipulation, and the resulting 
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effects on native healthy tissue due to the presence of foreign suture material at the anastomoses 
(i.e., iatrogenesis).  This was performed to substantiate or rule out the generation of adverse 
effects as a consequence of the surgery itself, instead of to the properties of the TEVG in the CIG 
experimental groups.  For example, the commonly used, non-resorbable suture for vascular 
applications, Prolene, has been associated with inflammation and intimal hyperplasia triggered 
by a foreign body inflammatory reaction [195].  The PTFE control for the AVG group was 
chosen based on it being the current standard for hemodialysis access requiring arteriovenous 
connection [196]. 
A summary of the study design described here is shown in Figure 7.1. 
After the selected survival period, pigs were sacrificed and a comprehensive set of 
endpoints were assessed, to evaluate the performance and the remodeling of the TEVG.  The 
planned endpoints included: fluoroscopy to test the patency and the structural consistency of the 
TEVG (absence of dilations or pseudo-aneurysms); gross pathology to detect the presence of 
infections, abscess formation, scaffold degeneration, and the formation of thrombus or intimal 
hyperplasia; histology to assess the TEVG remodeling; SEM to analyze the luminal surface of 
the scaffold and demonstrate endothelial coverage; immunohistochemistry to evaluate the 
phenotype of the remodeled TEVG; and, finally, mechanical testing to quantify the 
degradation/effective remodeling of the TEVG . 
A schematic of the endpoints evaluated for the explanted TEVGs is shown in Figure 7.2.
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 Figure 7.1  Schematic of the pig study design. 
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Figure 7.2  Summary of the endpoints assessed for the explanted TEVGs.  For each portion of the TEVG  (i.e., D = 
distal, M = middle, or P = proximal), the evaluation of three main endpoints – histology (Hist), SEM, and 
immunohistochemistry (IHC) was performed.  
 
 
7.2 PIG MUSCLE BIOPSY PROCEDURE 
All animal procedures and treatments were performed in compliance with the IACUC of the 
University of Pittsburgh.  
Pigs (domestic crossbred, weight = 30-35 kg, age = 4-6 months of both sexes) were 
brought into the animal facility at least 2 days prior to the day of the biopsy procedure, and kept 
nil per os 12 hours prior to surgery.  In preparation for the surgery, animals were anesthetized 
with acepromazine, 0.15 mg/kg, and ketamine, 15.0 mg/kg (both intramuscular) combination, 
intubated, and maintained at a surgical plane of anesthesia with isoflurane (1-3% in oxygen).  
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Once each animal was clipped and prepped for the procedures it was moved into the surgical 
suite and placed on positive pressure ventilation and instrumented with monitoring equipment 
(ECG).  Pulse oximetry and blood pressure were monitored throughout the surgical procedure.  
After the induction of anesthesia, aseptic surgery was performed.   
A monolateral, full thickness, semilunar skin incision (diameter ~ 8 cm) on the gluteus of 
the animal was performed by a Bovie in order to expose the underlying fat layer (Figure 7.3-A).  
The subcutaneous fat and muscle fascia were carefully dissected within a single flap to expose 
the lean striated muscle.  A superficial muscle biopsy (approximately 5x2x1 cm) was resected 
with a 10-blade scalpel following the natural orientation of the muscle fibers (Figure 7.3-B).  
The harvested tissue was subsequently placed in cold DPBS supplemented with 5% 
antibiotic/antimycotic (A/A) solution (Gibco, Invitrogen Corporation, Carlsbad, CA) and stored 
in ice until processing for cell isolation as described in Section 7.3.  The resulting muscle cavity 
was carefully observed for bleeding and cauterized or temporarily packed with sterile gauzes as 
needed to interrupt minor bleeding (Figure 7.3-C).  The skin and fat flaps were repositioned and 
sutured with 3-0 polyglactin absorbable suture (VICRYL, Ethicon, Inc.) with approximately 12-
15 separate stitches (Figure 7.3-D).  A povidone-iodine ointment was applied on the sutured 
incision at the end of the procedure to avoid post-operative infections upon return in the animal 
cage.  More details on the post-operative care of the animals is provided in Section 7.6.   
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 Figure 7.3  Pig muscle biopsy procedure.  A.  A semilunar incision is made with a Bovie.  B.  A flat muscle biopsy 
following the natural muscle fiber orientation is resected with a scalpel.  C.  The resulting cavity is inspected and 
dried from oozing blood before closure.  D.  The skin is closed with separate stitches. 
 
 
 
7.3 ISOLATION OF PIG SLOWLY ADHERING CELLS 
7.3.1 Methods 
The muscle tissue was processed within 1 hour from the harvesting.    The sterile tube filled with 
cold DPBS and antibiotic/antimycotic used to transport each biopsy was weighted prior to and 
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after storing the tissue to retrieve the weight of each biopsy.  The isolation procedure was 
performed in sterile conditions under a laminar flow hood.  The tissue was cleaned from 
macroscopic superficial fat residues with a sharp iris scissor and then serially washed in Petri 
dishes filled with Hank’s balanced salt solution (HBSS) (Gibco) (Figure 7.4-A).  Each biopsy 
was then meticulously minced into a coarse slurry in a Petri dish with HBSS (Figure 7.4-B), 
transferred into a 50 mL tube and centrifuged at 3500 rpm for 5 min (Figure 7.4-C) before 
undergoing a three-step enzymatic dissociation.  The supernatant solution with additional fat 
residues was removed and the pellet was resuspended in 0.2% collagenase-type XI (Sigma) and 
placed in a standard incubator at 37ºC for 1 hour (Figure 7.4-D).  Every 15 min the tube was 
gently shaken to facilitate the enzymatic digestion and then replaced in the incubator.  The tube 
was then centrifuged at 3500 rpm for 5 min and resuspended in dispase solution (Gibco; 2.4 
units/mL in HBSS) for 45 minutes.  After another centrifugation the tissue was finally incubated 
for 30 minutes in 0.1% trypsin-EDTA (Gibco).   
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 Figure 7.4  Pig SACs isolation via enzymatic dissociation.  A.  The muscle biopsy is cleaned and washed in separate 
Petri dishes under the laminar flow hood.  B.  The tissue is minced into a coarse slurry.  C.  The processed tissue is 
centrifuged to remove additional fat residues into the supernatant.  D. A three-step enzymatic dissociation allows the 
cells to separate from the muscle ECM.    
 
 
 
After completion of the enzymatic dissociation, cells were centrifugated and resuspended 
in DMEM (Gibco) supplemented with 10% HS (Gibco), 10% FBS (Gibco), 0.5% chicken 
embryo extract (Gibco), and 1% penicillin/streptomycin (Sigma) and plated into collagen-coated 
(collagen type I, Sigma) T175 culture flasks for 2 hours.  The media with a large number of non-
adherent floating cells was then removed and replated into another T175 flask for 24 hours, 
while cells attached to the first flask received additional fresh media.  This process, called “pre-
plating”, was repeated 5 times every 24 hours.  Cells attached to the first flask are defined as 
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preplating 1 (or PP1), those attached to the second flask PP2, and so on for the remaining 4 days 
of preplating.  The reported protocol is essentially that described for mouse cells [99], in which 
the PP6 cells are considered to be MDSCs; however, to increase the cell yield, preplatings 3, 4, 
5, and 6 were trypsinized and pooled in equal proportions into a single culture flask and 
expanded (Figure 7.5).  This population was defined as pig SACs; the name was derived from 
the variability in time of the adhesion properties of these cells.  This decision was made after 
initial pilot studies (APPENDIX G) suggested that the sole yield of the PP6 fraction, following 
isolation and expansion, was not sufficient to provide enough cellular density into the TEVG 
within the desired time frame.  A limited phenotypic characterization and comparison between 
the pooled population of PP3, PP4, and PP5 and the PP6 cells (see Section 7.4) did not allow us 
to draw reliable conclusions.  However, a speculation in favor of this approach relies on the 
potentially increased phenotypic heterogeneity of the pooled population compared to the more 
homogeneous PP6 fraction.  The heterogeneity might, in fact, translate to a better in vivo 
outcome, as suggested by the increasing body of evidence supporting developmental 
heterogeneity more than plasticity as the main mechanism behind the broad therapeutic efficacy 
of mesenchymal stem cells in vivo [197].   
 
 
 
 249 
 Figure 7.5  Pig SACs isolation via the pre-plating technique.   
 
 
 
However, the initial number of SACs plated on the sixth day was still limited by the 
number of PP6 cells available due to the established requirement of equal cell proportions for 
each preplating in the pooled culture (e.g., total number of PP6 cells obtained on the sixth day = 
x, plated number of SACs plated on the sixth day = 4x).   
Two days prior to seeding, SACs were transfected with a retrovirus carrying the gene 
encoding for β-galactosidase (LacZ) for 24 hours using a protocol previously described in 
Section 5.2.2, and used as needed.  A small amount of cells from different isolations (n = 5) were 
plated in 6-well plates, growth to confluency, and fixed for 10 minutes in 2.5% glutaraldheyde 
followed by multiple washes with PBS.  The plates were then stained with X-Gal overnight to 
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retrieve the efficiency of LacZ transfection by counting the percentage of transfected cells over 
the total number of cells visible per field of view. 
7.3.2 Results 
The isolation and expansion process (starting from the day of the biopsy to the day of cell use 
lasted 14.2±1.9 days.  While two week period was defined a priori, as previously explained in 
Section 7.1, the variability was due to schedule constraints.  The weight of the muscle biopsy 
was consistent (10.5±1.6 gr).  The total number of PP6 cells obtained on the sixth day, however, 
was quite variable, being equal to 3.1±4.0x105 cells.  This yield corresponded to a PP6 cell 
isolation density (number of cells per unit of weight of tissue) of 3.2±4.6x104 PP6 cells/gr.  The 
SACs populations were pooled 9.5±1.2 days after the muscle biopsy was harvested, and the time 
available for expansion of the SACs was 4.4±1.3 days.  Within the available expansion time the 
SACs PD and PDT (as defined in Section 5.1.2) were 1.3±0.6, and 93.4±36.3 hours.  The 
resulting transfection efficiency was < 1%.  
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7.4 CHARACTERIZATION OF PORCINE SACS  
No comprehensive characterization of porcine MDSCs is available in the literature.  A complete 
characterization of this cell type, which would require an extensive number of resources and 
experiments, was considered beyond the scope of the current work.  However, a limited 
characterization based on immunohistochemistry and FACS was performed for pig PP6 cells, as 
well as a qualitative and quantitative morphological analysis of pig SACs.  Due to the 
complexity and inherent variability in cell biology, this analysis was performed with a pure, 
phenomenological approach, limiting it to a description of the results obtained without 
establishing statistical relationships in order to define patterns of generalized features. 
7.4.1 Methods 
Dedicated pig PP6 isolations (n = 4) were processed for immunohistochemistry against a variety 
of cell markers for a basic phenotypic screening.  Immunostaining was performed following a 
protocol identical to what was previously described in Section 5.1.2.  In particular, a general 
endothelial antibody (APG993, Antigenix), and CD31 (555027, DB Biosciences), were used to 
detect endothelial markers, desmin (D1033, Sigma) and vimentin (V4630, Sigma) were used as a 
striated muscle markers, and finally GFAP (G3893, Sigma) was used as a nerve marker.  The 
percentage of positive cells was quantified via an image-based technique as previously described 
in Section 3.1.4.3 for the apoptosis quantification. 
The percentage of expression of an additional number of surface markers was quantified 
via FACS in different isolations (n = 5) using the same protocol used in Section 5.1.2.  In 
particular, VE-Cadherin (CD144) (V1514, Sigma) was used as an endothelial cell marker, CD45 
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(APG450F, Antigenix) as a hematopoietic cell marker, CD56 (304610, Biolegend) as a neural 
cell marker, CD146 (MCA2141F, Serotec) as a pericyte/endothelial cell marker, and finally 
CD34 (348801, BD Biosciences) as a hematopoietic and myogenic marker. 
A qualitative and quantitative morphological characterization of pig SACs in culture 
prior to their use in vivo was also performed.  In particular, a series of at least five 100x images 
per isolation (n = 8) was taken with an inverted, phase-contrast microscope (Nikon TS100, 
Nikon Digital Sight DS-L1).  Each image was quantified via a semi-automatic image processing 
technique performed with ImageJ, in order to recognize and quantify the size and circularity of 
cells.  To this end, an edge recognition algorithm was used, followed by a threshold filter and a 
binary filter to eliminate small gaps into well defined shapes.  Each image was then assessed 
with a particle analysis function for area and circularity.  The shape index is a shape function that 
is calculated for each cell as: shape index = 4π (cell area/cell perimeter2) [198].  This parameter 
approaches a value of 1 in cases where cells have a circle-like shape, while the value and to 0 in 
cases of spindle-shaped cells.  
7.4.2 Results 
All markers used for immunohistochemistry except for vimentin were negative for all tested 
isolations though no positive controls were used to determine the specificity of the antibodies.  
The percentage of cells positive for vimentin was 62.3±29.9% (mean ± standard deviation; n = 
3).   
  FACS results showed that pig PP6 cells expressed a variety of markers in different 
percentages.  Positivity for CD144 was 29.2±21.3%, while for CD45 it was 2.9±3.5%, for CD56 
it was 18.4±13.7%, for CD146 it was 15.1±19.9%, and finally for CD34 it was 19.5±15.2%. 
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These results are summarized in Table 7-1. 
 
 
 
Table 7-1  Percentage of expression of phenotypic markers for pig SACs. 
 
N Mean Standard deviation
CD144 4 29.2 21.3
CD45 4 2.9 3.5
CD56 4 18.4 13.7
CD146 4 15.1 19.9
CD34 4 19.5 15.2  
 
 
 
These results do not provide a robust phenotypic characterization of pig PP6 cells 
isolated via preplating.  However, they demonstrate the heterogeneity of the population, which 
might be desirable for in vivo applications as described in the previous section.      
A qualitative, morphological assessment of pig SACs for several isolations is shown in 
Figure 7.6, while the results of the image-based cell morphology quantification are summarized 
in Figure 7.7 and Figure 7.8. 
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 Figure 7.6  Pig SACs morphology.  The label on the top left corner of each panel represents the isolation ID of the 8 
isolations used for this purpose.  Pictures were taken at 200X.  
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Figure 7.7  Average cell area quantification for 8 different isolations of pig SACs.  Measures are presented as mean 
± SEM; n > 50. 
 
 
Figure 7.8  Shape index quantification for 8 different isolations of pig SACs.  A value of 1 would represent a 
circular cell, while a value of 0 is linear of highly spindle-shaped. Measures are presented as mean ± SEM.  
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 7.5 SEEDING AND DYNAMIC CULTURE OF PIG AUTOLOGOUS TEVGS 
At the end of the 2 week period allocated to isolating and expanding autologous SACs, a TEVG 
was prepared for each animal one day prior to implantation.  SACs from each isolation were 
trypsinized from the culture flasks and counted on the 14th day post-muscle biopsy.  The number 
of autologous pig SACs available on the designated day of seeding was 14.0±8.0x106 cells, far 
less than the expected 30 million.  Table 7-2 provides the number of SACs available from each 
isolation used for the TEVG seedings.   
 
 
 
Table 7-2  Summary of the number of seeded cells for each of the TEVGs implanted in the pig model.  * indicates 
animals that died shortly post-operatively. 
 
Pig ID Experimental Group Seeding Date Seeded Cell Number (x106)
P75-08 pG-2 04/13/08 6.53
P76-08 pG-2 04/14/08 11.01
P77-08 pG-2 04/15/08 4.52
P95-08 pG-2 05/05/08 10.35
P100-08 pG-1 05/14/08 13.65
P101-08 pG-3 05/15/08 15.61
P102-08* pG-1 05/15/08 14.83
P123-08 pG-1 06/10/08 5.78
P124-08 pG-1 06/11/08 22.57
P125-08 pG-1 06/10/08 22.75
P126-08* pG-3 06/10/08 27.61  
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 The average yield for the isolations obtained in these studies was significantly lower (p = 0.0095) 
than that obtained previously in the pilot study (37.3±24.7x106 cells).  The reasons for this are 
unknown. The combined low number of available cells and the high variability in cell yield 
among different isolations caused each TEVG to receive a low and variable number of 
autologous cells.  This limitation, although undesirable in the paradigm of the study, was 
unavoidable.  The low yields obtained in the isolations of the first TEVGs implanted needed to 
set the standard for cell number in all subsequent TEVGs to be consistent.   However, as 
suggested by the rat study, seeded MDSCs have a critical role in the maintenance of patency and 
in the remodeling of the TEVG in vivo (Section 6.1.5).  Despite this, due to the large number of 
people needed to be coordinated for each experiment, and to the tight schedule of the animal 
surgical suites and housing space, the time flexibility allowed for this study was minimal.  As a 
result, we were forced to settle for the cell yields obtained in each isolation. 
The scaffolds used for the pig study were the ID-4.7 ES-TIPS PEUU, prepared to a 
length of 5 cm.  At least two scaffolds per cell isolation were fabricated and sterilized as 
previously described (Section 4.2.2) in preparation for each seeding.  The availability of two 
scaffolds per isolation was originally planned for two purposes.  One was to provide a backup 
scaffold in case of inherent, macroscopic (e.g., delaminations, tears, etc.), or microscopic (e.g., 
low porosity, etc.) defects of the other, which could potentially have affected the seeding 
outcome.  The other was to serve as a TEVG backup in case of unexpected issues after the 
seeding was completed (e.g., contaminations, damages caused by handling or by surgical 
manipulation, etc.).  This redundant approach was also thought to simulate the scenario of a 
future clinical application of this technology.  However, the unexpected low cell yield obtained 
 258 
from each isolation did not allow for a TEVG backup approach and, therefore, only a scaffold 
backup approach was utilized.   
More than 95% of the total cell number available was suspended in 20 mL of complete 
SACs media (see Section 7.3) in preparation for seeding.  The remaining percentage of cells was 
replated and expanded for cell characterization purposes as described in Section 7.4.    
The scaffold for each animal was mounted onto the tees of the S-RVSD, secured with 2-0 
silk ligations, and primed with warm DPBS with the priming valve in the open position.  While 
infusing the DPBS for priming the lumen of the scaffold, the Diffuser was brought in the initial 
seeding position (in proximity of the Driving Tee; recall Figure 3.2).  The seeding parameters 
were consistent with those described in Section 3.1.4 for the testing of the S-RVSD.  The 
seeding process used for the TEVGs for the pig studies is shown in Figure 7.9. 
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 Figure 7.9  Representative seeding of a 5 cm-long ID-4.7 ES-TIPS PEUU scaffold seeded with pig SACs for one of 
the TEVGs.  The sequence is in chronological order during the seeding process.  The yellow arrows indicate the 
current position of the internal Diffuser identified by the local exudation of seeding suspension drops.  Note how the 
scaffold has two distinct colors during seeding: a left pink side denoting the portion already seeded, and a right 
white side denoting the portion yet to be seeded.  The red arrows indicate the increasing level of media exuded out 
of the scaffold and collected into the chamber during seeding. 
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Immediately after seeding, the scaffolds were left in the S-RVSD for approximately 10 
min to let the cell settle into the pores of the scaffold, and then transferred with minimal 
manipulation into a 50 mL tube filled with complete media and cultured in static condition for 2 
hours in a standard cell culture incubator specifically devoted for these preclinical tests.  The cap 
of the tube was partially unscrewed to allow for gas exchange between the cell culture media and 
the incubator.  Due to the lack of a TEVG control, no spare portion of the constructs (e.g., a 
small ring) could be dedicated for analysis of the seeding results.  Based on the S-RVSD testing 
results from Section 3.1.4, it was felt that this decision was fully justified.  Concurrent with the 
beginning of static culture, a Perfuser system for each TEVG was primed with 200 mL of 
complete culture media, placed with unscrewed caps into the same incubator on top of its 
electronic platform, and put in rotation at 20 rpm to equilibrate temperature and pH of the media.  
After the 2 hour period of static culture, each construct was mounted into its dedicated 
Perfuser via 4-0 silk ligation and placed in rotation for 24 hours at 20 rpm.  At the end of the this 
acute dynamic culture, scaffolds were transported to the surgical suite directly in the Perfuser, 
which was enclosed in an aluminum foil-coated styrofoam container to prevent heat loss and 
contamination during transport.   
Just prior to implantation, each TEVG was trimmed at the two ends for surgical sizing 
purposes, and the excised portions were fixed in 10% formalin, dehydrated following standard 
histological protocols, and embedded in paraffin blocks.  Sections (5 µm-thick) were cut and 
processed with H&E staining and imaged at 40x to evaluate the pre-implantation cellularity of 
each scaffold as well as the consistency in size between the scaffolds (Figure 7.10). 
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Figure 7.10  Pre-implantation histology of the TEVGs used in the pig study. The label in the top left corner of each 
panel represents the animal ID number.  The arrows indicate the lumen of the scaffolds.  Note that the sections cut 
for the P100-08 scafold experienced delamination between the ES and TIPS layers, due to inherent scaffold defect, 
leading to loss of the TIPS layer during the histology processing.  Therefore, only the ES layer is visible. 
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Consistent with the low cell numbers available for seeding (Table 7-2) all TEVGs 
exhibited a low level of cellularity prior to implantation, resulting in nearly acellular implants.  
The ES layers of the scaffolds were approximately (qualitatively) uniform in thickness from 
scaffold to scaffold, while the TIPS layer exhibited variability between scaffolds (e.g., different 
thicknesses, densities, etc).  Moreover, some partial or complete delaminations between the two 
layers were observed (Figure 7.10).  These defects were presumably generated by some 
variability in the ES-TIPS fabrication process and not due to the seeding, the dynamic culture of 
the TEVG, or sectioning artifacts.  Significant discrepancies in scaffold quality between what 
was observed during the testing of the S-RVSD (recall Section 3.1.4.5) and the Perfuser (recall 
Section 5.4.1), and the pre-operative results of these in vivo studies were observed.  While it is 
difficult to identify univocally the reasons for these discrepancies, some speculations will be 
provided in Section 7.10.   
 
7.6 CAROTID INTERPOSITION GRAFT PROCEDURE 
Following the consclusion of the seeding and dynamic culture approximately 2 weeks after the 
muscle biopsy procedure, each pig received an autologous TEVG.  Three days prior to the 
implantation, animals started receiving prophylactic platelet aggregation inhibitor therapy 
(clopidogrel, 75 mg by mouth, daily).  Animals were prepared and anesthetized for surgery as 
described in Section 7.2, and then placed in the supine position, and prepped.  A surgical field 
was created in the cervical area.  Bilateral cervical incisions (~ 15 cm) were made with a Bovie 
through the skin and the underlying Platysma.  In one side, a cannulation was performed on the 
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external jugular vein as an intravenous access during surgery.  For each side, the sterno-cleido-
mastoid was dissected and retracted from the underlying trachea and tissues by two Weitlaners.  
The common carotid arteries were exposed and completely dissected from the internal jugular 
veins for a length of approximately 8 cm.  Concurrently, the autologous TEVG was removed 
from the Perfuser and washed in a basin containing ~300 mL of sterile saline supplemented with 
~100 IU mL of heparin to remove culture media residues.   
One carotid (side randomly selected) chosen to receive the TEVG was operated on first, 
while the other exposed carotid was temporarily packed with saline-impregnated gauzes.  After a 
baseline ACT time was acquired, the animal was heparinized with an initial dose of 150 IU/kg, 
and subsequently re-heparinized as needed to maintain an ACT level higher than 2.5-fold the 
baseline level.  The carotid was then clamped with two Cooley’s vascular clamps, and a 2 cm 
portion was excised between the vascular clamps.  The subsequent retraction of the carotids 
created a gap of length ~5 cm due to the residual vascular longitudinal tension.  Vascular spasm 
due to the surgical manipulation was relieved with papaverine solution applied locally, as 
needed.    
The autologous TEVG was then interposed to the carotid gap and sized to a length of 
approximately 4 cm by cutting the ends.  These TEVG rings were fixed in 10% formalin and 
processed to assess pre-implantation histology.  The two ends of the graft and carotid were 
spatulated with Potts scissor to correct any size mismatch due to the onset of vascular spasm.  
The TEVG was then anastomosed in an end-to-end fashion with separate 7.0 Prolene (Ethicon) 
stitches.  Before completing the distal anastomosis and permanently resuming blood flow, the 
graft was carefully de-aired by briefly releasing the proximal vascular clamp.  The TEVG was 
pliable, simple to handle and to suture, and exhibited visible pulsatility under arterial blood flow.  
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In two animals, the graft required removal of small thrombi by internal release of a few boluses 
of heparinized saline with a syringe before completion of the distal anastomosis.  This issue was 
apparently caused by an erratic and unpredictable coagulatory behavior of these two animals, 
leading to sudden drops in ACT level during surgery, and unresponsiveness to additional 
administration of heparin.   
The contralateral side was then operated on in the same fashion, but using as a graft a 2 
cm portion of native carotid (i.e., a portion of carotid was excised and immediately reconnected 
via two end-to-end vascular anastomosis).   
Before closing the surgical access incisions, the surgical field was carefully checked for 
bleeding or oozing and cauterized or treated accordingly.  In some instances the anastomotic 
sites of the grafts were treated with absorbable hemostats (Surgicel, Ethicon) to address minimal 
blood leaking, or additional stitches were made to stop more significant bleeding from the 
anastomosis.  A summary of the surgical vascular procedure is shown in Figure 7.11. 
The Platysma was then closed with 2-0 Vicryl (Ethicon) with full thickness bites in a 
running fashion, while the skin was closed with intradermal running suture using 3-0 Vicryl 
(Ethicon).   
Following the surgical procedure and cessation of inhalation anesthesia, animals were 
extubated after exhibiting swallowing and protective cough reflexes, and kept warm and dry for 
the following post-operative hour to prevent hypothermia.  The animals were then monitored 
hourly for 24 hours.   
Analgesia (buprenorphine hydrochloride, 0.005-0.01 mg/kg, intramuscular, twice a day), 
and antibiotics (cefuroxime, 100 mg/kg, intramusclular, twice a day) were administered at 
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regular intervals for 4 days post-operatively, and were continued as needed if signs of pain or 
infection were noted.  
Anti platelet aggregation therapy (clopidogrel, 75 mg, and aspiring, 325 mg, per mouth, 
once a day) was maintained for the first 4 weeks to ensure proper tissue remodeling and 
endothelialization and to reduce chances of acute graft occlusion.  Aspirin administration was 
continued for the entire survival period.  
 
 
 
 
Figure 7.11  Summary of the carotid interposition graft procedure.  A.  Both carotids are dissected from the 
underlying internal jugular veins and pneumogastric nerves and a 2-cm portion is excised.  B.  The TEVG is 
properly sized to a length of 4 cm and anastomosed with separated stitches.  C.  Appearance of the TEVG after the 
blood flow is resumed.  D.  Appearance of the carotid sham after the blood flow is resumed. 
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7.7 PIG CAROTID-TO-INTERNAL JUGULAR ARTERIOVENOUS GRAFT 
PROCEDURE 
The preparation of the animal and the surgical access for the AVG procedure was identical to 
that described in Section 7.6 for the CIG configuration.  The carotid was dissected from the 
internal jugular vein (IJV).  The TEVG was sized to a length of 4.5 cm and spatulated at its ends.  
After administration of heparin, a 2 cm portion of carotid was isolated by two Cooley’s clamps 
in proximity of the distal end of the dissection from the underlying IJV.  The adventitial layer of 
the carotid was thinned with Potts scissors and access to the lumen of the carotid was gained via 
a short incision made with a #11 scalpel blade through the medial and intimal layers.  The 
incision was enlarged with a clean longitudinal cut by Potts scissors to a length of approximately 
8 mm.  The carotid incision was oriented laterally toward the IJV (i.e., the cut was positioned 45° 
from the anterior wall of the carotid (taken as 0°)).  A four-quarter running suture was performed 
with 7-0 prolene to anastomose the TEVG to the distal portion of the carotid.  After the arterial 
(proximal) anastomosis was performed, vascular clamps were briefly released to check for 
patency and immediately reclamped.  Likewise, an identical anastomosis was performed on the 
proximal portion of the dissected IJV.  The venous (distal) anastomosis was oriented at an angle 
of 225º from the anterior wall of the IJV (Figure 7.12-A). 
An identical procedure was performed contralaterally using a commercially available, 6 
mm-ID PTFE vascular graft (W. L. Gore & Associates, Inc., Flagstaff, AZ) as control (Figure 
7.12-B).  Following the completion of both anastomoses, the grafts were manually felt to check 
for the characteristic vibrations generated by the transitional flow at the venous anastomoses 
[199], demonstrating graft patency and high flow.  This effect is due to the reduced vascular 
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resistance following AVG shunting, which generates a supraphysiologic flow through the AVG 
leading to turbulences perceivable through the wall of the graft.   
 
 
 
 
Figure 7.12  AVG procedure.  A.  Aspect of the TEVG after completion of both anastomoses. B.  Contralateral 
PTFE graft used as control. 
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7.8 PIG CAROTID ARTERY HISTOMORPHOLOGICAL AND PHENOTYPIC 
ANALYSIS  
A qualitative histomorphological and phenotypic study was performed on porcine native 
common carotid arteries.  The purpose of the study was to define positive controls for any of the 
histological and immunohistochemical endpoints originally planned after in vivo remodeling, and 
to define some dimensional landmarks in terms of wall thickness and internal diameter.  This 
was considered paramount to demonstrate univocally the characteristics of the remodeled TEVG 
and, at the same time, to create a basis of comparison between native and tissue engineered 
vessels after remodeling.  
To this end, native porcine carotid arteries, harvested from pigs within the initial pilot 
studies, were processed following standard laboratory protocols for a set of histological staining 
including H&E, Movat’s pentachrome (fibrin and muscle), Masson’s thricrome (collagen), 
Verhoeff’s (elastin), and picrosirius red (collagen organization/maturation and orientation).  The 
results are shown in Figure 7.13. 
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 Figure 7.13  Histological positive control for porcine carotid arteries.  The arrows indicate the lumen of the artery.  
The images were taken at 10X.  Color codes:  H&E: purple = nuclei, pink = tissue; Masson’s: same as H&E and 
blue = collagen; Verhoeff’s: same as H&E and black = elastin; picrosirius: green = immature collagen fibers, yellow 
= partially mature collagen fibers, red = completely mature collagen fibers; Movat’s: black = elastin, red = muscle, 
yellow = collagen, blue = glycosamino-glycans. 
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Additional freshly excised porcine carotid arteries were fixed in 4% paraformaldehyde 
and processed for immunohistochemistry following the protocol previously described in Section 
5.1.2.  Several primary antibodies against smooth muscle and endothelial markers were used.  In 
particular, as smooth muscle markers, α-SMA (1:500) (A5228, Sigma), and h1-calponin (1:400) 
(M3556, Dako) were employed.  As an endothelial marker vWF (AB6994, AbCam) was used.  
Additional antibodies were previously attempted against MHC (1:400) (M3558, Dako), vWF 
(1:200) (A0082, Dako), and CD31 (1:40) (M0823, Dako) without success, so they are not 
reported here.   
The results are shown in Figure 7.14. 
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 Figure 7.14 Immunohistochemistry positive control for porcine carotid arteries.  The arrows indicate the lumen of 
the artery.  In the top and middle panes green = marker, blue = nuclei.  In the bottom panel red = vWF, bleu = 
nuclei.  The inset in the vWF panel shows positivity for vasa-vasorum in a peri-adventitial location of the artery.  
The images were taken at 20X.  The scale bar in the bottom panel applies to all panels. 
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 7.9 PERFORMANCE AFTER IN VIVO REMODELING 
Two animals did not complete the expected survival period.  The first pig (from pG-1) died 
overnight, approximately 12 hours after the TEVG implant surgery.  During necropsy, a very 
large volume of blood clot (~ 400 mL) was found in proximity to the carotid sham and allegedly 
caused a fatal trachea compression leading to asphixia.  The animal was replaced, in order to 
maintain the originally planned number of animals for pG-1.  The second animal (from pG-3) 
died within the first hour post-surgery.  The cause of death is not clear, however, due to some 
coagulatory anomalies recorded during the surgery, it is likely that the animal had a fatal stroke.  
Unfortunately, this animal could not be replaced due to financial constraints and therefore, only 
one animal was used for pG-3.  All the other animals completed the planned survival period 
without relevant issues.        
At the end of the designated survival period, each animal was euthanized.  To this end, 
anesthesia was induced with an intramuscular injection of telazol ketamine xylazine (0.03 
mL/kg).  The animal was then put on a mask infusing 5% isofluorane in 100% oxygen, a catheter 
was inserted into an ear vein, and systemic administration of heparin (30,000 IU) was followed 
by a lethal injection of KCl (120 mL).   
Each animal was then prepared for necropsy.  A circular cervical incision was made to 
remove completely the anterior skin and muscle wall of the neck, for easy access to the grafts.  
For both CIG and AVG configurations, the Sterno-cleido-mastoids were retracted and both 
carotids were exposed 2-5 cm upstream to the original surgical area and ligated with a 2-0 silk.  
 273 
Downstream to the ligation (~ 1 cm) a barbed cannula provided with a unidirectional valve was 
inserted into the lumen of the carotids and held in place by 2-0 silk suture.  The animals 
underwent dynamic angiography (OEC 9800 Plus, GE Healthcare, Piscataway, NJ), while 
contrast media (Renografin-60, Bracco Diagnostics, Princeton, NJ) was contemporaneously 
infused in both carotid arteries.  
According to fluoroscopy findings, the patency rate of the TEVG for all three 
experimental groups was 0%.  The patency rate for the carotid sham control in pG-1 and pG-2 
was 100%, while the only animal from pG-3 had a control PTFE graft patent after one month.  
Figure 7.15 shows a representative fluoroscopy of each experimental group. 
Following the fluoroscopy, the grafts were completely exposed and imaged with a digital 
camera by dissecting the adherent scar tissue resulting from the previous surgical procedure.  All 
the TEVGs were surrounded by a thick collagenous capsule, which created an external layer 
spanning between the anostomoses (Figure 7.16-A/C).  This finding suggests a foreign body 
response generated by the presence of the biomaterial (PEUU).  No signs of infection, abscess, or 
chronic inflammation were noticed in any of the grafts or in the surrounding tissues.  None of the 
TEVGs had any signs of mechanical failure or dilations, suggesting that, while patent, TEVGs 
were structurally stable and, in part therefore, met the design goals for scaffolds described in 
Chapter 4.  The sham carotid controls did not exhibit the same surrounding collagen capsule nor 
any sign of infection or inflammation (Figure 7.16-B/D).  The TEVG and PTFE grafts in the 
only successful animal from pG-3 were hidden by a very thick and rigid capsule which did not 
allow reasonable exposure of the grafts by further dissection; therefore, they were not 
photographed for inclusion in Figure 7.16.  
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 Figure 7.15  Fluoroscopies representing each group in pig studies.  A.  Representative aspect of a fluoroscopy from 
pG-1.  B.  Representative aspect of a fluoroscopy from pG-3.  C.  Fluoroscopy of the only animal from pG-3.  RCC 
= right common carotid artery, LCC = left common carotid artery, LIJV = left internal jugular vein.  None that none 
of the contralateral TEVGs can be visualized 
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 Figure 7.16  Pig necropsy.  A.  Representative aspect of a TEVG from pG-1.  B.  Representative aspect of a carotid 
sham from pG-1.  C.  Representative aspect of a TEVG from pG-2.  D.  Representative aspect of a carotid sham 
from pG-2.  The braces indicate the location and extension of the grafts.  Note the presence of the underlying blue 
stitches used for the anastomosis at the extremities of each graft.  The right side of each picture corresponds to the 
proximal portion of the graft. 
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The grafts were then excised and cut in three equi-sized sections (i.e., proximal, middle, 
and distal) with a razor.  The graft consistency under the razor was firm, supporting the presence 
of ECM within the TEVG lumen in all groups.  The external collagenous capsule was not 
adherent to the external surface of the TEVG in all groups.  After the cuts were made, the 
external capsule retracted consistently in all groups, presubably due to the presence of residual 
stress.  Each segment was then observed on end under a dissecting zoom stereo microscope 
(SMZ660, Nikon Instruments Inc., Melville, NY) and imaged. 
All TEVGs appeared obstructed by a glistening, pinkish matter consistent with intimal 
hyperplasia (Figure 7.17, Figure 7.18, and Figure 7.19). In most of the specimens it was 
possible to detect a small lumen in the center of the TEVG, likely a sign of a progressive 
reduction of internal diameter along with the development of intimal hyperplasia.   
The carotid sham grafts for both time points appeared free of thrombuses or any other 
irregularity.  The lumen seemed glistening and whitish, consistent with the presence of a healthy 
endothelium.  The observed internal diameter of this group was highly variable among animals, 
likely due to the presence of a residual spasm (Figure 7.17 and Figure 7.18).   
The PTFE graft appeared partially occluded by irregularly-shaped, organized thrombi 
adherent on a portion of the lumen.  The remaining luminal area seemed free of major issues 
(Figure 7.19). 
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Figure 7.17  Representative gross pathology images of pG-1. 
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 Figure 7.18  Representative gross pathology images of pG-2. 
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 Figure 7.19 Gross pathology images of pG-3.  Top panels show the macroscopic aspect of the explanted grafts.  
Note that the middle portion of the graft was not imaged.  
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 Following gross pathological analysis, grafts were finally processed for histology.  Due to 
the lack of patency in each of the implanted TEVGs, only the Masson’s thricrome was 
performed; the planned additional endpoints (recall Figure 7.2) were not performed due to the 
graft failure.  
Histological findings of the TEVGs from pG-1 and pG-2 suggest the formation of intimal 
hyperplasia at the two anastomotic levels (Figure 7.20 and Figure 7.21).  This likely led to 
progressive reduction of the graft internal diameter and blood flow, leading to subsequent 
thrombus formation.  The presence of intimal hyperplasia at the anastomotic levels was 
consistent with that found from the initial pilot studies.  At both 1 and 3 months the TIPS layer of 
the TEVGs appeared coarse, swollen, and highly infiltrated with biological matrix, suggesting 
remodeling and scaffold degradation.  However, the ES layer seemed to retain its original density 
and shape.  This effect confirms the role of the ES PEUU in providing mechanical and structural 
integrity as expected (recall Chapter 4). 
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Figure 7.20  Representative Masson’s trichrome images of pG-1.  The arrows indicate the lumen. 
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 Figure 7.21  Representative Masson’s trichrome images of pG-2.  The arrows indicate the lumen. 
 283 
 Figure 7.22  Histology Masson’s trichrome of pG-3.  The arrows indicate the lumen. 
 
 
 
7.10 DISCUSSION AND LIMITATIONS 
This chapter described the in vivo testing of an autologous pig LAC-based TEVG, implanted as a 
CIG or AVG in a paired fashion along with a native carotid artery or a standard PTFE graft, 
respectively.  This study was designed to test a paradigm to provide an autologous small-
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diameter TEVG suitable for implantation within a 15 day time frame from an initial muscle 
biopsy.  The time frame was defined in attempt to compromise the limited resources involved for 
cell isolation and the need for an off-the-shelf approach to meet clinical viability standards.  The 
paradigm developed to accomplish this goal included the use of several technologies developed 
throughout this research effort including the S-RVSD (Chapter 3), the ES-TIPS PEUU scaffold 
(Section 4.2), the Perfuser bioreactor (Section 5.3), and several lessons learned from in vitro 
(Sections 5.1, 5.2, and 5.4) and in vivo (Chapter 6) testing, including the use of murine, rat, and 
porcine cells.  
This study did not produce the expected results in terms of patency rate and remodeling.  
A 0% patency rate recorded for all the TEVGs and the development of high levels of intimal 
hyperplasia clearly suggested the presence of one or more important issues to be addressed.  It is 
difficult to demonstrate the causes for the poor in vivo performance of TEVGs due to the 
complexity of the in vivo remodeling and regeneration mechanisms, and to the lack of a 
mechanistic characterization of the biological processes involved with the TEVG culture and the 
in vivo remodeling.  However, some speculations based on evidence collected during the studies 
presented here suggests that the lack of seeded cells prior to implantation (Figure 7.10) played a 
major role in the graft failure.   
The results from the previous rat in vivo study defined a clear role for the cells 
incorporated into the scaffold in the maintenance of patency.  A similar patency rate was in fact 
obtained for the acellular control grafts implanted in rats.  Furthermore, the pig model is likely to 
be more prone than the rat to intimal hyperplasia and graft failure for genetic reasons.  Results 
obtained with the PTFE graft, which was patent but clearly affected by major thrombus 
formation, is supportive of a high tendency for the development of intimal hyperplasia in pigs.  A 
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number of reports in the literature have shown elevated intimal hyperplasia formation both in 
vein and PTFE arterial grafts in pigs [200, 201].  From this evidence it is inferable that the 
porcine model, although anatomically and genetically similar to humans, might be significantly 
more hyperplastic.  Therefore, some concerns arise when defining the validity of this model as a 
pre-clinical tool for vascular disease.  
The limited amount of cells found in the scaffolds prior to implantation was consistent 
with the low yield of cells after the isolation from the pig striated muscle.  However, some of the 
isolations yielded almost 100% of the expected 30 million cells (Table 7-2), but the associated 
TEVG still exhibited a lower-than-expected cellular density prior to implantation.  Therefore, 
while the cell isolation requires some optimization, in order to increase the cell yield while 
reducing the necessary time frame, it is not proper to identify it as the cause of the lack of 
cellularity prior to implantation.  Other possible causes for the observed lack of cellularity are: 
the seeding process through S-RVSD, the quality of the scaffolds used, or dynamic culture in the 
Perfuser.  It is prudent to rule out the S-RVSD since it has been extensively tested, showing 
consistent and reproducible results.   
The scaffold is instead a possible reason for this failure.  Many of the available ES-TIPS 
scaffolds for the pig studies had to be discarded due to macroscopic issues including 
delaminations between the two layers or poor quality (i.e., cracks, disseminated small holes, or 
suboptimal wall thickness).  Furthermore, the TIPS scaffold was the object of prior intensive 
optimization studies (data not shown) to solve some consistent microscopic issues, which 
resulted in a lack of porosity and transmural penetration of cells during seeding via the RVSD.  
Therefore, it is possible that the batches of scaffold used for the pig study were affected by any 
of the microscopic issues.  
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Finally, the Perfuser seems to be another possible cause for the observed lack of 
cellularity.  The limited characterization of its functioning in combination with a pig LAC-based 
TEVG (Section 5.4) might have caused oversight of some unexpected issues.  The most probable 
of those involves the premature exposure to intraluminal flow.  It is possible in fact, that a 2 hour 
period of static culture was not enough for pig SACs to establish proper adhesion into the 
scaffold pores, resulting in a significant cell loss when experiencing flow.   
This study, although affected by negative in vivo results, served the purpose of 
demonstrating the feasibility of the overall approach proposed here in a pre-clinical setup.  In 
particular, it showed that it was possible to coordinate several professionals spanning from 
biomaterial scientists, vascular surgeons, stem cell scientists, and animal facility and laboratory 
technicians in a synergistic manner, so that the approach proposed here was successfully put into 
practice.  This is probably the single most important accomplishment of this entire dissertation. 
 Furthermore, the 0% infections observed proved that the whole process was performed 
with proper sterile techniques.  Finally, the ES-TIPS scaffold proved to be structurally and 
mechanically suitable to withstand the demanding arterial environment and to exhibit proper 
suture retention properties without exhibiting any mechanical failure.   
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8.0  SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
A multidisciplinary framework for the creation of a stem cell-based tissue-engineered vascular 
graft has been developed and investigated in this study.  Along the way, several technologies 
were developed that may have wider applications.  A summary of the key accomplishments and 
findings as a result of this research project is provided next, followed by a description of the 
advantages and limitations of this study.  Finally, some recommendations for future studies are 
discussed.    
8.1 SUMMARY OF RESULTS 
8.1.1 Summary of Specific Aim 1 
Development and optimization of a seeding device to rapidly and efficiently deliver cells 
uniformly and reproducibly through porous, tubular scaffolds. 
Two generations of a rotational vacuum seeding device were designed, fabricated, and  
qualitatively and quantitatively tested for bulk cell seeding capabilities of porous tubular 
scaffolds.  Both device generations were compact and combined the synergistic action of 
vacuum, rotation, and controlled flow to produce a rapid, efficient, reproducible, and 
quantitatively uniform seeding (i.e., in the longitudinal, circumferential, and radial directions of 
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the scaffold wall).  The shear stresses, generated inside the rotating scaffolds, were analyzed with 
computational and analytical tools.  These results, combined with those of both a metabolic-
based viability assay and an apoptosis assay suggested the absence of injurious conditions for the 
cells during seeding.  The new features implemented in the second generation (i.e., the S-
RVSD), including a controllable local delivery of cells and computer-controlled operations, 
improved upon the first generation by extending the seedable length of the scaffold and 
increasing the precision and the reproducibility of the seeding process by reducing human 
interaction.       
8.1.2 Summary of Specific Aim 2 
Development of a composite scaffold to mimic the mechanical and structural properties of native 
arteries. 
A novel, bi-layered scaffold for vascular tissue engineering (i.e., the ES-TIPS PEUU) 
was fabricated and tested for morphological (i.e., microstructure, porosity, etc.), mechanical (i.e., 
tensile properties, compliance, burst strength, etc.), and biological (i.e., cell seeding via the S-
RVSD developed in Specific Aim 1) properties.  Morphologically, the scaffold was biomimetic 
mimicking the functional tunica media and the fibrous, external ES layer acting as the adventitial 
layer providing mechanical support.  Mechanically, ES-TIPS PEUU scaffolds showed suitable 
mechanical properties for arterial vascular applications, exhibiting appropriate strength, 
compliance, and suture retention properties when compared with native vessels.  Biologically, 
the scaffold was supportive of uniform cell integration with high seeding efficiencies. 
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8.1.3 Summary of Specific Aim 3 
Determination of the ideal acute culture conditions to optimize the construct via cellular 
proliferation, migration, and spreading.  
MDSC-based TEVGs were acutely cultured in dynamic conditions to understand general 
cell-scaffold interactions.  Cells derived from three different species – mice, rats, and pigs – were 
used for this purpose.  In all three studies, cells were seeded into the scaffold via either the 
RVSD or the S-RVSD developed in Specific Aim 1, and cultured within dynamic conditions for 
up to 3 days.  Mouse MDSCs proliferated within the scaffold during dynamic culture, retained 
their stem cell features, and produced collagen when stimulated with ascorbic acid.  Rat cells 
were seeded successfully into the ES-TIPS, developed in Specific Aim 2.  Constructs cultured in 
spinner flasks showed proliferation and spreading, demonstrating readiness for the subsequent rat 
in vivo study of Specific Aim 4. 
A novel perfusion bioreactor (the Perfuser) was developed and tested for the in vitro 
culture of larger scaffold sizes such as those required for the subsequent pre-clinical study in pigs 
of Specific Aim 4.  The device was able to induce physiologically relevant flow rates and shear 
stresses into the scaffolds, as expected.   
Finally, ES-TIPS scaffolds were seeded via the S-RSVD with pig SACs and cultured for 
up to 48 hours in the Perfuser.  After 24 hours, the scaffolds were populated with spread SACs, 
validating the capability of the Perfuser, and demonstrating achievement of the established 
requirements for implantation.    
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8.1.4 Summary of Specific Aim 4 
Assessment of the remodeling, patency, phenotype, and mechanical properties following in vivo 
remodeling. 
The remodeling of a MDSC-based TEVG was tested in vivo in both small (i.e., rats; 
allogeneic cell source; 8 weeks survival), and large (i.e., pigs; autologous cell source; 1 and 3 
months survival) animal models.  The allogeneic-based TEVG approach in rats has been 
investigated and compared to the behavior of acellular scaffolds.  Significant differences in 
patency rates were detected between seeded and acellular constructs, suggesting antithrombotic 
properties of the seeded MDSCs.  The presence of a neo-tissue formation within the TIPS layer 
of the scaffolds, characterized by densely cellular, organized collagen, and positive markers for 
smooth muscle and endothelial cells, demonstrated the remodeling of the TEVG toward an 
artery-like structure.  Seeded cells were engrafted in the remodeled TEVGs after 8 weeks in vivo, 
suggesting a role of MDSCs in the remodeling process toward a functional blood vessel.  The 
study confirmed the promising mechanical characteristics of the ES-TIPS PEUU scaffolds 
developed in Specific Aim 2, by showing absence of mechanical failure after 2 months in vivo. 
Following the promising results obtained in rats, an autologous study involving LAC-
based TEVGs, implanted as a CIG or AVG in a paired fashion in pigs along with a native carotid 
artery or a standard PTFE graft, was performed.  The study was designed to test a framework in 
which the animal received an autologous small-diameter TEVG suitable for implantation within 
a 15 day time frame from an initial muscle biopsy.  This study resulted in a 0% patency rate for 
all the TEVGs, and in the development of high levels of intimal hyperplasia, clearly suggesting 
the presence of one or more important issues to be addressed.  While the cause is yet to be 
demonstrated, it is quite likely that the limited amount of cells found in the scaffolds prior to 
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implantation was the main contributing factor for the poor in vivo performance.  Although 
affected by negative results in a large animal model in vivo, this study served the purpose of 
demonstrating the feasibility of the overall autologous approach.   
8.2 ADVANTAGES OF THE APPROACH 
The inherent advantage of the approach proposed here relies on its initial definition of criteria 
necessary for clinical viability, and on the ad hoc development of a number of innovative 
technologies based upon those criteria.  This advantage can be described by the expression 
“translational research”.  In particular, the basic driving guidelines for this research effort, 
toward the development of a clinically viable TEVG, were: time/cost efficiency, 
reproducibility/seeding efficiency, and autologous cell sourcing.  Each of these basic 
requirements forced the development of several solutions in a “clinically meaningful” way.  For 
example, the time factor and the concept of reproducibility were fundamental specifications in 
the design of the RVSD/S-RVSD, which lead to unique technologies and methodologies 
emphasizing, for the first time, the importance of cell seeding and the quantification of its results.  
Any future “product” in regenerative medicine entailing the combination of cells and scaffolds, 
in fact, will certainly need to comply with those requirements.  The need for an efficient use of 
the available cells, suggested (along with other factors) the need of a new scaffold, able to retain 
almost 100% of the seeded cells immediately after seeding.  From a clinical perspective, the 
number of “wasted” cells might be a viable indicator of the success for a determined approach.  
Finally, the requirement of autologous cell sourcing fostered the creation of a model of 
collaborative effort between surgical facilities, “manufacturing” and testing facilities (i.e., 
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laboratories), and stem cell isolation facilities, which is paramount for the clinical success of any 
stem cell-based tissue-engineered product.   
Two additional advantages of this approach are in its characteristics as a “platform 
technology” and the multidisciplinary nature of the subjects investigated, resulting in the 
development of a plethora of solutions.  Although, the approach presented here was conceived 
and tested for small-diameter vascular applications, it is conceivable to use the same approach 
for a variety of applications requiring tissue-engineered tubular grafts, either using the entire 
paradigm proposed here, or only some parts of it.  
8.3 LIMITATIONS OF THIS APPROACH 
Paradoxically, the general limitation of this approach is also in its translational nature.  
Technology-oriented research, such as the one proposed here, characterized by the development 
of a number of innovative technologies across a wide spectrum of subjects has, unavoidably, the 
downside of possessing many limitations.  First, many of the studies performed here were carried 
out with a phenomenological approach, limited to the description of the methods and results of 
experiments based on reasonable assumptions or a priori decisions, but unable to establish a 
mechanistic, functional model.  Second, the large diversity of studies necessary to develop and 
test a new approach in a preclinical animal model, spanning from device fabrication, biomaterial 
science, molecular biology, and surgical studies, leads to a large number of possible 
complications.  
Specific limitations are now summarized for each specific aim. 
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8.3.1 Limitations of Specific Aim 1 
Due to the development of two generations of a seeding device, in which the second was 
designed to solve most of the limitations of the first generation, Specific Aim 1 suffers the least 
amount of limitations within this framework.  However, one limitation consists in the lack of a 
rigorous sensitivity analysis to determine how the different seeding parameters (i.e., rotational 
velocity, vacuum level, flow rate, etc.) affect the seeding outcome, and an optimization study to 
determine, for a specific scaffold type, which are the best seeding parameters to obtain the most 
efficient seeding.   
8.3.2 Limitations of Specific Aim 2 
The major limitation affecting the ES-TIPS scaffold was the absence of a quality-controlled 
manufacturing process.  This often led to batch-to-batch variability in mechanical and structural 
properties, as well as the presence of defects, such as delaminations between the two layers, tears 
or small holes, skins preventing cell penetrations, etc.   Furthermore, the porous nature of the 
TIPS PEUU, which allows for excellent cell penetration and proliferation, might hamper, to a 
certain extent, processes such as cell spreading and alignment.  
8.3.3 Limitations of Specific Aim 3 
The in vitro studies utilizing rat and pig cells suffered from a lack of a rigorous cell 
characterization.  In fact, while mice MDSCs have been extensively characterized in the 
literature, both rat MDSCs and pig SACs do not have any supportive background available.  
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These circumstances are not ideal since they imply the loss of the reference values that are 
normally used to understand the influence of exogenous factors, such as their incorporation into 
a 3D scaffold or the subsequent dynamic culture in vitro.  The biological characterization of the 
Perfuser was also affected by a very limited availability of porcine cells, which did not allow 
additional studies to corroborate or confute the loss of spreading detected after 48 hours of 
dynamic culture.   
8.3.4 Limitations of Specific Aim 4 
The rat in vivo study was limited by the use of allogeneic cells, which might have resulted in a 
decreased patency rate.  Furthermore, the study failed to demonstrate a fundamental theoretical 
milestone for a tissue-engineered vascular graft, “the constructive remodeling”, which implies 
full degradation of the scaffold material and replacement with mechanically, structurally, and 
functionally sound neo-vessel formation.  Longer time points are therefore necessary to complete 
the degradation of the ES-TIPS in vivo and demonstrate long-term patency.  The pig study was 
affected by major limitations including: poor cell yield from the muscle biopsy isolations, poor 
to null phenotypic and behavioral characterization of the cell population, very slow population 
doubling time, very low transfection efficiency for the LacZ promoter, and the lack of a 
comprehensive characterization of the in vitro culture on pig cells into the Perfuser.  These 
limitations resulted in very low pre-implantation cellularity into the ES-TIPS scaffolds, which 
might have directly caused the poor in vivo performance detected.  Therefore, the cell source 
used, while promising due to supposed heterogeneity of the SACs, might not represent the best 
candidate for our approach.   
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8.4 FUTURE WORK 
Each specific aim of the framework proposed here would benefit from several areas of potential 
future work.  In general, future studies should focus on the troubleshooting of the limitations 
summarized in Section 8.3.   
8.4.1 Future work for Specific Aim 1 
8.4.1.1 Sensitivity and optimization study 
The S-RVSD should be further assessed using a sensitivity study with medical grade scaffolds 
having reproducible permeability and pore size distribution.  This characteristic is critical to test 
how the three main variables of the device (rotational speed, vacuum level, and flow rate) affect 
the seeding outcome eliminating “the noise” introduced by the batch-to-batch variability of the 
scaffolds.  A thorough sensitivity study would allow us to better understand the underlying 
mechanisms of functioning for the device and possibly lead to rationally-guided modifications or 
simplifications.  Once defined, the scaffold of interest and the cell type (depending on each 
specific application) would need to undergo a separate optimization study to understand which 
combination of seeding parameters would lead to an optimal seeding outcome.  The definition of 
an optimal target outcome depends on each specific application and represents the starting point 
of any optimization study.  The problem of the “optimization” is a complex subject involving the 
use of algorithms based on mathematical and stochastic formulations.  These algorithms allow 
one to navigate through the space of the available variables (in this case three) with a relatively 
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small number of attempts (experiments or simulations) in order to identify the location within the 
variables space corresponding to the absolute or relative maximum of the performance indicator.   
8.4.1.2 Design of a disposable cartridge for clinical applications 
An additional effort should be made toward a more clinically-realistic implementation of the S-
RVSD consisting of a disposable component.  While the technology of cell seeding was 
conceived, built, tested, and validated with the multiple prototypes of the RVSD, the 
development of the prototype of a possible clinical “product” was not pursued or implemented, 
despite the patenting of the technology (USPTO Appl. No.: 11/243,818. See Appendix H).  
However, a preliminary conceptual design of a seeding system for possible future clinical use 
was prepared.   
The conceived system consists of two units: 1) a disposable, sterile seeding cartridge 
incorporating within its design most of the key features of the S-RVSD; and 2) a reusable base 
unit device.  This conceptualization follows a very common model for medical devices: the 
razor-razor blade model.  A new cartridge containing a porous scaffold would be inserted into 
the base unit for each seeding and then disposed of, following removal of the seeded construct.     
The perceived disposable cartridge consists of an external, cylindrical clear 
polycarbonate shell with two vented, removable end caps (Figure 8.1).  Each cap has a central, 
circular opening sealed externally with a 0.2 μm PTFE filter, to maintain the internal sterility 
while allowing for gas transfer and pressure equilibration.  The internal side of the cap is 
pressure fit with a plastic contact bearing component, including a short central cylindrical socket 
supported by radially-oriented prongs in contact with the internal side of the cap.  An internal 
rotating body is fit between the two cap contact bearings.  When the cartridge is closed, it is free 
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to rotate around its longitudinal axis (Figure 8.2).  The internal rotor is a single plastic 
component, obtained by injection molding techniques and consists of two aligned tees, connected 
by a three-arm torque transmission.  The hollow space within each of the two tees has a thin, 
medical grade polyurethane tubular sac, having a diameter equal to the internal diameter of the 
scaffold (Figure 8.1).   
 
 
 
 
Figure 8.1  Schematic of the disposable cartridge for the perceived S-RVSD modified for clinical use. 
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 Figure 8.2  Schematic of the internal bearing of the perceived S-RVSD cartridge. 
 
 
 
The open sides of the two sacs are sealed to the internal edge of the opening of the tees, 
while the opposite ends of the sacs are initially placed inside the tees at the periphery of the 
rotating body.  Each tee has a small rubber port able to be punctured by a syringe needle.  One 
side of the rotating body has a magnetic plate embedded within it, which transfers the torque to 
the rotating body from a rotating magnetic stage placed in the base unit. 
The base unit is an electronically-controlled system, incorporating a vacuum regulator 
system, a DC motor, a power supply, and a socket for the seeding cartridge, enclosed in an 
illuminated air-tight compartment.  The device receives vacuum from an external source, such as 
a hospital line, and automatically regulates the vacuum levels to the desired value inside the 
cartridge socket upon receiving the seeding signal.  The internal electrical motor rotates a 
 299 
magnetic stage, in proximity of the cartridge magnetic plate, to transfer the rotational motion to 
the internal rotating body of the cartridge. 
Prior to seeding, a porous tubular scaffold is mounted on the two tees by opening one cap 
of the cartridge and removing the rotating body. The scaffold is attached to the rotating body tees 
by a custom-designed sealing ring device.  The inflatable seal consists of a cylindrical plastic 
case and an internal inflatable, toroidally-shaped polyurethane bag.  A small rubber valve is 
attached to the toroidal bag and is exposed externally to the casing by a small aperture in the 
plastic (Figure 8.3).  Once one end of the scaffold is inserted onto one tee, the sealing ring 
device is overlapped with the scaffold and inflated by puncturing the rubber valve with an air-
filled syringe until a firm compression of the scaffold on the tee is obtained.  The rotor with the 
attached scaffold is then primed with a cell suspension via the priming port and reintroduced in 
the cartridge.  The cartridge is then inserted in the dedicated base unit socket and the seeding is 
initiated.   
During seeding, the base unit applies an external vacuum to the cartridge while putting its 
internal body in rotation.  The vacuum is transferred to the interior of the cartridge via the PTFE 
filters and initiates a transmural flow of seeding suspension, similar to that seen in the RVSD.  
While exuding through the scaffold wall, the cell suspension causes a progressive inward 
collapse of the internal polyurethane bags from the rotating central body toward the center of the 
scaffold, mimicking the function of the Diffuser in the S-RVSD.  During the exudation of the 
liquid phase of the cell suspension through the scaffold, the two collapsible bags retract into the 
scaffold until they touch each other in the center, completing the seeding procedure.   
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At the end of the process, the disposable cartridge is removed from the base unit, the 
scaffold is retrieved by unscrewing the cartridge cap and deflating the inflatable ring devices, 
and the cartridge is discarded.   
 
 
 
 
Figure 8.3  Schematic of the inflatable ring device within the cartridge of the perceived S-RVSD modified for 
clinical use. 
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8.4.2 Future work for Specific Aim 2 
The ES-TIPS PEUU scaffold should be further characterized by a predictive analytical model.  A 
constitutive structural and mechanical model of the composite scaffold could be obtained by 
coupling the properties of its two distinct layers via a parametric model of which parameters 
would be estimated through empirical data.  It would also be important to perform oxygen 
diffusivity experiments to define the influence of the scaffold thickness on the cell viability 
within the scaffold to identify a rational compromise between nutrient diffusivity and mechanical 
properties.  
  Moreover, the bi-layered scaffold should be better characterized for its biodegradation 
properties with standard in vitro and in vivo degradation assays, and this should be optimized for 
the specific application in which it would be used. 
Basic thrombogenicity assays should be performed in vitro to evaluate the inherent 
tendency of the scaffold (with and without seeded cells) to cause clot formation.  Perfusion with 
animal whole blood and quantification of platelets adherence would be a cost-effective way to 
quantify thrombogenicity.  A possible improvement to reduce thrombogenicity could be the 
surface modification of the luminal layer in order to inhibit platelet adhesion with biomimetic 
molecules such as phospholipidic substrates, or heparin binding domains.   
8.4.3 Future work for Specific Aim 3 
A complete species-specific phenotypic characterization of MDSCs used for future in vitro or in 
vivo experiments is paramount to univocally identify the cell population used, to demonstrate the 
reproducibility of the isolation technique, and to define phenotypic landmarks to show the effects 
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of different culture conditions or the course of the remodeling in vivo.  A possible solution to this 
end could entail the utilization of mRNA microarrays and proteomics microarrays to identify 
patterns of phenotypic (transcriptional and traslational) expression from isolations obtained from 
a large number of animals (i.e., rats or pigs) with exact same isolation protocols and baseline 
conditions.  This would allow to point out a number of surface markers that can be used to sort 
cell populations via flow cytometry hence reducing the isolation time (without the need for the 
preplating technique), and increasing the reproducibility of the cell population.  
 An alternative to the use of adult stem cells derived from the striated muscle would be the 
adoption of bone marrow- or adipose-derived progenitor cells.  For example, mesenchymal stem 
cells obtained from these two tissue sources would be valid candidates for tissue engineering 
applications due to their multipotentiality, self-renewal capabilitites (recall Section 1.5.2), and 
accessibility.  The relatively low invasiveness of the procedures required to harvest bone marrow 
(e.g.,. iliac crest aspiration), or fat (e.g., liposuction), and the relatively loose consistency of both 
tissues, which eliminates or reduce the need for enzymatic digestions, are important indicators of 
their potentially successful use for TEVG applications.  
 Furthermore, it is recommendable the utilization of human stem cells to provide a further 
step toward clinical feasibility which require functional characterization of human cells behavior 
in vitro and in vivo (e.g., implantation into immune-tolerant or immune-suppressed animals).  In 
fact, our laboratory has already begun initial investigations toward this end [202].   
 The Perfuser would require a more rigorous biological characterization to demonstrate its 
full potentiality as a bioreactor for tissue-engineered tubular constructs.  In particular, its 
capability to foster cell growth within the engineered tubular construct along the longitudinal 
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direction of the scaffold, and the possibility of stimulating luminally seeded cells via shear 
stress-mediated mechanotrasduction should be demonstrated. 
8.4.4 Future work for Specific Aim 4 
8.4.4.1 General considerations 
Future animal studies (regarless of the animal model used) should be aimed at demonstrating 
constructive remodeling (see Section 8.3.4).  Therefore, longer time points should be tested to 
allow complete degradation of the scaffolds.  Ideally, medical imaging techniques (e.g., 
ultrasound-based imaging) would be used to track patency and the degradation of the scaffold 
over the duration of the study. 
  A quality control study should be directed toward the achievement of high levels of cell 
density into the ES-TIPS PEUU scaffolds prior to implantation in an autologous animal model.   
The aim of this study would be to substantiate or confute the speculative conclusions made in 
this work (see Section 7.10) based on the inconsistent results obtained in the pig study.  It is 
likely, in fact, that the lack of patency in those grafts was caused mainly by the quasi-acellular 
characteristic of the implanted TEVG.  Additionally, a more clinically-relevant control should be 
used for the carotid interposition graft, such as the IJV as an arterial vein graft.  Arterial vein 
grafts, in fact, are still the gold standard for revascularization in CABG and peripheral bypass 
surgeries [203, 204]. 
Upon remodeling, a number of functional characterizations should be performed to 
demonstrate the functionality of the remodeled TEVGs for both vascular lineages.  Endothelial 
function can be tested with specific assays such as the uptake of acetylated low-density 
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lipoprotein, or antithrombogenicity assays such as platelet adhesion quantification or indirectly 
via immunohistochemistry, by detecting specific markers including CD31 and e-NOS.  Both 
endothelial and smooth muscle function can be tested with a vasoactivity assay.  The TEVG 
response to endothelial-independent vasoconstrictors (e.g., epinephrine, etc.), and endothelial-
dependant vasodilators (e.g., sodium nitroprusside, etc.) would represent an excellent indicator of 
the capacity of the TEVG to respond to environmental stimuli [205].     
8.4.4.2 Autologous bone marrow to enable full off-the-shelf use of a TEVG 
Finally, an autologous in vivo approach involving an alternative cell source should be considered 
to allow for an effective off-the-shelf approach and to avoid the hurdles and time constraints of 
an inefficient stem cell isolation technique.  Based upon the approach of Shin’oka et al.[38], 
consisting of the use of autologous bone marrow-derived mononuclear cells, manually seeded 
onto porous scaffolds, a large animal pilot study was performed in dogs to investigate this 
possible cell source within our framework.  Conceptually, the patient needing a TEVG would 
receive a bone marrow aspiration in the morning under local anesthesia (Figure 8.4-A), a simple 
Ficoll gradient would be performed to isolate the mononuclear fraction of the bone marrow by 
centrifugation [206] (Figure 8.4-B) within a 1-2 hour time frame.  The cells would then be 
seeded intra-operatively via the disposable implementation of the S-RVSD described in Section 
8.4.1.2 (Figure 8.4-C) and, shortly thereafter, the seeded scaffold would be implanted into the 
patient.  
This proposed approach appears ideal for three basic reasons.  First, the patient would be 
able to receive an autologous blood vessel completely off-the-shelf, requiring only a same-day 
non-invasive bone marrow isolation, while the disposable seeding cartridge would be available at 
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any time with an extended shelf life.  Second, bone marrow cells have been extensively 
investigated and characterized in a number of cell therapy studies [207, 208] and, due to their 
heterogeneity and/or plasticity, have resulted in a number of successes in terms of re-
establishment of in vivo functionality for several clinical applications [209].  Third, from a 
regulatory standpoint, the intraoperative use and handling of cells would be subjected to a lesser 
burden of requirements since it would be likely perceived as a minimal manipulation procedure 
according to FDA standards (i.e., autograft instead of a processed (cultured), autologous cell 
source) and, therefore, it might result in a more tractable regulatory approval pathway.              
 
 
 
 
Figure 8.4  Sequence showing the main steps of the study design proposed as a future study.  A.  Aspiration of the 
bone marrow.  B.  Cytospin of the mononuclear fraction of the bone marrow.  C.  Seeded bone marrow in the large 
scaffold described in Figure 2.29.         
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APPENDIX A 
APPENDIX A:  MECHANICAL DRAWINGS 
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 Figure A.1  Mechanical drawing of a truncated cone-shaped tip designed to adapt the RVSD to a 17 mm of ID 
scaffold (see Section 2.2.6.1).    
 
 308 
 Figure A.2  RVSD chamber. 
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 Figure A.3  Lid for the RVSD chamber. 
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 Figure A.4  RVSD Base 
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 Figure A.5  Design of both the Driving and the Driven Tees for the RVSD. 
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 Figure A.6  Head for the RVSD torque transmission. 
 313 
 Figure A.7  Stem for the RVSD torque transmission. 
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 Figure A.8  Joint support for the RVSD. 
 315 
 Figure A.9  Cap for the rotating joint support for the RVSD.  
 316 
 Figure A.10  Stylet holder for the S-RVSD. 
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 Figure A.11  Motor 2 base support for the S-RVSD. 
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 Figure A.12  Motor 2 stand support for the S-RVSD. 
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 Figure A.13  Motor 1 base support for the S-RVSD. 
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 Figure A.14  Motor 1 stand support for the S-RVSD. 
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 Figure A.15  Diffuser for the S-RVSD. 
 322 
 Figure A.16  Base for Driving Tee rotating joint support for the S-RVSD. 
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 Figure A.17  Support for Driving Tee rotating joint for the S-RVSD. 
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 Figure A.18  Feet for Driven Tee rotating joint support for the S-RVSD. 
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 Figure A.19  Support for Driven Tee rotating joint for the S-RVSD. 
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 Figure A.20  Cap for rotating joints supports for the S-RVSD. 
 327 
 Figure A.21  Driven Tee for the S-RVSD. 
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 Figure A.22  Tee adaptor for the Driven Tee of the S-RVSD. 
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 Figure A.23  Driving Tee for the S-RVSD. 
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 Figure A.24  Cuff for Perfuser. 
 331 
 Figure A.25  Arm for Perfuser. 
 332 
 Figure A.26  Plug for the Perfuser. 
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APPENDIX B 
APPENDIX B:  ΔP DUE TO THE CENTRIFUGAL ACCELERATION 
These calculations are in support of the material presented in Section 2.2.6.1.  
Area of a circular sector shown in Figure B. 1: 
 
 
Mass of the circular sector: 
 
 
Centrifugal acceleration:   
 
 
Centrifugal force acting on the center of inertia of a sector of angle θ:   
 
 
Pressure variation due to centrifugal forces: 
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Figure B. 1  Schematic showing the terminology used in the calculations. 
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APPENDIX C 
APPENDIX C:  RELATIONSHIP BETWEEN ROTATIONAL AND TRANSLATIONAL 
VELOCITIES IN THE S-RVSD 
These calculations are in support of the material presented in Section 3.1.3.2.  
Number of nozzles in the Diffuser = 8 
Angular velocity of the scaffold [rpm] = ωScaffold  
Period of revolution [sec] = TScaffold = 60 / ωScaffold  
Time required to rotated the scaffold of 1/8 of a revolution = tarc = 1/8 TScaffold = 7.5 / ωScaffold    
Diameter of a nozzle of the Diffuser = 0.62 mm 
Translational velocity of the Diffuser (vDiffuser) = Translational velocity of the nozzle (vNozzle) 
Time required to move the Diffuser of a length equal to its nozzle diameter = tNozzle = 0.62 / 
vDiffuser 
Relationship to satisfy:  tarc ≤ tNozzle 
Substituting: 7.5 / ωScaffold ≤  0.62 / vDiffuser  
Therefore:  ωScaffold [rpm] ≥ 12 vDiffuser [mm/sec] 
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APPENDIX D 
APPENDIX D:  ESTIMATION OF THE SHEAR STRESS WITHIN THE STYLET 
These calculations are in support of the material presented in Section 3.1.5.  
The shear stress inside the lumen of the Stylet was estimated using Equation 2-6 (cross-ref) 
valid for steady laminar flows in a rigid cylinder (Poiseuille equation assumptions) substituting 
the values of dynamic viscosity of the cell culture media (1.03 cP) and the radius of the internal 
channel of the Stylet (0.45 mm) for a range of flow rates (1-10 mL/min).   
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 Figure D. 1  Estimation of the shear stress in the Stulet for different flow rates. 
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APPENDIX E 
APPENDIX E:  IN VITRO ASSESSMENT OF A ES PEUU SCAFFOLD SURFACE-
SEEDED WITH MDSCS AND SUBJECTED TO SHEAR STRESS 
This preliminary study investigated the response to shear stress of MDSCs surface-seeded onto 
the lumen of ES PEUU scaffolds in support of the material presented in Section 4.1.2.  To this 
end, a simple perfusion bioreactor allowing for independent control of pressure and flow was 
fabricated.  Briefly, a perfusion chamber was machined from a cast acrylic block (external 
dimensions: 25x25x7 cm) to perfuse up to 6 tubular conduits simultaneously in a sterile 
environment (Figure E. 1).  The system holds internally 6 pairs of stainless steel tees in a 
parallel fashion, which constitute the perfusate circuit.  The tees are immersed in a bath of media 
internally to the chamber.  The compact chamber can be kept in standard incubators during 
culture to maintain a physiologic temperature and pH in the culture media.  Both perfusate and 
bath circuits are fed by a roller pump (Masterflex) provided with two pump heads (Masterflex, 
Cole-Palmer, Vernon Hills, IL) connected to the same shaft (one pump for each circuit) to 
provide accurate control of the flow.  A common reservoir feeds both circuits and is vented by a 
0.2 micron PTFE filter to allow for gas exchange within the incubator, and to prevent 
contaminations.  Gas permeable silicone tubing (Masterflex) was used to allow for additional gas 
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exchange into the incubator.  Additionally, the perfusate circuit was provided with a pulse 
dampener (placed immediately after the pump head) to eliminate the inherent high frequency 
pulsatility of the roller pump, a flow resistor (placed immediately after the perfusion chamber) to 
control the pressure inside the perfused conduits, a pressure transducers and a flow probe to 
control the pressure and flow rate, respectively.    
 
 
 
 
Figure E. 1  Perfusion bioreactor system.  A.  Perfusion setup into a standard incubator.  B.  Flow/pressure control 
consoles. 
 
 
 
ES PEUU scaffolds (recall Section 4.1.2) (length: 10 mm, ID: 4.7 mm, thickness: 150-
200 μm, porosity: 80-95%, pore diameter: 5-20 μm) were surface-seeded with 20x106 mouse 
MDSCs via the RVSD using the same protocol described in Section 2.2.4.  Immediately after 
seeding, the constructs were cultured in Petri dishes for 24 hours.  Constructs were then mounted 
in the flow bioreactor and subjected to ~1 dynes/cm2 shear stress under steady flow (100 
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mL/min) for another 24 hours, while a control group was maintained in static conditions. Cell 
viability was assessed with MTT assay, while cell morphology, distribution, and alignment were 
assessed using nuclear (DAPI, Draq5) and cytoskeletal (rhodamine phalloidin) staining with 
fluorescence microscopy.   
Immediately after seeding, a high number of cells adhered on the luminal surface of the 
scaffolds. The distribution appeared (qualitatively) uniform along the length and the 
circumference of the constructs.  After the first 12 hours of static culture, the scaffolds appeared 
lined with attached cells that started to spread on the luminal surface surface (Figure E. 2).   
 
 
 
 
Figure E. 2  Representative results after 12 hours of static culture. Green = F-actin, blue = nuclei, red = ES scaffold. 
The arrow indicate the lumen of the scaffold. 
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 After 24 hours the cell appeared completely spread on the luminal surface providing an 
endothelium-like layer (Figure E. 3-A).  Samples cultured for 48 hours in static conditions 
exhibited a significant increase in cell number compared to the first 24 hours (n = 3, p < 0.01) 
(Figure E. 4).  The luminal surface appeared covered with a confluent layer of cells (Figure E. 
3-B).  The constructs exposed to low shear stress had a significant decrease in cell number 
compared with both the 24 and 48 hours static culture groups (n = 3, p < 0.01) (Figure E. 4).  
The luminal surface presented several clusters of randomly aligned cells (Figure E. 3-C).  
 
 
 
 
Figure E. 3  Representative results for the three different culture conditions.  A.  Static culture for 24 hours. Green = 
F-actin, blue = nuclei.  B. Static culture for 48 hours.  Red = F-actin, blue = nuclei.  C.  Exposure to shear stress for 
24 hours.  Green = F-actin, blue = nuclei.  
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 Figure E. 4  Quantification of cell proliferation. 
 
 
 
In this preliminary study it was shown that MDSCs can be successfully seeded via the 
RVSD and statically cultured on the surface of an ES PEUU tubular scaffold to create a 
confluent endothelium.  However, exposure to minimal levels of shear stress (1 dynes/cm2) after 
only 24 hours of static culture from seeding was not well tolerated, leading to cluster formation, 
and cell loss.   
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APPENDIX F 
APPENDIX F:  PARALLAX ERROR 
The calculations presented in this section are in support of the material presented in Section 
5.3.3.  
A parallax analysis was performed to correct the error introduced by measuring the 
distance between 2 points (i.e., a random curl in the dye flow and the edge of the Perfuser plug 
for a defined frame (recall Figure 5.15)) in a 3D space by its projection on a 2D image.  This 
method would be fully correct if the distance measured would lay on a plane parallel to the 
observer’s plane; however, in our case the projection required a correction since the measured 
distance was lying on an oblique plane that was rotating with respect to the obsterver’s plane.   
  Analyzing the plug of the Perfuser rotating clockwise toward the camera (Figure F. 1), 
is possible to identify, in a convenient way, three parameters: the inlet area of the Perfuser plug 
(magenta circle in Figure F. 1), the vector of the relative velocity between the dye and the plug 
(blue line in Figure F. 1), and the measured distance between a random point outside the Perfuser 
plug (i.e., an arbitrary curl in the dye) and the right edge of the Perfuser plug inlet (green line in 
Figure F. 1).  The movement of these three parameters is completely defined in the space since 
the geometric and kinematic values are known.  
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Figure F. 1  Schematic of the parallax calculations. 
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By some trigonometric calculations was possible to measure the projection of each of 
these parameters on the observer’s plane (i.e., the camera; Figure F. 1), and therefore establish a 
corrective factor to apply to the measured values from the images (i.e., observer’s plane) to 
retrieve the original values in the 3D space. 
In particular the projections of the area and the velocity vector were simply obtained by 
multiplying the actual area by the cosine and the sine of the relative angle (α) between the 
observer’s plane and the plug’s inlet plane, respectively.  The projection of the distance was 
instead, a little more complicated.  To solve this, the projection of the distance (L’) was 
decomposed in two components and calculated as a function of α as shown in Figure F. 2.   
 
 
 
 
Figure F. 2  Schematic showing the calculation of the parallax. The plain green line indicate the real distance to 
measure (L), while the dashed green line represents the measure obtained via machine vision (L’).  The red line 
represents the horizontal diameter of the Perfuser inlet area.  The blue line indicates the velocity vector of the dye. 
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A summary of the corrective factors is shown in Figure F. 3. 
 
 
 
 
Figure F. 3  Parallax corrective factors.  For simplicity, each parameter has been considered having a unitary 
measure in the 3D space. 
 
 
 
Once the relationship between corrective factor and relative angle was obtained, the 
current angle was calculated by the simply dividing the measured distance (i.e., the projected 
distance, L’) by its relative correction factor to retrieve the real distance value (L).  
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APPENDIX G 
APPENDIX G:  PILOT STUDY FOR AUTOLOGOUS LARGE ANIMAL MODEL  
The large animal model study described in Chapter 7 was preceded by a pilot study (using the 
same animal model and endpoints described in Section 7.1) to test the feasibility of the proposed 
approach, and to troubleshoot a number of potential issues.  This pilot study was characterized 
by the same basic protocols as the official study but resulted in the variation of several 
parameters to address a number of issues encountered during the course of the study.  
Furthermore, the pilot study did not entail the use of the Perfuser bioreactor (recall Section 5.3), 
which was replaced by a simple culture in spinner flask, as described for the small animal study 
in Chapter 6.  
A total of 9 animals (n = 7 females and n = 2 males) were used for the three experimental 
groups described in Section 7.1.  In particular n = 6 animals were used to test the experimental 
group pG-1, n = 2 animals were used for pG-2, and one animal was used for pG-3.  All animal 
from the first two groups received a contralateral carotid sham interposition, while the two 
animals from pG-3 did not have any paired control. 
Table G-1 summarizes the animal belonging to each experimental group and the number 
of available cells after the 2 weeks period for cell isolation and expansion. 
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Table G-1  Summary of the seeding procedures in the pilot study.  The star indicates an animal that died days after 
the muscle biopsy procedure for unrelated causes. 
 
Pig ID Experimental Group Seeding Date Available Cell Number (x106)
P120-07 pG-1 05/02/07 6.6
P121-07 pG-1 05/02/07 4.65
P314-07 pG-2 10/08/07 90
P315-07 pG-1 10/09/07 44
P316-07 pG-3 10/14/07 16
P317-07 pG-1 10/14/07 28.5
P389-07 pG-1 12/11/07 30
P390-07* pG-1 n/a 25
P391-07 pG-3 12/13/07 27.25  
 
 
 
The first two animals of these studies (P120-07 and P121-07) served the important 
purpose of troubleshooting two main issues: the protocol for autologous cell isolations, and the 
scaffold characteristics (i.e., ID, and thickness).  These studies were originally conceived using 
only the PP6 fraction (MDSCs).  However, the low cell yield (6.6x106 and 4.7x106 cells, 
respectively) obtained after a two week period appeared immediately not adequate to match the 
expected 30x106 cells.  Therefore, at this point a decision was made to create a pooled population 
of cells as explained in Section 7.3.1 for the future isolations.   
Furthermore, the initial scaffold conceived for the large animal study was an ES-TIPS 
scaffold with an ID of 6.3 mm and a thickness of the ES layer of ~ 100 µm.  These geometrical 
characteristics resulted in two issues once implanted in vivo: a size mismatch, and some 
mechanical inadequacies, which led to TEVG dilation after in vivo remodeling.  Therefore, based 
on the actual size of the pig carotid arteries harvested, it was decided to reduce the ID of the ES-
TIPS scaffold to 4.7 mm.  This required a modification of the molds used for the TIPS layer 
(recall Figure 4.1), as well as a reduction in size for the Diffuser and the tees of the S-RVSD 
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(recall Figure 3.4).  Moreover, the external ES layer thickness was increased to 250 µm by 
extending the ES time to 1 hour.   
Both animals had very similar overall results.  In particular, after seeding and dynamic 
culture in spinner flask both scaffolds exhibited a low number of cells (Figure G. 1-A).  Upon 
implantation it was noticeable a significant mismatch in size between the IDs of the TEVG and 
the native carotid (Figure G. 1-B).  After 1 month in vivo, a thick capsule formation surrounded 
the TEVG, which appeared dilated (Figure G. 1-C).  No signs of acute inflammatory response or 
infections were detected.  Fluoroscopy showed patency in both constructs with some stenosis at 
both anastomoses (more pronounced in the proximal anastomosis), and confirmed the scaffold 
dilation (Figure G. 1-D).  Gross pathology showed a clear intimal hyperplasia formation, 
significantly more pronounced at the anastomosis levels, confirming the fluoroscopy findings 
(Figure G. 1-E).  One animal had a pseudo-aneurysm which caused some blood infiltration in 
the central portion of the scaffold between the TIPS layer and the neointimal tissue formation 
leading to formation of an intramural thrombus.  In some area of the remodeled scaffold was 
visible delamination between the two scaffold layers (Figure G. 1-D).   
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 Figure G. 1  Representative results of the first two pigs of the pig pilot study.  A.  Pre-implantation histology.  B.  
Surgical view immediately after completion of both anastomoses.  C.  Surgical view during necropsy.  D.  
Fluoroscopy.  E.  Gross pathology findings at the proximal anastomosis level.  F.  Gross pathology finding in the 
central region of the scaffold. 
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Histological analysis confirmed the formation of intimal hyperplasia, which was more 
pronounced at the anastomotic levels (Figure G. 2-A) than in the central portion of the scaffolds 
(Figure G. 2-B).  The neo-tissue formation was characterized by the presence of a highly 
cellularized, organized collagenous layer, highly cellularized.  The ES-TIPS PEUU scaffolds 
appeared significantly degraded and/or remodeled, and presented some delaminations between 
the two layers, confirming the findings of the gross pathological assessment.  SEM of the 
luminal of the TEVG demonstrated the presence of a significant restriction when transitioning 
between the native carotid and the TEVG (Figure G. 2-C).  The TEVGs had a confluent layer of 
endothelial-like cells more pronounced at the peri-anastomotic levels (Figure G. 2-D) than in the 
central portion of the TEVG, in which the cell coverage was present, but with a lower density  
(Figure G. 2-E).  Finally, the TEVG and portions of native porcine carotid were mechanically 
tested for uniaxial tensile properties via the ring test (recall Section 4.2.5.2).  The results 
confirmed the elevated scaffold degradation detected histologically by showing macroscopical 
difference in strength between the native vessels and the TEVGs (Figure G. 2-F). 
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 Figure G. 2  Representative results of the first two pigs of the pig pilot study.  A.  Masson’s trichrome of the peri-
anastomotic site.  B.  Masson’s trichrome of the central site of the TEVG.  C.  Low magnification SEM focusing at 
the proximal anastomosis level.  D.  Higher magnification of the SEM at the anastomotic levels.  E.  Higher 
magnification of the SEM in the central portions of the TEVG.  F.  Uniaxial ring test. 
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All the remaining animals were implanted with the ID-4.7 ES-TIPS PEUU fabricated as 
described in Section 4.2, seeded with autologous SACs (see Section 7.3) previously transfected 
with the LacZ promoter as described in Section 5.2.2.  
One of the following 4 pG-1 animals was euthanized a few days after muscle biopsy 
procedure for causes unrelated to this study (i.e., suspected vertebral dislocation while moving in 
the cage).  The remaining 3 pigs completed the 1 month survival period without complications.  
The patency rate of this group of animals was 67% (2/3).  The results of the two patent vessels 
were similar to each other.  In particular, the pre-implantation histology was consistently better 
than the first two animals but still not dense as expected (Figure G. 3-A).  The new diameter 
appeared to have a good size matching with the native carotid (Figure G. 3-B).  After one month 
in vivo the patent constructs were not surrounded by the same a thick collagenous layer seen with 
the first two animals (Figure G. 3-C).  No signs of acute inflammatory response or infections 
were detected.  Fluoroscopy showed no signs dilations and the presence of stenosis at 
anastomotic sites (Figure G. 3-D).  The scaffold had a glistening, whitish neo-intimal formation, 
and some stenosis at the anastomoses; the scaffold appeared delaminated in some areas (Figure 
G. 3-E/F). 
Masson’s trichrome confirmed the presence of a thick neo-intimal tissue with variable 
thicknesses and the delamination of the scaffold.  The TIPS layer appeared well remodeled with 
the presence of collagen, while the ES layer did not show sign of biological infiltration or 
significant remodeling Figure G. 4-A/B.  The lumen of the scaffold was lined with a confluent 
layer of endothelial-like cells at the proximal a distal portions Figure G. 4-C, while the central 
portion of the TEVG was still covered with cells but not at the same level of confluency Figure 
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G. 4-D.  The obstructed TEVG was characterized by the presence of an organized thrombus 
developed throughout the entire length of the TEVG Figure G. 4-E/F. 
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Figure G. 3  Representative results of the 67% patent constructs of pG-1 following the initial two animals 
experiments.  A.  Pre-implantation histology.  B.  Surgical view immediately after completion of both anastomoses.  
C.  Surgical view during necropsy.  D.  Fluoroscopy.  E.  Gross pathology findings at the proximal anastomosis 
level of the patent constructs.  F.  Gross pathology finding in the central region of a patent TEVG. 
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 Figure G. 4  Representative results of the additional three pigs from pG-1.  A.  Masson’s trichrome of the peri-
anastomotic site.  B.  Masson’s trichrome of the central site of the TEVG.  C.  SEM at the proximal anastomosis.  D.  
SEM in the central portion of the TEVG.  E.  The obstructed TEVG had an organized thrombus throughout its entire 
length.  F.  Masson’s trichrome of the obstructed TEVG. 
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The only TEVG implanted for three months had an acceptable pre-implantation cellularity 
Figure G. 5-A, during necropsy the TEVG showed encapsulation with native tissue (Figure G. 
5-B), and did not show any sign of dilation or infection.  The TEVG was obstructed by intimal 
hyperplasia/organized thrombus formation as seen in Figure G. 5-C.  Masson’s trichrome 
showed the presence of a remodeled TIPS layer surrounded by a thick ES layer poorply 
infiltrated with biological matrix (Figure G. 5-D).    
After 1 month in vivo the pig was sedated with acepromazine, 0.15 mg/kg, and ketamine, 
15.0 mg/kg (both intramuscular) and echo-color Doppler was performed to assess patency.  The 
TEVG appeared completely patent at 1 month (Figure G. 6). 
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 Figure G. 5  Results for the pG-2 pig.  A.  Pre-implantation histology.  B.  Surgical view during necropsy.  C.  
Gross pathology.  D.  Masson’s trichrome. 
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 Figure G. 6  Echo-Doppler performed after one month on the pG-2 pig.  The complete patency of the TEVG (red 
signal) is clearly detectable.  The blue signal represents the IJV. 
 
 
 
The two pG-3 animals showed the most promising results among all the pigs performed.  
In particular, immediately after necrospsy it was found that both AVG grafts were encapsulated 
with a thick collagenous sheath, suggesting scaffold dilation (Figure G. 7-B).  Fluoroscopy 
revealed that both scaffolds were patent with some stenosis at the distal (venous) anastomosis. 
Moreover, both scaffolds did not show any sign of dilations in contradiction with the external 
appearance of the TEVGs during necropsy (Figure G. 7-C).  While examining the remodeled 
TEVGs for gross pathology analysis, a hematoma was found enclosed between the scaffold and 
the external capsule surrounding both scaffolds (Figure G. 7-D/E).  The scaffold showed a 
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lumen with the usual luminal neo-tissue formation (Figure G. 7-F), with a more pronounced 
thickness in proximity to the anastomoses, as seen for the other groups.  
Histological assessment (Masson’s trichome) showed a substantially remodeled TEVG 
throughout the entire length of the TEVG (Figure G. 8).  Immunohistochemical assessment 
demonstrated the presence of smooth muscle and endothelial markers co-localized with LacZ+ 
cells suggesting a role of the seeded SACs in the remodeling toward an arterial like tissue  
(Figure G. 9).  
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Figure G. 7  Representative results for both patent constructs of pG-3.  A.  Pre-implantation histology.  B.  Surgical 
view immediately after completion of both anastomoses.  C.  Surgical view during necropsy.  D.  Fluoroscopy.  E.  
Gross pathology findings at the proximal anastomosis level of the patent constructs.  F.  Gross pathology finding in 
the central region of a patent TEVG. 
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 Figure G. 8  Representative Masson’s trichrome images of pG-3.  A. Proximal location (arterial).  B.  
Central location.  C. Distal location (venous).  The arrows indicate the lumen of the graft.  
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 Figure G. 9  Representative results for the pG-3 animals after 1 month in vivo.  A.  α-SMA staining.  Green = α-
SMA; blue = nuclei.  B.  Calponin staining . Red = Calponin; blue = nuclei.  C.  vWF staining.  Red = vWF; blue = 
nuclei.  D.  XGal Staining. Blue = LacZ+ cells; purple = nuclei. 
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APPENDIX H 
APPENDIX H:  RVSD PATENT APPLICATION 
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